{"articleList":{"__iterable":"Map","data":[["state",{"__iterable":"Map","data":[["isLoading",false]]}],["edges",null],["firstCursor",null],["lastCursor",null],["totalCount",null],["authFields",{"__iterable":"Map","data":[]}],["stats",{"__iterable":"Map","data":[["repliedCount",0],["notRepliedCount",0]]}]]},"replyList":{"__iterable":"Map","data":[["state",{"__iterable":"Map","data":[["isLoading",true]]}],["edges",null],["firstCursor",null],["lastCursor",null],["totalCount",null]]},"articleDetail":{"__iterable":"Map","data":[["state",{"__iterable":"Map","data":[["isLoading",false],["isAuthLoading",false],["isReplyLoading",false]]}],["data",{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",0],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_73PMgrd4gJfLlrOvw12pjtYy1L1rQUUFJqV9NJud7sU"],["name","謹慎的嘉義華莉絲"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","Sizzly Jam: Roast Game App - App Store"],["url","https://apps.apple.com/app/id6757414421"],["summary","Download Sizzly Jam: Roast Game by Tianjin Zhongdetai Network Technology Co., Ltd on the App Store. See screenshots, ratings and reviews, user tips, and more…"],["topImageUrl",null],["error",null]]}]}],["text","https://apps.apple.com/app/id6757414421"],["replyRequests",{"__iterable":"List","data":[{"__iterable":"Map","data":[["id","bb3b7pwgb9su__j4S8C_73PMgrd4gJfLlrOvw12pjtYy1L1rQUUFJqV9NJud7sU__RUMORS_LINE_BOT"],["reason",""],["positiveFeedbackCount",0],["negativeFeedbackCount",0]]}]}],["id","bb3b7pwgb9su"],["createdAt","2026-07-03T05:26:25.457Z"]]}],["replyConnections",{"__iterable":"List","data":[]}],["relatedArticles",{"__iterable":"List","data":[{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_rTykobDDYz7U4UvNReSpG_Gf9p3ienHeSkBIB5m0HqU"],["name","守信的鳳林唐恩"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","Zoom! You are using the video conference application (mostly) developed by Chinese"],["url","https://pandayoo.com/2020/03/10/zoom/"],["summary","On March 9, 2020, the U.S. stock market ushered in a comprehensive decline. But the stock of zoom video bucked the trend and its stock price has risen 67% in the past month.\n\n\n\nThis is novel coronavirus related to some extent. As the epidemic becomes more and more serious, many companies and organizations have to start work at home, and zoom is the most important basic tool for home office.\n\n\n\nPeople use zoom to launch teleconferencing and carry out daily communication. Zoom supports the daily operation of Companies in many epidemic areas.\n\n\n\nWhat many people don’t know, however, is that most of zoom’s engineers are in China, the country heavily affected by the virus outbreak.\n\n\n\nZoom makes it clear in the “risk factors” section of its prospectus:\n\n\n\nFor example, our product development team is largely based in China, where personnel costs are less expensive than in many other jurisdictions. If we had to relocate our product development team from China to another jurisdiction, we could experience, among other things, higher operating expenses, which would adversely impact our operating margins and harm our business. In addition, we would need to spend considerable time and effort recruiting a new product development team, which would distract management and adversely impact our ability to continue improving our platform’s features and functionality.\n\n\n\nAs of January 31, 2019, Zoom’s R&D HQ in China has more than 500 employees, accounting for about 30% of its total employees. This makes the research and development cost of zoom far lower than that of similar SaaS enterprises in the United States.\n\n\n\nAccording to the information of State Administration for Industry and commerce, Zoom has two companies in China, namely Soft Video Software (Suzhou) Co., Ltd. and Soft Video Software (Hangzhou) Co., Ltd.\n\n\n\n\n\n\n\nAmong them, the highest-paid position is “system architect engineer”, with a monthly salary of between 20, 000 and 34,000 yuan, requiring more than eight years of relevant experience, according to a job posting released by Zoom’s company in Suzhou on March 4. The average pre-tax monthly salary for all posts is about 20,000 yuan.\n\n\n\nFor Zoom, having a Chinese founder and CEO seems to be more helpful in recruiting talent in China. Zoom also wrote in the prospectus:\n\n\n\nEric S. Yuan, is critical to our overall management, as well as the continued development of our products, services, the Zoom platform, our culture, our strategic direction, engineering and our operations in China.\n\n\n\nThe international version of Zoom was banned in mainland China in September last year, and users in mainland China can only use its Chinese version. It has been announced that services will be provided free of charge to users in mainland China during the epidemic.\n\n\n\nA Chinese business owner said in an interview that when users of the Chinese version of Zoom video conferencing with foreign users, the video and audio quality deteriorated significantly, accompanied by stutters and disconnections. By contrast, he prefers to communicate with foreign customers through Google Meet with VPN.\n\n\n\nIn the App Store ranking on March 7th, the first Tencent Meeting, the second was Ding Talk, and the fifth was WeChat for Work.\n\n\n\nIn China, Zoom has a strong rival, Tencent meeting, a free online conference system launched by Tencent, a Chinese social giant. On March 6, Tencent meeting topped the free app list of Apple App Store in China.\n\n\n\nIn addition, “Ding talk”, an office application developed by Alibaba, and “Lark” developed by byte skipping, also achieved high-speed growth in this epidemic. These two are not just video conferencing software, but “Slack” integrated with video conferencing function.\n\n\n\nWith the end of the winter vacation in mid-February, almost all Chinese schools began to use the Internet for classes. Most of them use “Ding Talk” because it is an enhanced version of the chat software. Teachers can manage classes through group functions, collect students’ homework, count attendance information, and generate various statistical reports-functions that were originally used for business management.\n\n\n\nThe proudest feature of Ding Talk is called “Ding”, which is a kind of push notification that gradually enhances the effect of notification over time. When you send a “Ding”, if the message is not read by the recipient for a period of time, the notification method of the message will gradually escalate: the user will initially receive a App notification, followed by a text message, then a voice call from App, and finally a phone call (dialed by Ding Talk’s call center, a machine voice will read out the message. )\n\n\n\nJapanese users describe nail as Monkey King’s tight hoop Mantra\n\n\n\nDue to the convenience of function, some schools in Japan also begin to use Ding Talk. As primary and middle school students do not want to take online classes, Ding Talk has received a large number of poor reviews in App Store in many countries, Alibaba regards it as an honor."],["topImageUrl",null],["error",null]]},{"__iterable":"Map","data":[["title","Wolfgang ʬ on Twitter: \"Everyone working remotely:\n\nZOOM monitors the activity on your computer and collects data on the programs running and captures which window you have focus on. \n\nIf you manage the calls, you can monitor what programs users on the call are running as well. It's fucked up.\" / Twitter"],["url","https://twitter.com/Ouren/status/1241398181205889024"],["summary","Everyone working remotely:\n\nZOOM monitors the activity on your computer and collects data on the programs running and captures which window you have focus on. \n\nIf you manage the calls, you can monitor what programs users on the call are running as well. It's fucked up.— \"Whether you have Zoom account or not,\" the company's privacy page states, \"we may collect Personal Data from or about you when you use or otherwise interact with our Products.\"All's you gotta do is search for \"Zoom attention monitoring\" and read their privacy policy. (Their policy is that there is no privacy)\n\nTech startups can neve be trusted. Ever.Additional information from the :I don't have a real soundcloud, but here are various links where you can buy our games, request keys, hire our services and more:\nhttp://listography.com/poppyworks\n\n(we only work on games, not infosec, sorry!)"],["topImageUrl",null],["error",null]]},{"__iterable":"Map","data":[["title","What You Should Know About Online Tools During the COVID-19 Crisis"],["url","https://www.eff.org/deeplinks/2020/03/what-you-should-know-about-online-tools-during-covid-19-crisis"],["summary","A greater portion of the world’s work, organizing, and care-giving is moving onto digital platforms and tools that facilitate connection and productivity: video conferencing, messaging apps, healthcare and educational platforms, and more. It’s important to be aware of the ways these tools may impact your digital privacy and security during the COVID-19 crisis. \nHere are a few things you should know in order to make informed decisions about what works best for you and your communities, and ways you can use security and privacy best practices to protect yourself and others.\nFree Slacks\nEFF has written a lot about Slack’s data retention issues when it comes to free versions of the software. With so many mutual aid networks and organizing groups coalescing on Slack to support our communities, it’s important that users are aware that the company retains their messages if they're using a free plan—and they can't automatically delete them. By default, Slack retains all the messages in a workspace or channel (including direct messages) for as long as the workspace exists. \nIf you are using a paid workspace, you can change how many messages are retained in Slack’s databases by setting shorter retention periods. If you’re using the free version though, that option is not available to you. Additionally, free workspace users only have the ability to search through the most recent 10,000 messages. And while users can’t see messages sent prior to the 10,000 message mark, they are still available to Slack, law enforcement, and any third-party hackers through a data breach. Leaking or sharing of this data could prove catastrophic, especially for groups who are working to provide aid and support for our most at-risk communities.\nZoom Conferencing\nThe best way to stave off the effects of isolation is to maintain contact with friends, family, and coworkers. Zoom has quickly become a popular option to work and keep in touch with others in the midst of social distancing and shelter-in-place protocols. There are a few things to keep in mind when using Zoom, particularly in instances where users are relying on the conferencing tool for their studies, or for work-related activities.\nAttendee Attention-Tracking\nThe host of a Zoom call has the capacity to monitor the activities of attendees while screen-sharing. This functionality is available in Zoom version 4.0 and higher. If attendees of a meeting do not have the Zoom video window in focus during a call where the host is screen-sharing, after 30 seconds the host can see indicators next to each participant’s name indicating that the Zoom window is not active.\nAdministrators and User Tracking\nZoom allows administrators to see detailed views on how, when, and where users are using Zoom, with detailed dashboards in real-time of user activity. Zoom also provides a ranking system of users based on total number of meeting minutes. If a user records any calls via Zoom, administrators can access the contents of that recorded call, including video, audio, transcript, and chat files, as well as access to sharing, analytics, and cloud management privileges. \nFor any meeting that has occurred or is in-process, Zoom allows administrators to see the operating system, IP address, location data, and device information of each participant. This device information includes the type of machine (PC/Mac/Linux/mobile/etc), specs on the make/model of your peripheral audiovisual devices like cameras or speakers, and names for those devices (for example, the user-configurable names given to AirPods). Administrators also have the ability to join any call at any time on their organization’s instance of Zoom, without in-the-moment consent or warning for the attendees of the call.\nSchools Moving to Online Learning\nSurveillance shouldn’t be a prerequisite for getting an education. But even before more school districts started moving their classes and coursework to digital forums for purposes of social distancing, surveillance has become more and more common in schools. With the advent of COVID-19 and the associated uptick in distributed digital learning, the potential for this surveillance to ramp up is alarming. \nThis is true from kindergarten all the way through graduate school, though it is most prevalent and insidious in K-12 schools. School administrators are choosing to use tools and tactics that encroach on students’ privacy in ways that can break down trust amongst students and their peers, teachers, families, and administrators. Many K-12 schools offer or mandate the use of school-issued devices, and those devices come with pre-installed spyware that monitors all student activities and reports them to school administrators.\nMany schools are already experimenting with mass surveillance technologies with no evidence, and no way for concerned parents and students to opt out. If your school is using or is considering using technologies like Bark, GoGuardian, Gaggle, Securly, or Social Sentinel, check out our guide to Privacy for Students. It covers many of the privacy and surveillance concerns that these technologies raise, with ways to minimize the data being tracked, risk mitigation strategies, and advocacy tactics.\nTelehealth and Non-HIPAA Platforms\nThe HHS has altered HIPAA rules during the COVID-19 crisis, allowing health care providers to use applications such as FaceTime, Facebook Messenger, Hangouts, Skype, Zoom, etc so they are able to provide care to patients remotely:\nDuring the COVID-19 national emergency, which also constitutes a nationwide public health emergency, covered health care providers subject to the HIPAA Rules may seek to communicate with patients, and provide telehealth services, through remote communications technologies. Some of these technologies, and the manner in which they are used by HIPAA covered health care providers, may not fully comply with the requirements of the HIPAA Rules.\n\nIf your healthcare provider is using an application or platform that is not covered under HIPAA, check with them on what safeguards they have in place to ensure your privacy is protected, and what their plans and timelines are for moving to platforms that do fall under HIPAA compliance.\nTools for Assessing Risk and Staying Safe Online\nOne of the best things you can do to keep yourself and others safe during this crisis is to learn how to minimize risk. Many of the problems presented in this post can be mitigated or circumvented with careful consideration of the risks, employing “privacy as a team sport” tactics, and minimizing the data that corporations, employers, and others can track. Our resource site, Surveillance Self-Defense, is full of practical tips, tools, how-to’s, and explainers for communicating safely online. Here’s a list of useful guides with concrete steps you can take to get started:\n\nEvaluate and choose the tools you use to make sure they work for you.\nLearn about best practices for communicating with others and incorporate them into your routines and tools.\nUse a password manager to create strong passwords.\nEnsure that you have two-factor authentication (also known as 2FA) enabled for as many accounts as possible.\nConsider your needs and choose the VPN that’s right for you.\n\nAnd lastly, remember—we’re all in this together. Take care of each other by safeguarding each others’ physical and digital health."],["topImageUrl",null],["error",null]]}]}],["text","最近大紅的 ZOOM 繼「透過大量僱用中國工程師大幅降低成本」後\nhttps://pandayoo.com/2020/03/10/zoom/\n現在又被發現會收集與會者電腦上正在執行的「其它程式」跟視窗切換的紀錄，並回報雲端\nhttps://twitter.com/Ouren/status/1241398181205889024\n\n不行我覺得太噁心了，無論是企業風格跟程式的設計思路的都讓人作嘔\n\n以後不會再用他，也會盡量不參與任何使用 zoom 開啟的會議，盡量用其他程式替代（Ex: google meet, jitsi meet）\n\n歡迎參考 EFF 電子前線基金會的報告：https://www.eff.org/deeplinks/2020/03/what-you-should-know-about-online-tools-during-covid-19-crisis"],["id","2jz0pw77he53s"],["createdAt","2020-03-25T03:11:10.899Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_1pI4sPMubeGfSifN1GEyPRwt2GYYgd2y3Rc1CKi_Ht8"],["name","坐懷不亂的二崙金百莉"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Download the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","3tzjka74yu4q3"],["createdAt","2020-02-20T14:17:06.630Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",3],["user",{"__iterable":"Map","data":[["id","j4S8C_YhMeMo1VPxLp00MgoGM7c2NgL0De7zuTuBRvfzxAEU0"],["name","反應快的龍井阿爾娃"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title",""],["url","https://sg.newsrepublic.net/s/SyvcUppQvR"],["summary",""],["topImageUrl",null],["error","UNKNOWN_UNFURL_ERROR"]]},{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Check out what I found on News Republic:\nhttps://sg.newsrepublic.net/s/SyvcUppQvR\nDownload the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","2xcajysgnzsgg"],["createdAt","2020-07-22T06:30:01.580Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",3],["user",{"__iterable":"Map","data":[["id","j4S8C_LpXJiXfGMLmoGeWcMzhjQB-TXKK0zF0keV9gnlp6ekY"],["name","忠誠的水林紐曼"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title",null],["url","http://sg.newsrepublic.net/s/UFhdmQed"],["summary",null],["topImageUrl",null],["error","UNKNOWN_SCRAP_ERROR"]]},{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Check out what I found on News Republic:\nhttp://sg.newsrepublic.net/s/UFhdmQed\nDownload the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","1uinlucs2ey4c"],["createdAt","2019-09-14T10:19:28.723Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",4],["user",{"__iterable":"Map","data":[["id","j4S8C_gooTjXnlbjEIA9pYAgP4mA6F_DyPCORZZx6i8FbBUeQ"],["name","細節的苓雅李維"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎Hi-Life VIP"],["url","https://appsto.re/tw/sNfmhb.i"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n\n \n \n \n \n Hi-Life\n \n \n \n \n \n #25 in Lifestyle\n \n \n \n \n \n \n \n \n\n 2.1, 107 Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n Hi-Life Enjoy Your Life!Hi-Life VIP 為會員提供Hi點優惠兌換、店到店寄件、優惠訊息、超值購等多元服務，處處給您驚喜與便利，立即下載加入會員就有好康註冊禮喔！萊爾富總有新鮮事！快載Hi-Life VIP，消費輕鬆累點，優惠、便利一把罩！【會員中心】快速設定會員卡資訊、會員資料及查看優惠票券夾；消費時出示會員條碼即可進行累點！我們還增加了財政部發票載具設定，減少紙本電子發票，讓生活更便利！【我的點數】一目了然的點數資料及兌換記錄，輕鬆兌換優惠商品，還能贈送點數給親朋好友！【我的票券】會員於門市消費購買超值購可存入票券匣，便利管理超值購票券與點數兌換的票券以及會員專屬的免費兌換票券。【店到店寄貨服務】可於Hi-Life VIP上填寫寄貨單資料，至萊爾富門市Life-ET印出後於櫃台完成店到店寄貨服務；只要輸入寄件代碼即可快速查詢貨件狀況，讓您隨時隨地掌握配送進度！【最新消息】提供萊爾富最新促銷活動及優惠訊息，給您最優惠的商品及最便利的服務！【更多服務】萊爾富官方網站、Facebook、Instagram以Line等社群網站，歡迎一同成為萊爾富的粉絲！我們會不定期舉辦各種活動～快來追蹤我們吧！\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 2.10.0\n 11 Sep 2018\n \n\n 萊爾富自家Hi Pay上線啦！1.首次綁台新卡，送大杯熱美式乙杯!2.首次消費滿100元，再送大杯熱美式乙杯!!3. 9/14前，首次消費滿100元，再送10,000Hi點!!!4.持Hi Pay消費Hi點2倍送!!!!詳細活動方式，請見APP最新消息:)\n \n \n \n 2.9.1\n 15 Aug 2018\n \n\n 1. 首次註冊，贈送好禮2. 首次消費滿100元，再加送1,000Hi點3. 提高Hi點贈送上限，點數交流更方便4. 17咖啡日，每月17~19日，會員專屬買一送一\n\n\n \n \n \n 2.9.0\n 15 May 2018\n \n\n 1. 107/4/1起到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App3. 雲端超商超好買，優惠商品好划算！跨店領取還能贈送好朋友唷\n \n \n \n 2.8.0\n 20 Apr 2018\n \n\n 1. 107/4/1起到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App3. 雲端超商超好買，優惠商品好划算！跨店領取還能贈送好朋友唷\n \n \n \n 2.7.0\n 13 Apr 2018\n \n\n 1. 到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App\n \n \n \n 2.5.7\n 15 Jan 2018\n \n\n 按鈕視覺優化：新按鈕優化，新年新氣象～新增「萊儲值」功能：Life-ET上的E購卡與遊戲點數，現在也能在APP上挑選囉！挑選商品更方便～\n \n \n \n 2.5.6\n 20 Dec 2017\n \n\n 新增「消費金額查詢」功能：會員現在就能在App上查詢消費金額囉！(不含菸品、代收、代售、手續費)新增「代收記錄查詢」功能：繳交代收、停車費、信用卡費的記錄，都能在App上查詢囉！記錄查詢好方便～\n\n\n \n \n \n 2.5.5\n 18 Dec 2017\n \n\n 新增「消費金額查詢」功能：會員現在就能在App上查詢消費金額囉！(不含菸品、代收、代售、手續費)新增「代收記錄查詢」功能：繳交代收、停車費、信用卡費的記錄，都能在App上查詢囉！記錄查詢好方便～\n\n\n \n \n \n 2.5.4\n 15 Nov 2017\n \n\n 手機條碼申請介面優化：改善無法輸入載具條碼的狀況。綁定載具後，消費累點同時也能將發票存入載具唷！\n\n\n \n \n \n 2.5.3\n 19 Oct 2017\n \n\n 手機條碼申請，連結優化：發票載具設定，新增手機條碼申請功能！透過APP就可以申請手機條碼，發票存入載具，更佳方便啦～\n\n\n \n \n \n 2.5.2\n 18 Sep 2017\n \n\n (1) 超值購票券匣，贈送功能優化：到門市櫃台前，看超值購DM，購買現場超值購，存入APP，贈送親友更方便<3(2) Widget小工具優化：快使用Widget小工具，直接在手機桌面就可以進行累點啦！(3) 推播功能優化：每次都錯過小萊的超值優惠嗎？打開推播通知功能！讓您第一手掌握，成為VIP~\n\n\n \n \n \n 2.5.1\n 15 Aug 2017\n \n\n (1) Widgets小工具新上線：到小萊消費，集點更輕鬆！不用開啟APP，也能直接顯示會員條碼，超開心～(2) 雲端冰箱按鈕開通：豐富商品任你選！優惠價格、分次享用、跨店領取～還能分享給親朋好友一起同樂！\n\n\n \n \n \n 2.5.0\n 17 Jul 2017\n \n\n (1) 點數兌換篩選功能：豐富的小萊商品，讓你快速尋找！再也不用在茫茫大海中尋覓所愛～(2) 點數兌換瀏覽優化：商品不用一支一支看，多品項瀏覽，讓你不會再錯過任何一支！(3) 廣告頁面縮放功能：廣告看不清怎麼辦？就把它放大吧！\n\n\n \n \n \n 2.4.0\n 26 Jun 2017\n \n\n (1) 超值購兌換流程優化(2) 廣告頁面視覺優化(3) 點數兌換頁面視覺優化\n\n\n \n \n \n 2.3.0\n 20 Jun 2017\n \n\n (1) 超值購兌換流程優化(2) 廣告頁面視覺優化(3) 點數兌換頁面視覺優化\n\n\n \n \n \n 2.2.4\n 14 May 2017\n \n\n (1)按鈕介面優化(2)推播功能優化(3)遊戲功能擴充\n\n\n \n \n \n 2.2.1\n 17 Apr 2017\n \n\n 1. 最愛門市新增2. 累點按鈕優化3. 寄件服務優化\n\n\n \n \n \n 2.1.3\n 15 Mar 2017\n \n\n 1. 財政部發票載具功能優化2. 使用介面優化\n\n\n \n \n \n 2.1.1\n 10 Feb 2017\n \n \n \n\n \n\n \n\n \n \n \n \n \n 11 Sep 2018Version 2.10.0\n \n \n \n \n\n 萊爾富自家Hi Pay上線啦！1.首次綁台新卡，送大杯熱美式乙杯!2.首次消費滿100元，再送大杯熱美式乙杯!!3. 9/14前，首次消費滿100元，再送10,000Hi點!!!4.持Hi Pay消費Hi點2倍送!!!!詳細活動方式，請見APP最新消息:)\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n \n \n \n \n 滿滿更新加油吧\n\n\n \n 28 Feb 2018\n \n\n\n\n 可能才出不久很多東西不是很完整可以學一下別的超商一些東西\n\n\n\n\n \n\n \n\n \n \n 滿滿更新加油吧\n\n\n \n 28 Feb 2018\n \n\n\n\n \n\n 可能才出不久很多東西不是很完整可以學一下別的超商一些東西\n\n\n \n\n\n\n\n \n \n \n \n 無言到爆\n\n\n \n 12 Jul 2018\n \n\n\n\n 註冊後一直等不到驗證碼，一直按從新發送，結果一天後才收到，收到後又沒辦法使用，原因超過三次了！結果剛才看到有人四月多就有這種狀況，現在七月了還存在，這真的很有效率！董事長不管事了嗎？養了一推IT在睡覺！\n\n\n\n\n \n\n \n\n \n \n 無言到爆\n\n\n \n 12 Jul 2018\n \n\n\n\n \n\n 註冊後一直等不到驗證碼，一直按從新發送，結果一天後才收到，收到後又沒辦法使用，原因超過三次了！結果剛才看到有人四月多就有這種狀況，現在七月了還存在，這真的很有效率！董事長不管事了嗎？養了一推IT在睡覺！\n\n\n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Hi-Life INTERNATIONAL CO.,LTD\n \n \n \n Size\n 32.2 MB\n \n \n \n Compatibility\n \n\n Requires iOS 8.0 or later. Compatible with iPhone, iPad and iPod touch.\n\n\n \n\n \n \n Languages\n \n\n Traditional Chinese\n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this application.\n \n \n \n Infrequent/Mild Simulated Gambling\n \n \n \n Gambling and Contests\n \n \n Copyright\n © Hi-Life International Co., Ltd.\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is1-ssl.mzstatic.com/image/thumb/Purple118/v4/80/6b/3e/806b3e69-6cbe-135e-c0a9-4d259bc907b4/AppIcon-1x_U007emarketing-85-220-4.png/1200x630wa.png"],["error",null]]},{"__iterable":"Map","data":[["title","Hi-Life VIP - Apps on Google Play"],["url","https://play.google.com/store/apps/details?id=com.hilife.vipapp"],["summary","Hi-Life Enjoy Your Life!Hi-Life VIP 為會員提供Hi點優惠兌換、店到店寄件、優惠訊息、超值購等多元服務，處處給您驚喜與便利，立即下載加入會員就有好康註冊禮喔！萊爾富總有新鮮事！快載Hi-Life VIP，消費輕鬆累點，優惠、便利一把罩！【會員中心】快速設定會員卡資訊、會員資料及查看優惠票券夾；消費時出示會員條碼即可進行累點！我們還增加了財政部發票載具設定，減少紙本電子發票，讓生活更便利！【我的點數】一目了然的點數資料及兌換記錄，輕鬆兌換優惠商品，還能贈送點數給親朋好友！【我的票券】會員於門市消費購買超值購可存入票券匣，便利管理超值購票券與點數兌換的票券以及會員專屬的免費兌換票券。【店到店寄貨服務】可於Hi-Life VIP上填寫寄貨單資料，至萊爾富門市Life-ET印出後於櫃台完成店到店寄貨服務；只要輸入寄件代碼即可快速查詢貨件狀況，讓您隨時隨地掌握配送進度！【最新消息】提供萊爾富最新促銷活動及優惠訊息，給您最優惠的商品及最便利的服務！【更多服務】萊爾富官方網站、Facebook、Instagram以Line等社群網站，歡迎一同成為萊爾富的粉絲！我們會不定期舉辦各種活動～快來追蹤我們吧！"],["topImageUrl","https://lh3.googleusercontent.com/2j5rnoMzBb0hnQinVUWDR3u90gA6wKow958tNyHSZD-1MaZZqAR5vd5iHTiATUtcfw"],["error",null]]}]}],["text","萊爾富最近推出的APP，只要花三分鐘依照下面的步驟完成任務，照片裡面包含兩杯咖啡，一瓶養樂多，一條77乳加巧克力跟茶葉蛋全都免費....\n\n步驟一:\n手機下載Hi-Life Vip APP\n【iPhone App Store 下載】\nhttps://appsto.re/tw/sNfmhb.i\n\n【安卓Play Store下載】\nhttps://play.google.com/store/apps/details?id=com.hilife.vipapp\n\n* 下載完後用電話號碼註冊會員\n* 並在【推薦門市】一欄填寫【】<==可不填\n\n 註冊完後會送你一杯大杯咖啡跟100點！！！\n\n這時候就完成任務一了！\n\n步驟二:\n到【我的點數】選取【點數兌換】\n換一個100點內的東西，預設兌換養樂多70點 \n（這裡請不要把點數都換完，請留一些進行步驟三)\n\n步驟三:\n* 到【我的點數】選取【點數贈送】\n* 輸入贈送的號碼(必須要是會員)，\n可兩人申請互相贈送\n( 如果步驟二點數不小心換完，這邊就沒辦法贈送了)\n\n步驟三這邊做完，在【我的票卷】裡面就會有一杯咖啡、一條77乳加、紅利點數兌換內會有一個養樂多，這時候只要去萊爾富兌換養樂多後，又會贈送一顆茶葉蛋跟一杯咖啡。"],["id","AVqaMM-kyrDaTqlmmqBl"],["createdAt","2017-03-04T16:39:34.562Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",null],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","NOWnews 今日新聞"],["url","https://www.facebook.com/nownews"],["summary","社群查看全部444,825 人說這讚423,626 個人正在追蹤關於查看全部NOWnews.com 今日新聞http://www.nownews.com www.nownews.comsocialservice@nownews.com用戶444,825 個讚1,043 個打卡次此專頁按讚的粉絲專頁IFUN NOW保庇 NOW今日觀點相關的粉絲專頁聯合報媒體／新聞公司壹週刊雜誌東森新聞廣播與媒體製作公司蘋果日報台灣媒體／新聞公司udn.com 聯合新聞網媒體／新聞公司TVBS 新聞媒體／新聞公司ETtoday新聞雲媒體／新聞公司Yahoo!奇摩新聞新聞媒體網站中時電子報新聞媒體網站國家地理雜誌雜誌中央社新聞粉絲團新聞媒體網站自由時報媒體／新聞公司快點TV媒體／新聞公司蘋果日報即時新聞媒體／新聞公司三立新聞媒體／新聞公司愛奇藝台灣站媒體／新聞公司遠見雜誌出版商商業周刊（商周.com）雜誌大家來說鬼媒體／新聞公司民視新聞媒體／新聞公司查看更多triangle-down地標台北市NOWnews 今日新聞中文(台灣) · English (US) · Español · Português (Brasil) · Français (France)隱私政策 · 使用條款 · 廣告 · Ad Choices · Cookie · 更多 Facebook © 2018貼文NOWnews 今日新聞贊贊贊助贊 · 5 分鐘 · 拉拉太美了❤️(#瞎到天編：已被閃瞎)nownews.com緊牽老公比爾賈　徐佳瑩曬婚紗照甜喊：家宴達成！ | 娛樂 | NOWnews 今日新聞金曲歌后徐佳瑩（LaLa） 8 月在臉書宣布和交往 3 年的導演男友比爾賈登記結婚的喜訊，今（22）日更在社群網站上 po 出婚紗照，開心報喜「家宴達成！」徐佳瑩和比爾賈交往 3 年，兩人雖相差 11 歲，但感情相當穩定，今（2018.....NOWnews 今日新聞贊贊贊助贊 · 32 分鐘 · 演員轉導演的潤東讓人深深著迷呢😍(#瞎到天編)nownews.com金鐘專訪／何潤東全心投入導演職：沒入圍演員奬是對的 | 娛樂 | NOWnews 今日新聞何潤東出道20年首度執導《翻牆的記憶》入圍第53屆金鐘獎8項大獎，當時何潤東發表感言時曾說：「彌補了收視的遺憾。」確實，《翻牆》探討的多為社會黑暗面、校園霸凌，並不屬於大眾喜愛的口味，加上沒有配合與無線台做....顯示全部影片欲改善老屋問題　義消分隊長參選新北市議員拚監督51國瑜不要跟紫棋搶唱Hook啊 XDDD (#助海編)\n \n韓國瑜 #高雄市長候選人 #政見Rap1547為什麼他們可以那麼狠心！！ (#助海編)4027查看全部相片顯示全部查看更多"],["topImageUrl","https://scontent.ftpe7-1.fna.fbcdn.net/v/t1.0-1/p200x200/22050172_10155343315677663_8574432092587348135_n.jpg?_nc_cat=1&oh=8ea12ccee835e00231f2222d39a22877&oe=5C5CBA38"],["error",null]]},{"__iterable":"Map","data":[["title","‎今日新聞"],["url","https://goo.gl/HWEXx"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n 《NOWnews今日新聞》APP提供每日600則以上最新、最快即時新聞，還有多元化深度報導及多樣化影音節目，提供最完整的新聞資訊；它是新聞APP程式，更是一個無時無刻不貼近你視聽需求的全方位工具。NOW News跟你想的不一樣！就從NOWnews開始！-- -- -- -- -- 你一定要下載NOWnews App的四大理由-- -- -- -- --1. 每日最即時的新聞推播，從出門天氣到周遭大小事，掌握重要資訊不漏接。2. 政治、財經、生活、運動、娛樂、國際、社會、旅遊、美食、3C、消費、地方等軟硬性內容，多元化主題深入新聞核心，每日幫你專題解析新聞重點。3. 重量級人物面對面訪談Live直播，針對時下熱門議題與網友即時互動。4. 多元化主題標籤，多元化主題深入新聞核心，帶領讀者解析新聞重點，並深度探討熱門專題。-- -- -- -- -- -四大NOWnews APP功能及特色-- -- -- -- -- -◆即時新聞：24小時即時更新國內外最新資訊，重要新聞推播，不錯過重大頭條新聞。◆多元影音：利用影音方式呈現熱門新聞、議題，直擊新聞現場。◆精選圖輯：提供新聞現場高畫質優質圖片，第一手現場幕後花絮。◆嚴選特輯：因應時下熱門話題提供特輯專區，完整新聞內容整理，全方位了解趨勢。《NOWnews今日新聞》於2008年4月正式上線，是臺灣第一個，同時也是臺灣最大、最即時的網路原生新聞網站，它還是臺灣前10大網站之一。《NOWnews今日新聞》以多元資訊內容為主，每日產製逾600則新聞，類別包括：政經、生活、運動、娛樂、國際、社會、地方等軟硬性新聞。《NOWnews今日新聞》官網： http://www.nownews.com/手機版官網： https://m.nownews.comFacebook 粉絲團： https://www.facebook.com/nownews/LINE官方帳號：NOWnews\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 4.2.3\n 6 Feb 2018\n \n\n 更新10週年logo修正圖片顯示異常其他bugfix\n\n\n \n \n \n 4.2.2\n 19 Dec 2017\n \n\n 新增支援iOS 11圖片資料更新\n\n\n \n \n \n 4.2.1\n 11 Oct 2017\n \n\n 新增介面更新暫時下架直播暫時下架我的最愛圖輯其他錯誤修正\n\n\n \n \n \n 4.2.0\n 16 Aug 2017\n \n\n 新增左側漢堡選單顯示版本資訊新增內頁置頂按鈕修正圖片模糊問題修復內頁崩潰問題修復推播格式判斷錯誤修復內頁載圖尺寸錯誤\n \n \n \n 4.1.9\n 15 Jul 2017\n \n\n 修復推播格式判斷錯誤修復內頁載圖尺寸錯誤調整影音新聞配置影音廣告音量問題\n\n\n \n \n \n 4.1.8\n 3 Jul 2017\n \n\n 版面調整並做資料更新\n\n\n \n \n \n 4.1.7\n 23 Jun 2017\n \n\n 緊急修復推播異常\n\n\n \n \n \n 4.1.6\n 19 Jun 2017\n \n\n 修復黑屏無法使用修復推播無法關閉其他問題修復\n\n\n \n \n \n 4.1.5\n 14 Jun 2017\n \n\n 直播功能調整其他問題修正\n\n\n \n \n \n 4.1.4\n 28 Apr 2017\n \n\n 修正直播bar版面顯不完整修正直播bar在某些系統版本無法使用其他bug fix\n\n\n \n \n \n 4.1.3\n 24 Apr 2017\n \n\n 1.新增直播BAR功能當我們有最新的直播實況會透過ＡＰＰ來提醒您唷2.其他bugfix\n\n\n \n \n \n 4.1.2\n 19 Apr 2017\n \n\n 修復推播數字顯示異常修正直播部分功能其他錯誤修正\n\n\n \n \n \n 4.1.1\n 10 Mar 2017\n \n\n 1. UI大改版 2. 新增推播功能 3. 新增直播收看\n\n\n \n \n \n 4.1.0\n 12 Jan 2017\n \n\n 修正第三方套件Key值錯誤\n\n\n \n \n \n 4.0.9\n 7 Jan 2017\n \n\n 緊急修復異常套件\n\n\n \n \n \n 4.0.8\n 30 May 2016\n \n\n 修正網路異常錯誤修正其他錯誤\n\n\n \n \n \n 4.0.7\n 14 Apr 2016\n \n\n 修正 weChat 分享無法支援 iOS 9.3修正新聞加載異常修正其他錯誤\n\n\n \n \n \n 4.0.6\n 2 Dec 2015\n \n\n 1.新增微博新聞分享2.新增WeChat新聞分享\n\n\n \n \n \n 4.0.5\n 29 Oct 2015\n \n\n 本次修正項目：1.上拉新聞加載2.內頁新聞分享3.N瞎拼加入HappyGo4.網路狀態判斷5.修正支援iOS 96.圖集列表圖尺寸修正7.網路斷線狀態判斷\n\n\n \n \n \n 4.0.4\n 19 Sep 2015\n \n\n 本次修正項目：1.修正內頁新聞圖片尺寸不正常顯示2.修正圖集與顯示內容不符合問題3.下拉更新即時取得分類最熱新聞4.新增首頁蓋版廣告5.其他程式優化\n\n\n \n \n \n 4.0.3\n 25 Aug 2015\n \n\n 全新介面更新1.選單改採左上方隱藏試選單2.內頁介面更新3.新聞瀏覽更快速4.圖集瀏覽更加便利5.新增內頁可直接選取字體大小\n \n \n \n 4.0.2\n 5 Jul 2013\n \n\n 效能優化、修復錯誤(新版支援iOS 5.0以上, 舊iOS版本還請更新)\n\n\n \n \n \n 4.0.0\n 1 Apr 2013\n \n\n - 界面更新 * 美化界面 * 新增圖集功能, 包含影劇 / 正妹 / 要聞 / 新奇 / 寵物等數十萬張圖庫 * 透過 \"往下拉\", 可以自動更新 * 透過 \"往上滑\", 可一直讀取更舊的新聞 * 透過 \"左右滑動\", 可以切換分類 / 內文 * 新增白天黑夜主題切換模式, 顯示不同的顏色與背景 * 用戶可調整新聞內容的字體大小以符合需求- 自訂分類 * 可以選擇, 訂閱/取消訂閱分類- 即時通知 * 如遇重大訊息公佈, 可以即時提醒您\n \n \n \n 2.2.3\n 9 Dec 2012\n \n\n NOW購了沒手機購物網站上線囉！！提供優質商品，安全的交易平台。好康驚喜天天有！你今天NOW購了沒！\n\n\n \n \n \n 2.0\n 17 Nov 2010\n \n\n update iPhone and iPod touch Screenshots.\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n\n 更新10週年logo修正圖片顯示異常其他bugfix\n\n\n \n\n \n \n\n \n \n Ratings and Reviews\n \n \n \n \n \n \n \n 新版好用\n\n\n \n 2 Jul 2018\n \n\n\n\n 很乾淨的介面新聞分類清楚\n\n\n\n\n \n\n \n\n \n \n 新版好用\n\n\n \n 2 Jul 2018\n \n\n\n\n \n\n 很乾淨的介面新聞分類清楚\n\n\n \n\n\n\n\n \n \n \n \n 我會分享成功。\n\n\n \n 16 Jul 2016\n \n\n\n\n 我是台灣人，我是黃獨立，我主張台灣人都愛有台灣獨立建國成功活命贏得勝利，所有的台灣人都愛有活命，所有的台灣人都愛有在，愛有梨的台灣人。\n\n\n\n\n \n\n \n\n \n \n 我會分享成功。\n\n\n \n 16 Jul 2016\n \n\n\n\n \n\n 我是台灣人，我是黃獨立，我主張台灣人都愛有台灣獨立建國成功活命贏得勝利，所有的台灣人都愛有活命，所有的台灣人都愛有在，愛有梨的台灣人。\n\n\n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n NOWnews Network Co.,Ltd\n \n \n \n Size\n 56 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.3 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 頻繁/強烈的粗話或低俗幽默\n \n \n \n 頻繁/強烈的卡通或幻想暴力\n \n \n \n 頻繁/強烈的色情內容與裸露\n \n \n \n 頻繁/強烈的驚悚/恐怖題材\n \n \n \n 頻繁/強烈的成人/性暗示題材\n \n \n \n 頻繁/強烈的模擬賭博\n \n \n \n 頻繁/強度醫藥/醫療資訊\n \n \n \n 頻繁/強烈的現實暴力\n \n \n \n 頻繁/強烈的酒精、菸草或藥物使用或相關內容\n \n \n Copyright\n © NOWnews.com\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is5-ssl.mzstatic.com/image/thumb/Purple128/v4/7d/f5/02/7df502c6-adc6-68f4-624c-3845c8238a8e/AppIcon-1x_U007emarketing-0-0-GLES2_U002c0-512MB-sRGB-0-0-0-85-220-0-0-0-4.png/1200x630wa.png"],["error",null]]},{"__iterable":"Map","data":[["title","NOWnews今日新聞 - Google Play 應用程式"],["url","https://goo.gl/oPBNJ"],["summary","《NOWnews今日新聞》APP提供每日600則以上最新、最快即時新聞，還有多元化深度報導及多樣化影音節目，提供最完整的新聞資訊；它是新聞APP程式，更是一個無時無刻不貼近你視聽需求的全方位工具。NOW News跟你想的不一樣！就從NOWnews開始！----------你一定要下載NOWnews App的四大理由----------1. 每日最即時的新聞推播，從出門天氣到周遭大小事，掌握重要資訊不漏接。2. 政治、財經、生活、運動、娛樂、國際、社會、旅遊、美食、3C、消費、地方等軟硬性內容，多元化主題深入新聞核心，每日幫你專題解析新聞重點。3. 重量級人物面對面訪談Live直播，針對時下熱門議題與網友即時互動。4. 多元化主題標籤，多元化主題深入新聞核心，帶領讀者解析新聞重點，並深度探討熱門專題。-----------四大NOWnews APP功能及特色-----------◆即時新聞：24小時即時更新國內外最新資訊，重要新聞推播，不錯過重大頭條新聞。◆多元影音：利用影音方式呈現熱門新聞、議題，直擊新聞現場。◆精選圖輯：提供新聞現場高畫質優質圖片，第一手現場幕後花絮。◆嚴選特輯：因應時下熱門話題提供特輯專區，完整新聞內容整理，全方位了解趨勢。《NOWnews今日新聞》於2008年4月正式上線，是臺灣第一個，同時也是臺灣最大、最即時的網路原生新聞網站，它還是臺灣前10大網站之一。《NOWnews今日新聞》以多元資訊內容為主，每日產製逾600則新聞，類別包括：政經、生活、運動、娛樂、國際、社會、地方等軟硬性新聞。《NOWnews今日新聞》官網： http://www.nownews.com/手機版官網： https://m.nownews.comFacebook 粉絲團： https://www.facebook.com/nownews/LINE官方帳號：NOWnews"],["topImageUrl","https://lh3.googleusercontent.com/VOq0mkKn52NOPZDUiTA8H2irRQT52FBiOetnT-bWDEeXOiFtGU6Lnyu4ziTP1mhatsuD"],["error",null]]}]}],["text","親愛的朋友您好！(haha)\n歡迎加入NOWnews成為您的好友\n我們將一天發送2次重點新聞及精彩圖片\n提供最即時的新聞情報(clap)\n讓您一手掌握不錯過！(ok)(ok)\n\n想隨時了解更多天下事，快按讚加入NOWnews粉絲團：\nhttps://www.facebook.com/nownews\n\n(chick)NOW新聞都在行動APP上\n》》iOS APP請點這裡\nhttps://goo.gl/HWEXx\n》》Android APP請點這裡\nhttps://goo.gl/oPBNJ"],["id","5487035768113-rumor"],["createdAt","2017-01-11T12:30:00.000Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_8SU6w_lKU8142Pd-hyVJRULJNF7mjehuE3om7Vc6i8c"],["name","滿足的✖東勢✖艾薇拉"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","Diabetes drug is promising Alzheimer's treatment after 'significantly reversing' memory loss"],["url","http://www.independent.co.uk/news/health/alzheimers-diabetes-drug-memory-loss-reverse-disease-treatment-degenerative-a8133681.html"],["summary","A drug developed for type 2 diabetes significantly reverses memory loss and could have potential as a new treatment for Alzheimer’s disease and other neurodegenerative diseases, scientists say.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The study, by UK and Chinese universities, is the first to look at a new combined diabetes drug and found improvements in several characteristic symptoms of Alzheimer’s.\n \n\n \n \n \n \n \n\n\n\n \n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Lead researcher Professor Christian Holscher, from Lancaster University, said these “very promising outcomes” show multi-action drugs developed for type 2 diabetes “consistently show neurological protective effects”.\n \n\n \n \n \n \n \n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Independent academics said a reduction in nerve-cell-killing protein molecules was particularly interesting and this was likely to be another avenue in the search for an elusive drug to combat dementia.\n \n\n \n \n \n \n \n\n\n\n\n\n \n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n He has previously reported optimistic findings from an older diabetes drug, liraglutide, and clinical trials in humans are currently under way.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n This latest study, published in the journal Brain Research, looked at a “triple action” treatment that combine three different drugs for type 2 diabetes, acting on biological pathways that could also have an impact on dementia.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n \n\n \n \n \n Type 2 diabetes is a known risk factor for Alzhemier’s disease and impaired production of insulin – the hormone that people with diabetes don’t produce sufficiently to control their blood sugar – is linked to brain degeneration.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The identification of this link had a twofold benefit, according to charities.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n It opened up new research and drug development opportunities, such as this study.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n But it also means that by making lifestyle changes, like eating healthily and exercising, patients can avoid developing type-2 diabetes and lower their risk of Alzheimer’s disease as well.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n There are currently half a million people living with Alzheimer’s disease in the UK and more than five million people with diabetes, both conditions pose a major cost to the NHS, and health systems worldwide.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n \n\n \n \n \n The treatment in this study combined; GLP-1, GIP and glucagon, which, like insulin protect against neurological deterioration, and tested them in mice with genetic mutations that cause Alzheimer’s disease.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n After two months of daily injections the mice were shown to significantly improve their performance in a maze designed to test memory.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n Treated mice also had lower levels of proteins which clump together and form plaques in the brains of people with Alzheimer’s disease, inhibiting nerve cells’ ability to communicate and causing them to die.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The study also found these mice lost nerve cells to the disease at a slower rate and had lower levels of nerve inflammation.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n It concludes that the triple treatment “holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease”.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n \n \nThe seven Alzheimer's risk factors\n\n\n\n\n \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n \n\n \n \n \n The Alzheimer’s Society, a charity which part-funded the latest study research, said that after 15 years without a new drug for Alzheimer’s disease the promising results from these crossover treatments, which are already known to be safe for humans, are likely to bring earliest benefits.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Professor Holscher added that further tests to compare its benefits against other potential treatments, and its effects in humans were needed.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n But Professor John Hardy, a professor of neuroscience, at University College London who was not involved in the trial, said the study was “a first step, at best” towards a Alzheimer’s drug for humans.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n “The results showing less amyloid deposition of amyloid in mice treated with glucagon receptor stimulating drugs is interesting,” he said.\n \n\n \n \n \n \n \n \n “However, it should be noted that several other drugs have shown positive results in mice models of Alzheimer’s disease and then failed in human trials.”\n \n\n \n \n \n \n \n \n Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK, echoed this, but added: “There is a long road between studies that show an effect in animals and treatments in the hands of patients, and scientists will only be able to realise the potential of promising findings like these if we continue to invest in research.”"],["topImageUrl","https://static.independent.co.uk/s3fs-public/thumbnails/image/2015/04/14/21/web-alzheimers-2-alamy.jpg"],["error",null]]},{"__iterable":"Map","data":[["title","Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease"],["url","https://www.sciencedirect.com/science/article/pii/S0006899317304596"],["summary","AbstractType 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD). Previous studies have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that have anti-diabetic properties show very promising effects in animal models of AD. Glucagon (Gcg) is a hormone and growth-factor, and the Gcg receptor is expressed in the brain. Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. In the present study, the effects of the TA were evaluated in the APP/PS1 transgenic mouse model of AD. The TA was injected once-daily (10 nmol/kg i.p.) for two months. The results showed that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a spatial water maze test. Moreover, the drug reduced levels of the mitochondrial pro-apoptotic signaling molecule BAX, increased the anti-apoptotic signaling molecule Bcl-2 and enhanced the levels of BDNF, a key growth factor that protects synaptic function. Levels of synaptophysin were enhanced, demonstrating protection from synaptic loss that is observed in AD. Neurogenesis in the dentate gyrus was furthermore enhanced as shown in the increase of doublecortin positive cells. Furthermore, TA treatment reduced the total amount of β-amyloid, reduced neuroinflammation (activated microglia and astrocytes), and oxidative stress in the cortex and hippocampus. Thus, these findings show that novel TAs are a promising lead for the design of future treatment strategies in AD.Previous Next KeywordsInflammationGrowth factorBDNFBrainInsulinNeurodegeneration1. IntroductionAlzheimer’s disease (AD), is a progressive neurodegenerative disease, characterized clinically by progressive memory loss, cognitive decline, and aberrant behavior [1]. Currently, there is no treatment can improve this condition. Epidemiological studies have shown that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD) (Luchsinger et al., 2004, Ohara et al., 2011). The underlying mechanism is most likely that insulin signaling is impaired in the brains of AD patients (Moloney et al., 2010, Talbot et al., 2012). This motivated research in drugs that have shown good effects in treating diabetes to investigate if they could be helpful in treating AD as well. Previous studies have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can play a neuroprotective role in the brain and show very promising effects in animal models of AD (Duffy and Holscher, 2013, Faivre and Holscher, 2013b, Li et al., 2010, McClean et al., 2011, McClean and Holscher, 2014). Glucagon (Gcg) is a hormone and growth-factor, and the Gcg receptor is expressed in the brain (Hoosein and Gurd, 1984, Mayo et al., 2003). Activation of the receptor can activate neuronal activity and cellular Ca2+ signaling and may have neuroprotective properties (Ayush et al., 2015). Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. This novel drug has been developed as a potential treatment for diabetes (Finan et al., 2015). No studies have been published that test the neuroprotective effects of this novel drug. We therefore tested this promising TA in the APPSWE/PS1dE9 mouse model of AD. This mouse model recapitulates some of the hallmarks of AD, such as memory loss, synaptic loss, reduction of synaptic plasticity, reduction of neurogenesis in the dentate gyrus, chronic inflammation in the brain, and formation of amyloid plaques in the brain (Duffy and Holscher, 2013, Goto et al., 2008, Hamilton et al., 2011, Hamilton and Holscher, 2012, McClean et al., 2011). We tested the effects of TA in this transgenic mouse model and evaluated the neuroprotective effects. We analyzed memory formation, hippocampal neurogenesis, the expression levels of Brain Derived Neurotrophic Factor (BDNF) (Blurton-Jones et al., 2009), mitochondrial apoptosis signaling proteins, neuroinflammation and oxidative stress levels.2. Results2.1. TA-treatment improved the learning and memory impairment of APP/PS1 mice in the water mazeA two-way ANOVA found a significant difference between groups (p < 0.0001) and over time (p < 0.001). In the Morris water test, it was observed that the control mice, APP/PS1 mice and TA-treated APP/PS1 mice had a similar escape latency (P > 0.05). On day 5, the average escape distance in searching for the hidden platform in the APP/PS1 mice was significantly longer than that in the control mice (P < 0.05). Compared to the APP/PS1 group, the TA-treated APP/PS1 group’s average escape distance was decreased (P < 0.01). There was no difference in swimming speed among these three groups in training days (P > 0.05).Then on day 6, the platform was removed and the probe trail test was conducted. A one way ANOVA analysis showed an overall difference between groups. The APP/PS1 mice spent less time in the target quadrant (P < 0.01) and had fewer times passing through the original position of the hidden platform (P < 0.01), compared with control mice. In the TA-treated APP/PS1 group, the time spent in target quadrant (P < 0.05) and the frequencies to cross the platform significantly increased (P < 0.05), compared to the APP/PS1 group Fig. 1.Download high-res image (302KB)Download full-size imageFig. 1. The novel TA improved the learning ability of APP/PS1 mice in the spatial water maze task. (A) The escape latency and swimming speed in the training trails. (B) The percentage of time in target quadrant and crossing platform times in the probe trials. The circle indicates the position of the platform during acquisition (C) Representative swimming tracks of the probe trial. * = P < .05, ** = P < .01 compared to the control group, ## = P < .01, # = P < .05 compared to the APP/PS1 group; Two-way ANOVA with Bonferroni repeated measures post hoc tests.2.2. TA-treatment ameliorated amyloid plaques in the brains of APP/PS1 miceIn the immunohistochemical analysis, we analyzed the amount of amyloid plaques present in the brains of APP-PS1 mice. A one-way ANOVA found an overall difference on the amyloid deposits in the cortex (F = 31.10, P < 0.0001) and the hippocampus (F = 30.38, P < 0.0001) of mice between groups. The Aβ1-42 depositions in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased the deposition (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 2.Download high-res image (211KB)Download full-size imageFig. 2. TA treatment reduced amyloid deposits in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared to the control group; ### = P < .001 compared to the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.3. TA-treatment reduced the chronic inflammation response in the cortex and hippocampus of the APP/PS1 miceIn the immunohistochemical analysis, an anti-GFAP antibody was used as an indication of activated astrocytes. A one-way ANOVA found an overall difference on the GFAP expression in the cortex (F = 77.03, P < 0.0001) and the hippocampus (F = 86.51, P < 0.0001) of mice between groups. The levels of GFAP in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 3.Download high-res image (362KB)Download full-size imageFig. 3. TA-treatment reduced the number of GFAP positive cells in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA. Scale bar in image D: 50μm. A higher magnification image has been added to show stained astroglia. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.In the immunohistochemical analysis, an anti-IBA1 antibody was used as an indication of microglia activation. A one-way ANOVA found an overall difference on the IBA-1 expression in the cortex (F = 28.71, P < 0.0001) and the hippocampus (F = 66.42, P < 0.0001) of mice between groups. The levels of IBA-1 in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001, P < 0.01) compared to the APP/PS1 group. N = 6 per group. See Fig. 4.Download high-res image (347KB)Download full-size imageFig. 4. TA treatment reversed the increase of IBA-1 positive cells in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. A higher magnification image has been added to show stained microglia. *** = P < .001 compared to the control group; ## = P < .01, ### = P < .001 compared to the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.4. TA-treatment suppressed oxidative stress in the cortex and hippocampus of APP /PS1 miceIn the immunohistochemical analysis, 4-HNE was measured as an indicator of lipid peroxidation. A one-way ANOVA found an overall difference on the 4-HNE expression in the cortex (F = 60.60, P < 0.0001) and the hippocampus (F = 35.22, P < 0.0001) of mice between groups. The expressions of 4-HNE in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001) compared to the APP/PS1 group. N = 6 per group, see Fig. 5a.Download high-res image (397KB)Download full-size imageFig. 5. Oxidative stress was reduced by the TA. 5A. TA-treatment reduced the increase of 4-HNE levels in the cortex and hippocampus in APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared with controls; ###=P < .001 compared to the APP/PS1 group. 5B. TA treatment reduced the increase of 8-OHdG levels in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared to the control group; ## = P < .01, ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures ***post hoc tests. N = 6 per group.In the immunohistochemical analysis, 8-OHdG was measured as an indicator of DNA oxidation. A one-way ANOVN found an overall difference on the 8-OHdG expression in the cortex (F = 38.72, P < 0.0001) and the hippocampus (F = 56.60, P < 0.0001) of mice between groups. The expressions of 8-OHdG in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.01, P < 0.001) compared to the APP/PS1 group. N = 6 per group, see Fig. 5b.2.5. TA-treatment increased immature neurons in the dentate gyrus of APP/PS1 miceIn the immunohistochemical analysis, numbers of neurogenesis, assessed by doublecortin (DCX). A one-way ANOVN found an overall difference on the DCX positive cell in the dentate gyrus (F = 43.61, P < 0.0001) of mice between groups. The numbers of DCX were much reduced in the APP/PS1 mice (P < 0.001) compared to the control mice. While TA-treatment partially prevented the reduction (P < 0.001) compared to the APP/PS1 mice. N = 6 per group. See Fig. 6.Download high-res image (169KB)Download full-size imageFig. 6. TA-treatment enhanced neurogenesis and increased numbers of DCX positive cell numbers in the dentate gyrus of APP/PS1 mice. A: control group; B: APP/PS1 group; C: APP/PS1+TA group. Scale bar in image A: 100 μm. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.6. TA-treatment reversed the decrease of BDNF levels in the hippocampus of APP/PS1 miceBDNF, a key neurotrophic factor in the brain, was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 20.01, P < 0.001). The expression of BDNF in hippocampus was reduced in APP/PS1 group (P < 0.001) compared to the control group. TA-treatment reversed the decreased (P < 0.05) compared to the APP/PS1 group. N = 6 per group. See Fig. 7a.Download high-res image (304KB)Download full-size imageFig. 7. A) TA-treatment increased levels of BDNF in the hippocampus of APP/PS1 mice. *** = P < .001compared with the control group; # = P < .05 compared with the APP/PS1 group. N = 6 per group. B) TA-treatment increased levels of synaptophysin in the hippocampus of APP/PS1 mice. *** = P < .001 compared with the control group; ## = P < .01 compared with the APP/PS1 group. N = 6 per group. C) TA-treatment increased the ratio of BAX/Bcl-2 in the hippocampus of APP/PS1 mice. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.7. TA-treatment reversed the reduction of synaptophysin levelsSynaptophysin (SYN), a synaptic markers, was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 20.46, P < 0.001). The level of SYN in hippocampus was decreased in the APP/PS1 group (P < 0.001) compared to the control group. While TA-treatment prevent the reduction (P < 0.01) compared to the APP/PS1 group. N = 6 per group. See Fig. 7b.2.8. TA-treatment showed potential anti-apoptotic effects by decreasing the BAX/Bcl-2 ratio in APP/PS1 miceThe expression of apoptotic proteins, including Bcl-2 (that suppress apoptosis) and BAX (that promotes apoptosis), was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 77.64, P < 0.001). The ratio of BAX/Bcl-2 in hippocampus was increased (P < 0.001) compared to the control group. While TA-treatment partly decreased the ratio of BAX/Bcl-2 (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 7c.3. DiscussionThe results demonstrate for the first time that the novel GLP-1/GIP/Gcg receptor agonist has clear neuroprotective effects in the APP/PS1 mouse model of AD. Memory formation in the spatial water maze task was improved by the drug, and the amyloid plaque load in the cortex and hippocampus was reduced. This result confirms our previous findings that single GLP-1 or GIP analogues can protect from memory loss in this mouse model of AD (Faivre and Holscher, 2013a, Faivre and Holscher, 2013b, McClean et al., 2011, McClean and Holscher, 2014). The chronic inflammation response as seen in the activation of microglia and astrocytes is much reduced by the novel TA, similar to single GLP-1 or GIP receptor agonists (Duffy and Holscher, 2013, Ji et al., 2016a, McClean et al., 2011). Levels of the peroxidized lipid 4-HNE that also acts as a pro-apoptotic signal in mitochondria have been reduced by the TA. 4-HNE is one of the markers of membrane lipid peroxidation induced by cytotoxic radicals such as OH. 4-HNE has cytotoxic, mutagenic and genotoxic properties and 4-HNE is reported to stimulate apoptosis via caspase 3 activation and by inducing mitochondrial damage as shown in cytochrome c release (Ji et al., 2001). The levels of the mitochondrial apoptosis signal BAX (Kim et al., 2005) were also reduced. Importantly, the anti-apoptotic signaling molecule B-cell lymphoma 2 (Bcl-2) which is active in functioning mitochondria that have normal inner membrane voltage potentials (Kavitha et al., 2013) is upregulated by the TA, adding to the neuroprotective effect. The level of chronic oxidative stress as measure by the levels of the oxidized nucleotide 8-Hydroxiguanosine (8-OHdG) was also reduced by the drug. Neurogenesis in the dentate gyrus was normalized. Importantly, the levels of the key growth factor BDNF were normalized in the brain. BDNF has shown clear neuroprotective effects in a range of animal models of disease (Allen et al., 2013, Benedetti et al., 2014, Blurton-Jones et al., 2009, Nagahara et al., 2013). An important factor of BNDF activity is that it maintains synaptic activity and protects synapses from stressors (Kuipers and Bramham, 2006). The observation that the synaptic marker synaptophysin was expressed at normal levels after TA treatment also indicates that synaptic numbers and function was improved in the AD mouse. We have shown previously that GLP-1 and GIP analogues protect synapses from amyloid induced stress and keeps them functional (Faivre and Holscher, 2013b, Gault and Holscher, 2008a, Gault and Holscher, 2008b, McClean and Holscher, 2014).Recently, multiple receptor agonists have been developed to treat type II diabetes (Finan et al., 2013, Finan et al., 2015). We have tested novel dual GLP-1/GIP receptor agonists that showed good neuroprotective effects that are superior to single GLP-1 analogues (Cao et al., 2016, Jalewa et al., 2017, Ji et al., 2016b, Yuan et al., 2017). The novel dual agonist DA3-CH was found to be superior to liraglutide in a mouse model of Parkinson’s disease (Yuan et al., 2017), demonstrating that the strategy of activating more than one incretin receptor type offers an advantage over single receptor agonists. Here, we show that a novel triple receptor agonist also shows promise as a potential treatment for AD, but further dose–response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drug is superior to previous ones.GLP-1, GIP and glucagon are members of the growth factor family (Hölscher, 2016). Their respective receptors are classic 7-membrane spanning domain, G-protein coupled receptors that activate cAMP synthesis (Campbell and Drucker, 2013, Doyle and Egan, 2007, Holst et al., 2011). The activation of the second messenger cascade cAMP-PKA-CREB induces a number of cytoprotective processes, including the normalization of energy utilization, cell repair and growth-factor related gene expression (Holscher, 2014, Jalewa et al., 2016, Perry and Greig, 2004, Sharma et al., 2013). Importantly, GLP-1 and GIP also have anti-inflammatory properties. Astroglia and microglia express the receptors, and activating these reduce the inflammation response (Duffy and Holscher, 2013, Jalewa et al., 2017, Parthsarathy and Holscher, 2013, Spielman et al., 2017). Chronic inflammation is a main driver of neurodegenerative disorders, and a reduction of the inflammation in the brain shows protective effects (Akiyama et al., 2000, Clark et al., 2012, Lee et al., 2010).Based on the impressive preclinical data that demonstrate neuroprotection of such drugs, clinical trials have started that investigate the neuroprotective effects of the GLP-1 receptor agonists exendin-4 (Byetta, Bydureon®) and liraglutide (Victoza®) in patients with AD or with Parkinson disease (PD). A pilot study testing the GLP-1 analogue liraglutide in AD patients showed promising results. In a double blind, placebo controlled trial, AD patients showed no deterioration in brain activity as measured in the 18FDG-PET scan after 12 months of drug treatment. In contrast, the placebo group showed clear reductions in cortical activity as expected for this progressive neurodegenerative disease (Gejl et al., 2016). A phase II clinical trial is currently ongoing (Hölscher, 2016). A pilot trial testing exendin-4 in PD patients has shown good effects (NCT01174810). This open-label study tested the effects of exendin-4 in 45 patients. There were clear improvements in the motor coordination as shown in the MDS-UPDRS part 3 assessment, and cognition was improved as measured by the Mattis DRS-2 test battery that had been designed to evaluate cognitive impairments in PD patients (Aviles-Olmos et al., 2013). Patients were re-tested 12 months later, and the differences in motor performance and cognitive scores were still visible (Aviles-Olmos et al., 2014). A phase II double-blind, placebo controlled clinical trial that tested the once-weekly formulation of exendin-4, Bydureon®, confirmed the results of the pilot study. The drug group did not deteriorate in the MDS-UPDRS part 3 assessment after 48 weeks of treatment, and after 12 weeks of a wash-out period, the disease-modifying effect was still visible. In contrast, the placebo group deteriorated over time as would be expected in this disease (Athauda et al., 2017). In addition, a phase II trial testing liraglutide in PD patients has started, testing patients in a double blind, placebo controlled trial for one year (NCT02953665). A further clinical trial testing the GLP-1 receptor agonist Lixisenatide in PD patients is in planning.These very promising preclinical and the first clinical outcomes demonstrate the efficacy of these novel multiple receptor agonists that originally were developed to treat type II diabetes, but have shown consistent neuroprotective effects in several studies. In the present study, the novel TA improved learning and memory, reduce amyloid plaque load, chronic inflammation and oxidative stress, as well as mitochondrial stress signaling, and improved BDNF release and synaptic markers while normalising neurogenesis in the dentate gyrus. The novel triple GLP-1/GIP/Gcg receptor agonist holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease.4. Materials and methods4.1. Peptide and chemicalsThe triple GLP-1/GIP/Gcg used in this study was synthesized by China Peptides Co, Ltd. (Shanghai, China) to 95% purity. The identity and purity of the peptide was confirmed by reversed-phase HPLC and characterized using matrix assisted laser resorption/ionization time of flight (MALDI–TOF) mass spectrometry. The peptide was stored in dry form and dissolved in double-distilled water containing 0.9% NaCl2 before experiments. A Bi-cinchoninicacid (BCA) protein assay kit was purchased from Apply gen Technologies Inc. (Beijing, China). 3, 3-diaminobenzidine (DAB) was purchased from ZSGB-BIO Co. (Beijing, China). The primary antibodies recognizing Aβ1-42, IBA-1, BDNF, 4-Hydroxynonenal (4-HNE), 8-Hydroxyguanosine (8-OHdG), synaptophysin (SYN) and β-actin were obtained from Abcam (Cambridge, UK). The primary antibody GFAP, Bcl-2, and BAX were obtained from Boster Biotechnology (Wuhan, China). The primary antibody doublecortin (DCX) buy from Santa Cruz Biotechnology. HRP-labeled goat anti-rabbit immunoglobulin was obtained from Abcam (Cambridge, UK). The biotinylated goat anti-rabbit IgG, biotinylated rabbit anti-goat IgG, avidinbiotin peroxidase complex reagent was purchased from Boster Biotechnology (Wuhan, China). All other reagents used in the research were of analytical grade and of the highest quality commercially available. The peptide sequence was as follows (Finan et al., 2015):HXQGTFTSDKSKYLDERAAQDFVQWLLDGGPSSGAPPPSX = aminoisobutyric acid, K = γE-C16 acylation (with a C16 fatty acid).4.2. Animals and treatmentsAPP/PS1 transgenic mice were purchased from the Academy of Military Medical Sciences (AMMS, China), were maintained in a constant temperature (22 ± 1 °C) and humidity (relative 30%) under a 12 h light/dark cycle in animal house. As well as age-matched non-AD mice, which are wild-type animals as control. When animals were 6 months of age, TA was dissolved in saline. The dose was a once-daily injection of 10 nmol/kg body weight ip. for two months. Injections were given in the morning (8:00 am). Control mice received equal volumes of saline solution. All experimental procedures involving animals were approved by the Institutional Animal Care Committee of Shanxi Medical University and conform to the guidelines of National Institute of Health (NIH) guideline (NIH publication No. 85-23. Revised 1985). They were divided into three different groups (n = 12). (i): control group treated with saline only; (ii): APP/PS1 group treated with saline only; (iii): APP/PS1 group treated with TA. At the end of drug treatments, measurements of behavioral change, neuronal damage, oxidative stress and inflammatory markers were conducted.4.3. Morris water maze testThe water maze test is a standard method for assessing learning and memory in animals. The water maze (WM) task was performed 5 days after two months intraperitoneal injection. The apparatus was a circular, white painted pool (150 cm in diameter and 60 cm in height) which was filled to a depth of 40 cm with warm water at a temperature 23 ± 2 °C to avoid hypothermia, and was surrounded by a white curtain around the pool. The pool was divided into four quadrants with four starting locations, north (N), east (E), south (S) and west (W), the starting quadrant was randomly chosen. A perspex platform (diameter, 10 cm) was located in a specific location during the acquisition trials and submerged approximately 1.0 cm below the surface of the water. A video camera was mounted directly above the pool to record the movement and the trail of the mice. During the acquisition phase, each mouse was subjected to four consecutive training trials on each day. The mouse was gently placed in the water between the quadrants, and allowed 60 s to search the hidden platform. If it failed to find the platform within 60 s, it was guided to the platform and allowed to remain there for 10 s. Training continued for 5 days. On the sixth day, the hidden platform was removed and each mouse was allowed to swim in the pool for 60 s. The mean time spent in all four quadrants and the target area for searching the hidden platform was recorded.4.4. Brain tissue preparationHalf of the animals were decapitated after anesthetization with ethyl carbamate, hippocampus tissues were immediately isolated and stored at −80 °C for further investigations. The second half of each group was used for immunohistochemistry analysis. Animals were perfused intracardially with saline and cold 4% paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde for 24 h.4.5. ImmunohistochemistryFor DAB staining, fixed tissues were embedded in paraffin. Coronal sections (5 μm thick) of the brains were cut on a Leica microtome for immunohistochemistry. Paraffin was removed from the tissue sections with xylene, and the sections were rehydrated in graded ethanol solutions. Endogenous peroxidase activity was blocked with 3% H2O2 for 10 min at room temperature. Antigen retrieval was performed by heating in 10 mmol/L citrate buffer (pH 6.0) for 10 min. After blocked with 5% BSA, sections were incubated with the primary antibody for doublecortin (goat anti-DCX; 1:50), GFAP (rabbit anti-GFAP; 1:100), IBA-1 (goat anti-IBA1; 1:200), 4-Hydroxynonenal antibody (goat anti-4 HNE; 1:200) and anti-8 Hydroxyguanosine antibody (goat anti-8 OHdG; 1:200) at 37 °C for 2 h. For the Anti-8 OHdG histology, enzymatic antigen retrieval with 10 μm/ml proteinase K for 40 min at 37 °C was performed. To detect amyloid deposits, the primary antibody was Aβ1-42 (rabbit anti-Aβ1-42; 1:100), brain sections were pre-incubated with 70% formic acid and incubated at 4 °C for 24 h. They were rinsed in PBS and incubated with biotinylated goat anti-rabbit IgG or biotinylated rabbit anti-goat IgG at 37 °C for 0.5 h and incubated with the avidin-biotin peroxidase complex reagent at 37 °C for 0.5 h. Samples were stained in DAB solution in the presence of H2O2. All stained sections were viewed and photographed under a Zeiss light microscope, and images were captured by Motic Images Plus2.0ML software. The numbers of DCX positive neurons, the areas of Aβ1-42, GFAP, IBA-1, 4-HNE and 8-OHdG positive cells were determined using Image-pro plus6.0 software. The software counts objects that are defined in size and staining threshold by the user. This automated process avoided user bias.4.6. Western blotThe hippocampal tissues from mice was homogenized in ice cold RIPA buffer (containing 1% Triton X-100, 0.1% SDS, 1% deoxycholate) and PMSF (phenyl-methylsulfonyl fluoride). The homogenate was centrifuged 12,000 rpm/min for 5 min at 4 °C before taking the supernatant. Tissue containing 60 μg of protein was separated on 10–12% gradient Bis–Tris gel with molecular marker and electrophoresed in running buffer at 120 mV for 90 min followed by transfer to the PVDF membrane. Following protein transfer, the membrane was washed in TBST (tris buffered saline with 0.05% Tween-20, pH 8) and blocked in 5% skim milk for 1 h. Then incubated overnight at 4 °C with rabbit anti-synaptophysin (SYN) (1:10,000), rabbit anti-Bcl-2 (1:400), rabbit anti-BAX (1:400), rabbit anti-BDNF (1:5000), after three washes in TBS further incubation for 2 h at room temperature with the HRP-labeled goat anti-rabbit immunoglobulin (1:5000). In some cases, the blots were stripped and reprobed with a rabbit anti-β-actin (1:5000) to ensure equal sample loading. The bound antibodies were then visualized by ECL-enhanced chemiluminescence (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. Western blot images were captured with a chemiluminescent imaging system (Sage Creation, Beijing, China). All bands were quantified using the image system of Alpha View SA.4.7. Statistical analysisThe data were presented as the mean ± standard error of mean (S.E.M.) and analyzed by one-way or two way ANOVA followed by Bonferroni’s multiple comparison test using the software Prism 5 (Graph Pad Software Inc, La Jolla, CA, USA). Statistical significance is defined as P < 0.05.ContributorsJT, WL and YL conducted the experiments, LL and CH conceived the experiment and wrote the manuscript.AcknowledgementsThis work was funded by the Ministry of Human Resources and Social Security, Shanxi Province [(2010)255], by a Shanxi Scholarship Council of China, and supported by a grant from the Alzheimer Society UK. The authors declare no conflict of interestAppendix A. Supplementary dataReferencesAkiyama et al., 2000H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, T. Wyss-CorayInflammation and Alzheimer’s diseaseNeurobiol. Aging, 21 (2000), pp. 383-421Allen et al., 2013S.J. Allen, J.J. Watson, D.K. Shoemark, N.U. Barua, N.K. PatelGDNF, NGF and BDNF as therapeutic options for neurodegenerationPharmacol. Ther., 138 (2013), pp. 155-175Athauda et al., 2017D. Athauda, K. Maclagan, S.S. Skene, M. Bajwa-Joseph, D. Letchford, K. Chowdhury, S. Hibbert, N. Budnik, L. Zampedri, J. Dickson, Y. Li, I. Aviles-Olmos, T.T. Warner, P. Limousin, A.J. Lees, N.H. Greig, S. Tebbs, T. FoltynieExenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trialAviles-Olmos et al., 2013I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, T. Soderlund, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. FoltynieExenatide and the treatment of patients with Parkinson’s diseaseJ. Clin. Invest., 123 (2013), pp. 2730-2736Aviles-Olmos et al., 2014I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P.E. Fmedsci, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. FoltynieMotor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s diseaseJ. Parkinson’s Dis., 4 (2014), pp. 337-344Ayush et al., 2015E.A. Ayush, Y. Iwasaki, S. Iwamoto, H. Nakabayashi, M. Kakei, T. YadaGlucagon directly interacts with vagal afferent nodose ganglion neurons to induce Ca(2+) signaling via glucagon receptorsBiochem. Biophys. Res. Commun., 456 (2015), pp. 727-732Benedetti et al., 2014E. Benedetti, B. D'Angelo, L. Cristiano, E. Di Giacomo, F. Fanelli, S. Moreno, F. Cecconi, A. Fidoamore, A. Antonosante, R. Falcone, R. Ippoliti, A. Giordano, A. CiminiInvolvement of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE)Cell Cycle, 13 (2014), pp. 1335-1344Blurton-Jones et al., 2009M. Blurton-Jones, M. Kitazawa, H. Martinez-Coria, N.A. Castello, F.J. Muller, J.F. Loring, T.R. Yamasaki, W.W. Poon, K.N. Green, F.M. LaferlaNeural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProc. Natl. Acad. Sci. U.S.A., 106 (2009), pp. 13594-13599Campbell and Drucker, 2013J.E. Campbell, D.J. DruckerPharmacology, physiology, and mechanisms of incretin hormone actionCell Metab., 17 (2013), pp. 819-837Cao et al., 2016L. Cao, D. Li, P. Feng, L. Li, G. Xue, G. Li, C. HölscherA novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brainNeuroreport, 37 (2016), pp. 384-391Clark et al., 2012I. Clark, C. Atwood, R. Bowen, G. Paz-Filho, B. VisselTumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationalesPharmacol. Rev., 64 (2012), pp. 1004-1026Doyle and Egan, 2007M.E. Doyle, J.M. EganMechanisms of action of glucagon-like peptide 1 in the pancreasPharmacol. Ther., 113 (2007), pp. 546-593Duffy and Holscher, 2013A.M. Duffy, C. HolscherThe incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s diseaseNeuroscience, 228 (2013), pp. 294-300Faivre and Holscher, 2013aE. Faivre, C. HolscherD-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse modelJ. Alzheimers Dis., 35 (2013), pp. 267-283Faivre and Holscher, 2013bE. Faivre, C. HolscherNeuroprotective effects of D-Ala2GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse modelAlzheimers Res. Ther., 5 (2013), pp. 20-28Finan et al., 2013B. Finan, T. Ma, N. Ottaway, T.D. Muller, K.M. Habegger, K.M. Heppner, H. Kirchner, J. Holland, J. Hembree, C. Raver, S.H. Lockie, D.L. Smiley, V. Gelfanov, B. Yang, S. Hofmann, D. Bruemmer, D.J. Drucker, P.T. Pfluger, D. Perez-Tilve, J. Gidda, L. Vignati, L. Zhang, J.B. Hauptman, M. Lau, M. Brecheisen, S. Uhles, W. Riboulet, E. Hainaut, E. Sebokova, K. Conde-Knape, A. Konkar, R.D. DiMarchi, M.H. TschopUnimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humansSci. Transl. Med., 5 (2013), p. 209ra151Finan et al., 2015B. Finan, B. Yang, N. Ottaway, D.L. Smiley, T. Ma, C. Clemmensen, J. Chabenne, L. Zhang, K.M. Habegger, K. Fischer, J.E. Campbell, D. Sandoval, R.J. Seeley, K. Bleicher, S. Uhles, W. Riboulet, J. Funk, C. Hertel, S. Belli, E. Sebokova, K. Conde-Knape, A. Konkar, D.J. Drucker, V. Gelfanov, P.T. Pfluger, T.D. Muller, D. Perez-Tilve, R.D. DiMarchi, M.H. TschopA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodentsNat. Med., 21 (2015), pp. 27-36Gault and Holscher, 2008aV.A. Gault, C. HolscherGLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloidEur. J. Pharmacol., 587 (2008), pp. 112-117Gault and Holscher, 2008bV.A. Gault, C. HolscherProtease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloidJ. Neurophysiol., 99 (2008), pp. 1590-1595Gejl et al., 2016M. Gejl, A. Gjedde, L. Egefjord, A. Møller, S.B. Hansen, K. Vang, A.B. Rodell, H. Braendgaard, H. Gottrup, A. Schacht, N. Møller, B. Brock, J. RungbyIn Alzheimer’s disease, six-month treatment with glp-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled double-blind clinical trialFront. Aging Neurosci., 8 (2016), pp. 1-10Goto et al., 2008Y. Goto, T. Niidome, H. Hongo, A. Akaike, T. Kihara, H. SugimotoImpaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's diseaseEur. J. Pharmacol., 583 (2008), pp. 84-91Hamilton et al., 2011A. Hamilton, S. Patterson, D. Porter, V.A. Gault, C. HolscherNovel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJ. Neurosci. Res., 89 (2011), pp. 481-489Hamilton and Holscher, 2012A. Hamilton, C. HolscherThe effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's diseaseBrain Res., 1449 (2012), pp. 83-93Holscher, 2014C. HolscherInsulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseasesBiochem. Soc. Trans., 42 (2014), pp. 593-599Hölscher, 2016C. HölscherGLP-1 and GIP analogues as novel treatments for Alzheimer’s and Parkinson’s diseaseCardiovasc. Endocrinol., 5 (2016), pp. 93-98Holst et al., 2011J.J. Holst, R. Burcelin, E. NathansonNeuroprotective properties of GLP-1: theoretical and practical applicationsCurr. Med. Res. Opin., 27 (2011), pp. 547-558Hoosein and Gurd, 1984N.M. Hoosein, R.S. GurdIdentification of glucagon receptors in rat brainProc. Natl. Acad. Sci. U.S.A., 81 (1984), pp. 4368-4372Jalewa et al., 2016J. Jalewa, M.K. Sharma, C. HolscherNovel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cellsJ. Neurochem., 139 (2016), pp. 55-67Jalewa et al., 2017J. Jalewa, M. Sharma, S. Gengler, C. HölscherA novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson’s diseaseNeuropharmacology, 117 (2017), pp. 238-248Ji et al., 2001C. Ji, V. Amarnath, J.A. Pietenpol, L.J. Marnett4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c releaseChem. Res. Toxicol., 14 (2001), pp. 1090-1096Ji et al., 2016aC. Ji, G.F. Xue, G. Li, D. Li, C. HolscherNeuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's diseaseRev. Neurosci., 27 (2016), pp. 61-70Ji et al., 2016bC. Ji, G.F. Xue, C. Lijun, P. Feng, D. Li, L. Li, G. Li, C. HolscherA novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDFBrain Res., 1634 (2016), pp. 1-11Kavitha et al., 2013M. Kavitha, J. Nataraj, M.M. Essa, M.A. Memon, T. ManivasagamMangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease miceChem. Biol. Interact., 206 (2013), pp. 239-247Kim et al., 2005S.J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, C.H. McIntoshGlucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expressionJ. Biol. Chem., 280 (2005), pp. 22297-22307Kuipers and Bramham, 2006S.D. Kuipers, C.R. BramhamBrain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapyCurr. Opin. Drug Discov. Dev., 9 (2006), pp. 580-586Lee et al., 2010Y.J. Lee, S.B. Han, S.Y. Nam, K.W. Oh, J.T. HongInflammation and Alzheimer's diseaseArch. Pharm. Res., 33 (2010), pp. 1539-1556Li et al., 2010Y. Li, K. Duffy, M. Ottinger, B. Ray, J. Bailey, H. Holloway, D. Tweedie, T. Perry, M. Mattson, D. Kapogiannis, K. Sambamurti, D. Lahiri, N. GreigGLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's diseaseJ. Alzheimers Dis., 19 (2010), pp. 1205-1219Luchsinger et al., 2004J.A. Luchsinger, M.X. Tang, S. Shea, R. MayeuxHyperinsulinemia and risk of Alzheimer diseaseNeurology, 63 (2004), pp. 1187-1192Mayo et al., 2003K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, D.J. DruckerInternational Union of Pharmacology. XXXV. The glucagon receptor familyPharmacol. Rev., 55 (2003), pp. 167-194McClean et al., 2011P. McClean, V. Parthsarathy, E. Faivre, C. HölscherThe diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's diseaseJ. Neurosci., 31 (2011), pp. 6587-6594McClean and Holscher, 2014P.L. McClean, C. HolscherLixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseaseNeuropharmacology, 86C (2014), pp. 241-258Moloney et al., 2010A.M. Moloney, R.J. Griffin, S. Timmons, R. O'Connor, R. Ravid, C. O'NeillDefects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signallingNeurobiol. Aging, 31 (2010), pp. 224-243Nagahara et al., 2013A.H. Nagahara, M. Mateling, I. Kovacs, L. Wang, S. Eggert, E. Rockenstein, E.H. Koo, E. Masliah, M.H. TuszynskiEarly BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic miceJ. Neurosci., 33 (2013), pp. 15596-15602Ohara et al., 2011T. Ohara, Y. Doi, T. Ninomiya, Y. Hirakawa, J. Hata, T. Iwaki, S. Kanba, Y. KiyoharaGlucose tolerance status and risk of dementia in the community: the Hisayama studyNeurology, 77 (2011), pp. 1126-1134Parthsarathy and Holscher, 2013V. Parthsarathy, C. HolscherThe type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brainEur. J. Pharmacol., 700 (2013), pp. 42-50Perry and Greig, 2004T.A. Perry, N.H. GreigA new Alzheimer's disease interventive strategy: GLP-1Curr. Drug Targets, 5 (2004), pp. 565-571Sharma et al., 2013M. Sharma, J. Jalewa, C. HolscherNeuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to Methylglyoxal stressJ. Neurochem., 128 (2013), pp. 459-471Spielman et al., 2017L.J. Spielman, D.L. Gibson, A. KlegerisIncretin hormones regulate microglia oxidative stress, survival and expression of trophic factorsEur. J. Cell Biol., 96 (2017), pp. 240-253Talbot et al., 2012K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, A. Stucky, R.L. Fuino, K.R. Kawaguchi, A.J. Samoyedny, R.S. Wilson, Z. Arvanitakis, J.A. Schneider, B.A. Wolf, D.A. Bennett, J.Q. Trojanowski, S.E. ArnoldDemonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive declineJ. Clin. Invest., 122 (2012), pp. 1316-1338Yuan et al., 2017Z. Yuan, L. Li, P. Feng, G. Xue, C. Ji, G. Li, C. HölscherA novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease© 2017 Elsevier B.V. All rights reserved."],["topImageUrl","https://ars.els-cdn.com/content/image/1-s2.0-S0006899317X0022X-cov150h.gif"],["error",null]]}]}],["text","阿茲海默症(Alzheimer’s disease)疾病對於病人及家屬皆會帶來很大的影響，然而至目前為止，疾病的發生機轉及可能的治療方式卻仍在研究階段。《Cell Reports》日前刊登中國山西醫科大學(Shanxi Medical University)的最新發表，研究團隊表示，原先發展用來治療糖尿病的特定藥物，有機會反轉阿茲海默症的記憶喪失症狀。第二型糖尿病已知為阿茲海默症的風險因子之一，其病程會影響到胰島素的分泌，而在過去的研究中亦曾發現，這個影響人體血糖調節的荷爾蒙，其分泌不足可能與大腦的退化情形有關。本篇研究中，作者發現結合第二型糖尿病的特定藥物，可能改善數項阿茲海默症的獨特病徵。作者表示，這項研究發現，有助於未來發展阿茲海默症及其它神經退化疾病的新治療方法。\n \n新聞出處：Alzheimer's treatment: Diabetes drug holds promise for fighting disease after 'significantly reversing' memory loss《Independent》\nhttp://www.independent.co.uk/news/health/alzheimers-diabetes-drug-memory-loss-reverse-disease-treatment-degenerative-a8133681.html\n研究刊登在《Cell Reports》第1678卷第64-74頁\nhttps://www.sciencedirect.com/science/article/pii/S0006899317304596\n "],["id","AWEET-BFyCdS-nWhunGr"],["createdAt","2018-01-17T13:29:59.107Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_Pj0EHwRC4AHx_jeeEKxoaelKUOy7S7mNL8H7IVrRARM"],["name","溫和的南澳莉斯"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎發票集點王-唯一能中獎兩次的對獎機"],["url","http://cmy.tw/006RpJ"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n 歡慶年度改版狂抽免費好禮\n \n CWMoney.NET\n \n \n \n \n \n #1 in 財經\n \n \n \n \n \n \n \n \n\n 4.7, 6.4K Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n ｜雙平台全榜冠軍，用戶認證、擊敗抖音｜財務榜與熱門榜前十名常客｜Dcard、Ptt、多個社群網友熱情推薦｜用發票自動記帳集點，消費無所遁形｜超多好禮獎不完，點數加倍獎品爽拿！▼　發票集點王功能特色【快掃快對 + 自動對獎】- 掃描發票左方 QR Code， 0.5 秒迅速記帳- 開獎日自動對獎通知，絕不錯過中獎發票【雲端發票 + 愛心條碼 + 載具管理】- 支援手機條碼綁定與桌面 Widget 功能- 方便管理所有載具歸戶- 選擇想幫助的公益團體，還能捐贈發票、用愛關懷弱勢。【點數回饋 + 刮刮樂拉霸獎不完】- 每張發票都給予點數回饋- 天天掃天天送，集點還能免費抽獎- 周末限時加倍送、節慶大放送- 拉霸機、當日發票刮刮樂小遊戲【消費分析】- 能依時間地點分析常用店家、最愛品牌、消費時段與每月支出變化，掌握開支去向。- 小資、豪門都需要的究級理財術【豐盛好禮 + 點數狂飆】- 小米、Sony、7-11、名牌好禮等不定時上架- 每天都可換各式商城好禮- 也很歡迎廠商聯名，一起照顧用戶【傳統發票也不落掉 + 精準記帳】- 末3碼自助輸入快速對獎（不列入計點）- 記錄金額與備註，讓每筆消費都清清楚楚！【系統設定】- 內建不打擾用戶設定！- 可選擇開啟或關閉聲音與震動功能　　　　　　　　　　　　　　　　　　　　　　　　　　　　小資族最愛理財神器！最棒的雲端發票對獎機就在這裡。　　　　　　　如發現 APP 可改善或有更好的功能建議，請聯繫我們～若覺得 APP很棒，歡迎分享給好友，讓更多人知道唷▼ 隨時追蹤最新消息粉絲專頁：http://cmy.tw/006Q5Y LINE@：http://cmy.tw/0069o0發票集點王，給您高效率高回饋的美好生活。\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 3.00\n 20 Sep 2018\n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n 2.63\n 25 Aug 2018\n \n\n 1.修正已知問題\n\n\n \n \n \n 2.62\n 17 Aug 2018\n \n\n 1.新增主題色 2.修復已知問題\n\n\n \n \n \n 2.61\n 8 Aug 2018\n \n\n 1.修正掃描功能\n\n\n \n \n \n 2.60\n 4 Aug 2018\n \n\n 1.新增消費時間、地點、金額分析圖表功能2.新增中獎率分析3.修復已知問題\n\n\n \n \n \n 2.54\n 28 Jul 2018\n \n\n 1.修正發票數量顯示錯誤問題\n\n\n \n \n \n 2.53\n 6 Jul 2018\n \n\n 1. 優化手機條碼同步功能2. 修正發票重複出現的問題3. 感謝這段時間使用者的意見與支持，我們會努力持續優化！\n\n\n \n \n \n 2.52\n 28 Jun 2018\n \n\n 1. 修正 iPhone 5 與 5C 閃退現象2. 優化相關體驗！\n\n\n \n \n \n 2.51\n 25 Jun 2018\n \n\n - 對 iOS 新舊版本的支援更完美了！- 解決同步發票重覆顯示、部分手機閃退的問題- 優化拉霸機與大家最愛的當日發票刮刮樂- 修正用戶提出的重大問題，感謝大家長期的回饋與支持！\n\n\n \n \n \n 2.5\n 19 Jun 2018\n \n\n - 全新功能！可愛喵喵拉霸機來囉！- 全新粉紅色甜美介面登場- 掃描引擎大升級、商城顯示優化- 刮刮樂顯示速度調整，稍稍提速！- 可同時在線人數大幅提升，降低當機率- 增加頁面下拉更新資訊功能- 加大觸控範圍，按鈕更好點囉！- iOS 11 SDK 正式更新- 修正更多使用者提交的bug與建議，感謝大家讓發票集點王變得更好！\n\n\n \n \n \n 2.43\n 22 May 2018\n \n\n 1.新增馬上對獎按鈕2.修復已知問題\n\n\n \n \n \n 2.41\n 3 May 2018\n \n\n 1.手機條碼Widget小工具功能修復2.掃描中自動切換掃描引擎，增加辨識率3.修復已知臭蟲\n\n\n \n \n \n 2.40\n 20 Apr 2018\n \n\n 1.新增掃描當日發票獎勵-刮刮樂功能2.新增分享活動-分享到Line賺點數3.修復已知問題\n\n\n \n \n \n 2.32\n 12 Apr 2018\n \n\n 1.修復馬上對獎按鈕失效的問題\n\n\n \n \n \n 2.31\n 3 Apr 2018\n \n\n 1.發票掃描功能優化，提升掃瞄速度50%!!! (建議立即更新)2.改善「燒機」模式3.修正部份小臭蟲\n\n\n \n \n \n 2.30\n 31 Mar 2018\n \n\n 1.新增手動對獎功能2.新增打卡分享贈點活動3.手動收回成就訊息\n\n\n \n \n \n 2.21\n 28 Mar 2018\n \n\n 1.修正手機條碼無法綁定的問題\n\n\n \n \n \n 2.20\n 24 Mar 2018\n \n\n 1.新增開獎通知2.修正已知問題\n\n\n \n \n \n 2.10\n 17 Mar 2018\n \n\n 1.優化使用者體驗2.修正已知問題\n\n\n \n \n \n 2.01\n 10 Mar 2018\n \n\n 1.修正閃退問題\n\n\n \n \n \n 2.00\n 6 Mar 2018\n \n\n 1.新增成就功能，達成任務累積點數2.新增發票同步功能3.修正已知問題\n\n\n \n \n \n 1.91\n 14 Feb 2018\n \n\n 1.修復手動輸入發票閃退問題2.修正ios11以下版本，活動頁面跑版問題\n\n\n \n \n \n 1.90\n 11 Feb 2018\n \n\n 1.新增年節特別活動2.新增手機條碼使用說明3.新增手機條碼自動同步功能4.修正已知問題\n\n\n \n \n \n 1.81\n 27 Jan 2018\n \n\n 1.Fix Bug\n\n\n \n \n \n 1.80\n 23 Jan 2018\n \n\n 1.新增碎碎念語音功能2.優化使用者體驗3.修正已知問題\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.7 out of 5\n 6.4K Ratings\n \n \n\n \n \n \n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n\n \n\n \n\n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n \n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n\n \n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n \n\n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n \n \n\n\n\n\n \n \n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n\n \n\n \n\n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n \n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n\n \n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n \n\n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n \n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Chips Century Co., Ltd\n \n \n \n Size\n 76.3 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.0 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 偶而/輕微的模擬賭博\n \n \n \n 賭博與競賽\n \n \n Copyright\n © 2017 Money Inc\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is4-ssl.mzstatic.com/image/thumb/Purple118/v4/ac/c8/32/acc8326a-7cd4-bce8-c562-10f95b1d8cbd/AppIcon-1x_U007emarketing-85-220-0-5.png/1200x630wa.png"],["error",null]]}]}],["text","诶　你聽說了嗎? (surprise)\n免費霜淇淋+冰拿鐵...\n下載發票集點王APP\n立馬掃發票兌換！(beer)\n👉http://cmy.tw/006RpJ\n\n方法：\n1. 掃發票集點\n2. 兌換免費下午茶\n3. 每月還自動幫你對發票"],["id","1g3rnkfqsnr7k"],["createdAt","2018-05-17T05:44:41.778Z"]]},{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_raOUFJvrXmf2AaDgJBFY_mxk6goIley02YaMVYWCoe8"],["name","嚴以律已的褒忠艾倫"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎發票集點王-唯一能中獎兩次的對獎機"],["url","https://www.money.com.tw/go/invoice?referrer=ios_share"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n 歡慶年度改版狂抽免費好禮\n \n CWMoney.NET\n \n \n \n \n \n #1 in 財經\n \n \n \n \n \n \n \n \n\n 4.7, 6.4K Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n ｜雙平台全榜冠軍，用戶認證、擊敗抖音｜財務榜與熱門榜前十名常客｜Dcard、Ptt、多個社群網友熱情推薦｜用發票自動記帳集點，消費無所遁形｜超多好禮獎不完，點數加倍獎品爽拿！▼　發票集點王功能特色【快掃快對 + 自動對獎】- 掃描發票左方 QR Code， 0.5 秒迅速記帳- 開獎日自動對獎通知，絕不錯過中獎發票【雲端發票 + 愛心條碼 + 載具管理】- 支援手機條碼綁定與桌面 Widget 功能- 方便管理所有載具歸戶- 選擇想幫助的公益團體，還能捐贈發票、用愛關懷弱勢。【點數回饋 + 刮刮樂拉霸獎不完】- 每張發票都給予點數回饋- 天天掃天天送，集點還能免費抽獎- 周末限時加倍送、節慶大放送- 拉霸機、當日發票刮刮樂小遊戲【消費分析】- 能依時間地點分析常用店家、最愛品牌、消費時段與每月支出變化，掌握開支去向。- 小資、豪門都需要的究級理財術【豐盛好禮 + 點數狂飆】- 小米、Sony、7-11、名牌好禮等不定時上架- 每天都可換各式商城好禮- 也很歡迎廠商聯名，一起照顧用戶【傳統發票也不落掉 + 精準記帳】- 末3碼自助輸入快速對獎（不列入計點）- 記錄金額與備註，讓每筆消費都清清楚楚！【系統設定】- 內建不打擾用戶設定！- 可選擇開啟或關閉聲音與震動功能　　　　　　　　　　　　　　　　　　　　　　　　　　　　小資族最愛理財神器！最棒的雲端發票對獎機就在這裡。　　　　　　　如發現 APP 可改善或有更好的功能建議，請聯繫我們～若覺得 APP很棒，歡迎分享給好友，讓更多人知道唷▼ 隨時追蹤最新消息粉絲專頁：http://cmy.tw/006Q5Y LINE@：http://cmy.tw/0069o0發票集點王，給您高效率高回饋的美好生活。\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 3.00\n 20 Sep 2018\n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n 2.63\n 25 Aug 2018\n \n\n 1.修正已知問題\n\n\n \n \n \n 2.62\n 17 Aug 2018\n \n\n 1.新增主題色 2.修復已知問題\n\n\n \n \n \n 2.61\n 8 Aug 2018\n \n\n 1.修正掃描功能\n\n\n \n \n \n 2.60\n 4 Aug 2018\n \n\n 1.新增消費時間、地點、金額分析圖表功能2.新增中獎率分析3.修復已知問題\n\n\n \n \n \n 2.54\n 28 Jul 2018\n \n\n 1.修正發票數量顯示錯誤問題\n\n\n \n \n \n 2.53\n 6 Jul 2018\n \n\n 1. 優化手機條碼同步功能2. 修正發票重複出現的問題3. 感謝這段時間使用者的意見與支持，我們會努力持續優化！\n\n\n \n \n \n 2.52\n 28 Jun 2018\n \n\n 1. 修正 iPhone 5 與 5C 閃退現象2. 優化相關體驗！\n\n\n \n \n \n 2.51\n 25 Jun 2018\n \n\n - 對 iOS 新舊版本的支援更完美了！- 解決同步發票重覆顯示、部分手機閃退的問題- 優化拉霸機與大家最愛的當日發票刮刮樂- 修正用戶提出的重大問題，感謝大家長期的回饋與支持！\n\n\n \n \n \n 2.5\n 19 Jun 2018\n \n\n - 全新功能！可愛喵喵拉霸機來囉！- 全新粉紅色甜美介面登場- 掃描引擎大升級、商城顯示優化- 刮刮樂顯示速度調整，稍稍提速！- 可同時在線人數大幅提升，降低當機率- 增加頁面下拉更新資訊功能- 加大觸控範圍，按鈕更好點囉！- iOS 11 SDK 正式更新- 修正更多使用者提交的bug與建議，感謝大家讓發票集點王變得更好！\n\n\n \n \n \n 2.43\n 22 May 2018\n \n\n 1.新增馬上對獎按鈕2.修復已知問題\n\n\n \n \n \n 2.41\n 3 May 2018\n \n\n 1.手機條碼Widget小工具功能修復2.掃描中自動切換掃描引擎，增加辨識率3.修復已知臭蟲\n\n\n \n \n \n 2.40\n 20 Apr 2018\n \n\n 1.新增掃描當日發票獎勵-刮刮樂功能2.新增分享活動-分享到Line賺點數3.修復已知問題\n\n\n \n \n \n 2.32\n 12 Apr 2018\n \n\n 1.修復馬上對獎按鈕失效的問題\n\n\n \n \n \n 2.31\n 3 Apr 2018\n \n\n 1.發票掃描功能優化，提升掃瞄速度50%!!! (建議立即更新)2.改善「燒機」模式3.修正部份小臭蟲\n\n\n \n \n \n 2.30\n 31 Mar 2018\n \n\n 1.新增手動對獎功能2.新增打卡分享贈點活動3.手動收回成就訊息\n\n\n \n \n \n 2.21\n 28 Mar 2018\n \n\n 1.修正手機條碼無法綁定的問題\n\n\n \n \n \n 2.20\n 24 Mar 2018\n \n\n 1.新增開獎通知2.修正已知問題\n\n\n \n \n \n 2.10\n 17 Mar 2018\n \n\n 1.優化使用者體驗2.修正已知問題\n\n\n \n \n \n 2.01\n 10 Mar 2018\n \n\n 1.修正閃退問題\n\n\n \n \n \n 2.00\n 6 Mar 2018\n \n\n 1.新增成就功能，達成任務累積點數2.新增發票同步功能3.修正已知問題\n\n\n \n \n \n 1.91\n 14 Feb 2018\n \n\n 1.修復手動輸入發票閃退問題2.修正ios11以下版本，活動頁面跑版問題\n\n\n \n \n \n 1.90\n 11 Feb 2018\n \n\n 1.新增年節特別活動2.新增手機條碼使用說明3.新增手機條碼自動同步功能4.修正已知問題\n\n\n \n \n \n 1.81\n 27 Jan 2018\n \n\n 1.Fix Bug\n\n\n \n \n \n 1.80\n 23 Jan 2018\n \n\n 1.新增碎碎念語音功能2.優化使用者體驗3.修正已知問題\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.7 out of 5\n 6.4K Ratings\n \n \n\n \n \n \n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n\n \n\n \n\n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n \n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n\n \n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n \n\n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n \n \n\n\n\n\n \n \n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n\n \n\n \n\n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n \n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n\n \n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n \n\n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n \n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Chips Century Co., Ltd\n \n \n \n Size\n 76.3 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.0 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 偶而/輕微的模擬賭博\n \n \n \n 賭博與競賽\n \n \n Copyright\n © 2017 Money Inc\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is4-ssl.mzstatic.com/image/thumb/Purple118/v4/ac/c8/32/acc8326a-7cd4-bce8-c562-10f95b1d8cbd/AppIcon-1x_U007emarketing-85-220-0-5.png/1200x630wa.png"],["error",null]]}]}],["text","【發票集點王】\n獨樂樂不如眾樂樂, 邀請好友賺點數! 安裝最快速最好用的發票對獎App!\n到設定中\"分享賺點數\"輸入分享碼\"3VAG\", 馬上現拿500點分享紅利!\n https://www.money.com.tw/go/invoice?referrer=ios_share"],["id","3bm4a7vo4vsge"],["createdAt","2018-07-05T12:54:35.858Z"]]}]}],["relatedReplies",{"__iterable":"List","data":[{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_rTykobDDYz7U4UvNReSpG_Gf9p3ienHeSkBIB5m0HqU"],["name","守信的鳳林唐恩"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","Zoom! You are using the video conference application (mostly) developed by Chinese"],["url","https://pandayoo.com/2020/03/10/zoom/"],["summary","On March 9, 2020, the U.S. stock market ushered in a comprehensive decline. But the stock of zoom video bucked the trend and its stock price has risen 67% in the past month.\n\n\n\nThis is novel coronavirus related to some extent. As the epidemic becomes more and more serious, many companies and organizations have to start work at home, and zoom is the most important basic tool for home office.\n\n\n\nPeople use zoom to launch teleconferencing and carry out daily communication. Zoom supports the daily operation of Companies in many epidemic areas.\n\n\n\nWhat many people don’t know, however, is that most of zoom’s engineers are in China, the country heavily affected by the virus outbreak.\n\n\n\nZoom makes it clear in the “risk factors” section of its prospectus:\n\n\n\nFor example, our product development team is largely based in China, where personnel costs are less expensive than in many other jurisdictions. If we had to relocate our product development team from China to another jurisdiction, we could experience, among other things, higher operating expenses, which would adversely impact our operating margins and harm our business. In addition, we would need to spend considerable time and effort recruiting a new product development team, which would distract management and adversely impact our ability to continue improving our platform’s features and functionality.\n\n\n\nAs of January 31, 2019, Zoom’s R&D HQ in China has more than 500 employees, accounting for about 30% of its total employees. This makes the research and development cost of zoom far lower than that of similar SaaS enterprises in the United States.\n\n\n\nAccording to the information of State Administration for Industry and commerce, Zoom has two companies in China, namely Soft Video Software (Suzhou) Co., Ltd. and Soft Video Software (Hangzhou) Co., Ltd.\n\n\n\n\n\n\n\nAmong them, the highest-paid position is “system architect engineer”, with a monthly salary of between 20, 000 and 34,000 yuan, requiring more than eight years of relevant experience, according to a job posting released by Zoom’s company in Suzhou on March 4. The average pre-tax monthly salary for all posts is about 20,000 yuan.\n\n\n\nFor Zoom, having a Chinese founder and CEO seems to be more helpful in recruiting talent in China. Zoom also wrote in the prospectus:\n\n\n\nEric S. Yuan, is critical to our overall management, as well as the continued development of our products, services, the Zoom platform, our culture, our strategic direction, engineering and our operations in China.\n\n\n\nThe international version of Zoom was banned in mainland China in September last year, and users in mainland China can only use its Chinese version. It has been announced that services will be provided free of charge to users in mainland China during the epidemic.\n\n\n\nA Chinese business owner said in an interview that when users of the Chinese version of Zoom video conferencing with foreign users, the video and audio quality deteriorated significantly, accompanied by stutters and disconnections. By contrast, he prefers to communicate with foreign customers through Google Meet with VPN.\n\n\n\nIn the App Store ranking on March 7th, the first Tencent Meeting, the second was Ding Talk, and the fifth was WeChat for Work.\n\n\n\nIn China, Zoom has a strong rival, Tencent meeting, a free online conference system launched by Tencent, a Chinese social giant. On March 6, Tencent meeting topped the free app list of Apple App Store in China.\n\n\n\nIn addition, “Ding talk”, an office application developed by Alibaba, and “Lark” developed by byte skipping, also achieved high-speed growth in this epidemic. These two are not just video conferencing software, but “Slack” integrated with video conferencing function.\n\n\n\nWith the end of the winter vacation in mid-February, almost all Chinese schools began to use the Internet for classes. Most of them use “Ding Talk” because it is an enhanced version of the chat software. Teachers can manage classes through group functions, collect students’ homework, count attendance information, and generate various statistical reports-functions that were originally used for business management.\n\n\n\nThe proudest feature of Ding Talk is called “Ding”, which is a kind of push notification that gradually enhances the effect of notification over time. When you send a “Ding”, if the message is not read by the recipient for a period of time, the notification method of the message will gradually escalate: the user will initially receive a App notification, followed by a text message, then a voice call from App, and finally a phone call (dialed by Ding Talk’s call center, a machine voice will read out the message. )\n\n\n\nJapanese users describe nail as Monkey King’s tight hoop Mantra\n\n\n\nDue to the convenience of function, some schools in Japan also begin to use Ding Talk. As primary and middle school students do not want to take online classes, Ding Talk has received a large number of poor reviews in App Store in many countries, Alibaba regards it as an honor."],["topImageUrl",null],["error",null]]},{"__iterable":"Map","data":[["title","Wolfgang ʬ on Twitter: \"Everyone working remotely:\n\nZOOM monitors the activity on your computer and collects data on the programs running and captures which window you have focus on. \n\nIf you manage the calls, you can monitor what programs users on the call are running as well. It's fucked up.\" / Twitter"],["url","https://twitter.com/Ouren/status/1241398181205889024"],["summary","Everyone working remotely:\n\nZOOM monitors the activity on your computer and collects data on the programs running and captures which window you have focus on. \n\nIf you manage the calls, you can monitor what programs users on the call are running as well. It's fucked up.— \"Whether you have Zoom account or not,\" the company's privacy page states, \"we may collect Personal Data from or about you when you use or otherwise interact with our Products.\"All's you gotta do is search for \"Zoom attention monitoring\" and read their privacy policy. (Their policy is that there is no privacy)\n\nTech startups can neve be trusted. Ever.Additional information from the :I don't have a real soundcloud, but here are various links where you can buy our games, request keys, hire our services and more:\nhttp://listography.com/poppyworks\n\n(we only work on games, not infosec, sorry!)"],["topImageUrl",null],["error",null]]},{"__iterable":"Map","data":[["title","What You Should Know About Online Tools During the COVID-19 Crisis"],["url","https://www.eff.org/deeplinks/2020/03/what-you-should-know-about-online-tools-during-covid-19-crisis"],["summary","A greater portion of the world’s work, organizing, and care-giving is moving onto digital platforms and tools that facilitate connection and productivity: video conferencing, messaging apps, healthcare and educational platforms, and more. It’s important to be aware of the ways these tools may impact your digital privacy and security during the COVID-19 crisis. \nHere are a few things you should know in order to make informed decisions about what works best for you and your communities, and ways you can use security and privacy best practices to protect yourself and others.\nFree Slacks\nEFF has written a lot about Slack’s data retention issues when it comes to free versions of the software. With so many mutual aid networks and organizing groups coalescing on Slack to support our communities, it’s important that users are aware that the company retains their messages if they're using a free plan—and they can't automatically delete them. By default, Slack retains all the messages in a workspace or channel (including direct messages) for as long as the workspace exists. \nIf you are using a paid workspace, you can change how many messages are retained in Slack’s databases by setting shorter retention periods. If you’re using the free version though, that option is not available to you. Additionally, free workspace users only have the ability to search through the most recent 10,000 messages. And while users can’t see messages sent prior to the 10,000 message mark, they are still available to Slack, law enforcement, and any third-party hackers through a data breach. Leaking or sharing of this data could prove catastrophic, especially for groups who are working to provide aid and support for our most at-risk communities.\nZoom Conferencing\nThe best way to stave off the effects of isolation is to maintain contact with friends, family, and coworkers. Zoom has quickly become a popular option to work and keep in touch with others in the midst of social distancing and shelter-in-place protocols. There are a few things to keep in mind when using Zoom, particularly in instances where users are relying on the conferencing tool for their studies, or for work-related activities.\nAttendee Attention-Tracking\nThe host of a Zoom call has the capacity to monitor the activities of attendees while screen-sharing. This functionality is available in Zoom version 4.0 and higher. If attendees of a meeting do not have the Zoom video window in focus during a call where the host is screen-sharing, after 30 seconds the host can see indicators next to each participant’s name indicating that the Zoom window is not active.\nAdministrators and User Tracking\nZoom allows administrators to see detailed views on how, when, and where users are using Zoom, with detailed dashboards in real-time of user activity. Zoom also provides a ranking system of users based on total number of meeting minutes. If a user records any calls via Zoom, administrators can access the contents of that recorded call, including video, audio, transcript, and chat files, as well as access to sharing, analytics, and cloud management privileges. \nFor any meeting that has occurred or is in-process, Zoom allows administrators to see the operating system, IP address, location data, and device information of each participant. This device information includes the type of machine (PC/Mac/Linux/mobile/etc), specs on the make/model of your peripheral audiovisual devices like cameras or speakers, and names for those devices (for example, the user-configurable names given to AirPods). Administrators also have the ability to join any call at any time on their organization’s instance of Zoom, without in-the-moment consent or warning for the attendees of the call.\nSchools Moving to Online Learning\nSurveillance shouldn’t be a prerequisite for getting an education. But even before more school districts started moving their classes and coursework to digital forums for purposes of social distancing, surveillance has become more and more common in schools. With the advent of COVID-19 and the associated uptick in distributed digital learning, the potential for this surveillance to ramp up is alarming. \nThis is true from kindergarten all the way through graduate school, though it is most prevalent and insidious in K-12 schools. School administrators are choosing to use tools and tactics that encroach on students’ privacy in ways that can break down trust amongst students and their peers, teachers, families, and administrators. Many K-12 schools offer or mandate the use of school-issued devices, and those devices come with pre-installed spyware that monitors all student activities and reports them to school administrators.\nMany schools are already experimenting with mass surveillance technologies with no evidence, and no way for concerned parents and students to opt out. If your school is using or is considering using technologies like Bark, GoGuardian, Gaggle, Securly, or Social Sentinel, check out our guide to Privacy for Students. It covers many of the privacy and surveillance concerns that these technologies raise, with ways to minimize the data being tracked, risk mitigation strategies, and advocacy tactics.\nTelehealth and Non-HIPAA Platforms\nThe HHS has altered HIPAA rules during the COVID-19 crisis, allowing health care providers to use applications such as FaceTime, Facebook Messenger, Hangouts, Skype, Zoom, etc so they are able to provide care to patients remotely:\nDuring the COVID-19 national emergency, which also constitutes a nationwide public health emergency, covered health care providers subject to the HIPAA Rules may seek to communicate with patients, and provide telehealth services, through remote communications technologies. Some of these technologies, and the manner in which they are used by HIPAA covered health care providers, may not fully comply with the requirements of the HIPAA Rules.\n\nIf your healthcare provider is using an application or platform that is not covered under HIPAA, check with them on what safeguards they have in place to ensure your privacy is protected, and what their plans and timelines are for moving to platforms that do fall under HIPAA compliance.\nTools for Assessing Risk and Staying Safe Online\nOne of the best things you can do to keep yourself and others safe during this crisis is to learn how to minimize risk. Many of the problems presented in this post can be mitigated or circumvented with careful consideration of the risks, employing “privacy as a team sport” tactics, and minimizing the data that corporations, employers, and others can track. Our resource site, Surveillance Self-Defense, is full of practical tips, tools, how-to’s, and explainers for communicating safely online. Here’s a list of useful guides with concrete steps you can take to get started:\n\nEvaluate and choose the tools you use to make sure they work for you.\nLearn about best practices for communicating with others and incorporate them into your routines and tools.\nUse a password manager to create strong passwords.\nEnsure that you have two-factor authentication (also known as 2FA) enabled for as many accounts as possible.\nConsider your needs and choose the VPN that’s right for you.\n\nAnd lastly, remember—we’re all in this together. Take care of each other by safeguarding each others’ physical and digital health."],["topImageUrl",null],["error",null]]}]}],["text","最近大紅的 ZOOM 繼「透過大量僱用中國工程師大幅降低成本」後\nhttps://pandayoo.com/2020/03/10/zoom/\n現在又被發現會收集與會者電腦上正在執行的「其它程式」跟視窗切換的紀錄，並回報雲端\nhttps://twitter.com/Ouren/status/1241398181205889024\n\n不行我覺得太噁心了，無論是企業風格跟程式的設計思路的都讓人作嘔\n\n以後不會再用他，也會盡量不參與任何使用 zoom 開啟的會議，盡量用其他程式替代（Ex: google meet, jitsi meet）\n\n歡迎參考 EFF 電子前線基金會的報告：https://www.eff.org/deeplinks/2020/03/what-you-should-know-about-online-tools-during-covid-19-crisis"],["id","2jz0pw77he53s"],["createdAt","2020-03-25T03:11:10.899Z"]]}],["reply",{"__iterable":"Map","data":[["id","egczFnEBrhVJn3LNn83u"],["user",{"__iterable":"Map","data":[["id","HkXxOXABHjv_5zI2Qlbz"],["name","Ann"],["avatarUrl",null],["level",16]]}],["type","NOT_RUMOR"],["text","1.zoom提供了「注意力追蹤」（attention tracking）功能（聊天室管理員可以停用/啟用），能夠追蹤聊天室成員是否在zoom以外的視窗點擊、縮放，若參與者未聚焦在zoom視窗超過半分鐘，便會在名字旁顯示「時鐘圖式」。\n2.澳大利亞《金融評論報》指出2019年Zoom曾爆出嚴重資安問題，包括駭客可能利用程式漏洞，在用戶未允許下強制視訊通話等，如今隱私問題再度引發關注。由於用戶僅須透過「點擊連結」即可加入Zoom會議，等同Zoom在沒有提供「共享條款」、沒有徵得與會者同意或未正確告知他們的狀態下，收集了許多隱私數據，包括：cookie、工作訊息、地址、電話規格等。"],["reference","使用Zoom進行會議和通話，這應該是您該注意的隱私問題 If You’re Using Zoom for Meetings and Calls, These Should Be Your Privacy Concerns\nhttps://www.insidehook.com/daily_brief/tech/zoom-privacy-concerns\n\n居家辦公？Zoom將告訴老闆你是否專注在會議程式 Working From Home? Zoom Tells Your Boss If You're Not Paying Attention\nhttps://www.vice.com/en_us/article/qjdnmm/working-from-home-zoom-tells-your-boss-if-youre-not-paying-attention\n\nZoom的隱私風險 The trouble with Zoom\nhttps://www.afr.com/technology/zoom-is-the-next-privacy-challenge-20200324-p54dff\n\n【Zoom】與會者注意力追蹤功能\nhttps://support.zoom.us/hc/en-us/articles/115000538083-Attendee-attention-tracking\n\n【Zoom Blog】Zoom Tips For Educators: Attendee Attention Tracking\nhttps://blog.zoom.us/wordpress/2018/01/26/zoom-tips-for-educators-attendee-attention-tracking/\n\n矽谷企業的東方秘密武器是「中國工程師」：薪水只要三分之一，加班配合度高無怨言\nhttps://buzzorange.com/techorange/2019/10/17/engineer-in-china/\n\n駭客可能使用Zoom控制Mac視訊鏡頭 Hackers can hijack your Mac webcam with Zoom. Here’s how to prevent it.（2019.07.11）\nhttps://www.vox.com/recode/2019/7/9/20687689/zoom-mac-vulnerability-medium-jonathan-leitschuh-camera"],["hyperlinks",null],["createdAt","2020-03-26T09:36:54.266Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_1pI4sPMubeGfSifN1GEyPRwt2GYYgd2y3Rc1CKi_Ht8"],["name","坐懷不亂的二崙金百莉"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Download the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","3tzjka74yu4q3"],["createdAt","2020-02-20T14:17:06.630Z"]]}],["reply",{"__iterable":"Map","data":[["id","qEhCY3ABHjv_5zI2nlaI"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","NOT_ARTICLE"],["text","這是app活動廣告"],["reference",""],["hyperlinks",null],["createdAt","2020-02-20T15:41:15.276Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",3],["user",{"__iterable":"Map","data":[["id","j4S8C_YhMeMo1VPxLp00MgoGM7c2NgL0De7zuTuBRvfzxAEU0"],["name","反應快的龍井阿爾娃"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title",""],["url","https://sg.newsrepublic.net/s/SyvcUppQvR"],["summary",""],["topImageUrl",null],["error","UNKNOWN_UNFURL_ERROR"]]},{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Check out what I found on News Republic:\nhttps://sg.newsrepublic.net/s/SyvcUppQvR\nDownload the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","2xcajysgnzsgg"],["createdAt","2020-07-22T06:30:01.580Z"]]}],["reply",{"__iterable":"Map","data":[["id","v-WUvHMBb3SlMKoA2MO1"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","RUMOR"],["text","政務委員唐鳳說，健保卡不能存放跟醫療無關的紀錄，但是健保卡買三倍券就像報稅，沒有存放報稅紀錄，只是讀取。超商類似終端機角色，就像去網咖用讀卡機一樣，在超商繳地價稅跟綜所稅，也都跟健保署有同樣的連線。"],["reference","https://buzzorange.com/techorange/2020/06/03/coupon-security-concern/"],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","健保卡領「三倍振興券」有資安疑慮？唐鳳：去超商領券跟去網咖上網一樣 | TechOrange"],["url","https://buzzorange.com/techorange/2020/06/03/coupon-security-concern/"],["summary","【為什麼我們挑選這篇文章】疫情後，為了加速國內經濟復甦，行政院公佈「振興三倍券」，讓民眾花 1000 即買到 3000 元的商品，從 7/1 開始預購或綁定， 7/15 開始消費。\n「三倍券」購買的配套措施包含使用「口罩 3.0」超商健保卡預購的方式，有民眾質疑，是否有違法疑慮？（責任編輯：鍾佳瑀）\n民眾黨質疑用健保卡買振興三倍券不是醫療使用，有違法疑慮。政務委員唐鳳今天說，健保卡不能存放跟醫療無關的紀錄，但是健保卡買三倍券就像報稅，沒有存放報稅紀錄，只是讀取。\n用健保卡領券，觸及醫療個資外洩？\n行政院長蘇貞昌昨天宣布將推出「振興三倍券」，每人支付 1000 元換 3000 元三倍券，2300 萬國民加上 15 萬名有居留權的配偶都能領，不限年齡。從 7 月 15 日起使用至 12 月 31 日止。\n不過，民眾黨立委蔡壁如昨天質疑行政院授權超商接受健保卡購買振興三倍券，並不符合任何醫療使用目的，也與醫療服務內容無關，政院有帶頭違反健保法之嫌，且民眾有資安風險疑慮。\n編按：三倍券領取方式比照口罩 3.0 模式，可到超商將健保卡插入機台領取。此外，也開放使用悠遊卡、iCash、LINE Pay Money、街口支付綁定。廣告\n唐鳳：只是讀取驗證，不會存放數據\n對此唐鳳上午接受廣播節目「周玉蔻嗆新聞」訪問時表示，健保法是規定健保卡不能存放跟醫療無關的紀錄，但是像健保卡用來報稅，就沒有存放報稅紀錄，只是讀取。\n唐鳳表示，只要是跟健保署合作的公共服務，包含向財政部報稅、跟衛福部買口罩，或是現在的購買三倍券，超商就是提供讀卡機跟螢幕而已，只是確保沒有重複發放，超商並非服務主體。\n她說，購買紙本三倍券以健保卡為主，是因為 14 歲以下不一定有身分證。廣告\n對於個資是否會有外洩的問題，唐鳳說明，「個資只要不收集，就沒有外洩的問題」，超商只准許顯示前兩碼與後一碼，用於確認健保卡，但是身分證字號這些都不會存入超商；超商類似終端機角色，就像去網咖用讀卡機一樣，在超商繳地價稅跟綜所稅，也都跟健保署有同樣的連線，「我想沒有問題」。\n健保卡資安問題很重要，連券序號都要保密\n唐鳳說，台權會先前提醒，店員搞不好會抄下三倍券序號，跟別的商家比對消費紀錄，因此現在三倍券有信封遮住序號，屆時她想連信封一起捐給台權會。\n唐鳳表示，若有個資外洩問題當然是政府負責。這次實體券通路包含郵局，健保卡的資安在郵局很重要，因此需要比較久的時間來進行更多測試。\n編按：台灣人權促進會（台權會）為民間組織，主要調查國家是否侵害人民基本權利案件。\n（本文經中央社授權轉載，並同意 TechOrange 編寫導讀與修訂標題，原文標題為〈振興政策／唐鳳：健保卡買三倍券像報稅只讀取不存放紀錄〉。首圖來源：中央社）\n你可能有興趣\n◊ 【實名制 3.0】工程師搞出超強口罩數位化新招，可任選網購或持健保卡超商預購 \n◊ 【到底要不要讀卡機？】5 種科技報稅，今年做到使用「生物辨識」手段 \n◊ 【腦波控制？】日本嘻哈樂團新歌 feat. 唐鳳，連 MV 都用 AI 做 \n全方位掌握消費者數位軌跡\nAI 如何有效提升電商業績、降低導入成本？\n《領取白皮書》點關鍵字看更多相關文章：三倍券健保卡唐鳳振興三倍券資安超商"],["topImageUrl",null],["error",null]]}]}],["createdAt","2020-08-05T03:05:38.246Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",3],["user",{"__iterable":"Map","data":[["id","j4S8C_LpXJiXfGMLmoGeWcMzhjQB-TXKK0zF0keV9gnlp6ekY"],["name","忠誠的水林紐曼"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title",null],["url","http://sg.newsrepublic.net/s/UFhdmQed"],["summary",null],["topImageUrl",null],["error","UNKNOWN_SCRAP_ERROR"]]},{"__iterable":"Map","data":[["title","‎News Republic-World News,Video"],["url","http://va.newsrepublic.net/s/kyZrTd"],["summary","News beyond the headlines, News Republic gives you all the stories you’ve ever wanted in just one place. We provide you with the very best news from all the world’s top sources. Personalized and easy to use, News Republic gives you a customized news feed based on your interests. From Trump to the latest celebrity gossip to the funniest viral videos, get what’s trending right now before anyone else with News Republic. Always be the first to know! \n\nSpecial Reports:\nGet in-depth analysis on top stories with articles hand-picked by our experts.\n\nStay Informed:\nGet the very latest updates on the hottest global stories as they happen.\n\nNews You Can Trust:\nGet your news from the most recognized media outlets in the world.\n\nNews Made For You:\nOnly get the news you really want with our highly personalized “Home” screen.\n\nAmazing Videos:\nWatch top news and see what’s trending with our optimized video experience.\n\nEveryone has a dream: Do not be isolated from the world! Just keep this little news App on your phone and read news in your free time. Let you keep pace with the world!\n\n\n \n\n\n \n \n \n \n\n \n \n \n \n \n Jul 15, 2019Version 9.5.1\n \n \n \n \n\n \"Check out our new interface!\nFeature optimized including feedback and profile sections\"\n\n\n \n\n\n\n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.6 out of 5\n 4.6K Ratings\n \n \n\n\n \n \n \n\n\n \n \n\n\n\n\n\n I enjoy it Mostly\n\n\n \n\n I do find myself browsing through the headlines quite often, mainly to kill time. I find a lot of the articles hard to believe, and although they are captivating or interesting to read, they seem to be fake news. Now this could be credited to my choice or feeds and news providers it shows me specifically, I'm not sure. But I would recommend the application definitely.\n\n \n\n\n \n\n\n \n\n \n\n Hi, dear user! Sorry for unpleasant experience that may cause. Could you please send us the link of the content you're having issues with? You can do that by clicking \"Me\"-\"Feedback\" button in the app. We'll get on it as soon as we receive them. Thanks for your feedback! Have a nice day! ☀️\n\n \n\n\n \n\n\n \n\n \n \n \n\n\n \n \n\n\n\n\n\n Don’t waist your time\n\n\n \n\n Completely junk app that doesn’t work properly half the time (can’t view or send comments, stories won’t open, says I’m not connected to the internet when I’m on WiFi or regular data and it makes the volume on my iPhone go up and down as I attempt to browse stories. Not to mention the horrible propaganda, so much bs it’s ridiculous. Just look at the crazy headlines on the App Store pictures. Fn disgusting.\n\nEdit: Now at this point they give me nothing but sports news when I NEVER search for sports. I have blocked the sports news providers and they still give me the same stories I blocked. Also a good 80% of the time it tells me no new news, I have followed numerous providers so I know that is bs. YOUR TRASH APP IS BROKEN... FIX IT. Never mind you just got deleted off my phone.\n\n\n \n\n\n \n\n\n \n\n \n\n Hello. Thanks for your feedback and sorry for the unpleasant experience. Would you please send us more information and a screenshot about your problem through the feedback via “Me”---\"Feedback\"? Our support team will analyze your problem asap and fix the necessary functions for you. Thank you in advance!\n\n \n\n\n \n\n\n \n\n \n\n \n \n \n\n\n\n\n \n \n Information\n \n \n Seller\n \n News Republic\n \n \n \n Size\n 144.8 MB\n \n \n \n Compatibility\n \n\n Requires iOS 9.0 or later. Compatible with iPhone, iPad, and iPod touch.\n\n \n\n\n\n \n \n Languages\n \n\n English, Arabic, Bulgarian, Croatian, Czech, Danish, Dutch, French, German, Hindi, Hungarian, Indonesian, Italian, Japanese, Korean, Malay, Norwegian Nynorsk, Polish, Portuguese, Romanian, Russian, Serbian, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Thai, Traditional Chinese, Turkish, Vietnamese\n\n \n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this app.\n \n \n \n Unrestricted Web Access\n \n \n \n Infrequent/Mild Realistic Violence\n \n \n Copyright\n © News Republic\n \n \n Price\n Free\n \n\n \n \n \n \n\n\n\n \n \n App Support\n \n \n Privacy Policy\n \n \n\n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n With Family Sharing set up, up to six family members can use this app."],["topImageUrl",null],["error",null]]}]}],["text","Check out what I found on News Republic:\nhttp://sg.newsrepublic.net/s/UFhdmQed\nDownload the news app that has it all. 👇🏻👇🏻👇🏻👇🏻👇🏻👇🏻\nhttp://va.newsrepublic.net/s/kyZrTd"],["id","1uinlucs2ey4c"],["createdAt","2019-09-14T10:19:28.723Z"]]}],["reply",{"__iterable":"Map","data":[["id","LduNgm0BqwaEkHKwxy3_"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","NOT_RUMOR"],["text","和葡萄柚、蔓越莓一起服用的藥物，其濃度有可能會在病人的體內過高，而導致藥物中毒。（如：抗凝血藥物的濃度過高，可能會導致異常的出血）\n以目前的情況來說，柚子導致影響效用的結論可能無法完全肯定，不過不吃柚子不是什麼難事，建議還是遵照藥品的指示。"],["reference","http://pansci.asia/archives/85929\n吃柚子可能會中風嗎？\n\nhttp://www.rumtoast.com/5853/柚子＋藥等於服毒-？吃柚禁忌還有這款喔？\n柚子＋藥等於服毒？吃柚禁忌"],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","吃柚子可能會中風嗎？——藥物和食物的交互作用 - PanSci 泛科學"],["url","http://pansci.asia/archives/85929"],["summary","在國外，曾有服用抗凝血劑的病人，只因為喝蔓越莓汁和吃抗凝血劑，數週後卻死於腸胃道和心室大量出血。這究竟是怎麼一回事呢？\n藥物和食物的交互作用\n人體有許多酵素會和藥物作用，有些負責代謝、分解藥物，降低它的毒性；有些則是增強、提升藥物的療效。其中最為人熟知的酵素是細胞色素P450（cytochrome P450, CYP），此酵素會代謝許多的藥物，以臨床上用來防止血栓形成的抗凝血劑－－香豆素（warfarin）為例，香豆素會影響維他命K（vitamin K）的轉化，降低凝血的能力。而細胞色素 P450能將香豆素代謝排出體外，以避免香豆素在體內留存過久，過度延長藥物作用而導致藥物中毒。\n\t\t\t\t\t\n\t\t\t\t\t\n再介紹一個有意思的蛋白質，P-醣蛋白（p-glycoprotein, P-gp）。癌細胞上的P-醣蛋白大家已經耳熟能詳，是讓癌細胞獲得抗藥性的小惡魔之一。但在小腸細胞膜上P-醣蛋白的任務，是將已被腸壁細胞吸收的藥物吐回小腸中。以抗排斥用藥環孢靈（cyclosporine）和普樂可復（tacrolimus）為例，腸壁細胞的P-醣蛋白會將部分藥物排回腸道內，避免過多的藥物進入全身循環，引起過高的藥物濃度而導致藥物中毒。\n記住前情題要的兩位主角，細胞色素P450和P-醣蛋白，我們繼續再看下去。\n小腸壁細胞的P450和P-gp作用圖。作者自己畫的\n那麼葡萄柚、蔓越莓這些好吃的水果又怎麼變成兇手了呢？原因在於這些水果含有furanocoumarins一族的化合物，此類化合物會抑制小腸壁細胞內的細胞色素P450，減緩藥物的代謝，而同時furanocoumarins化合物同時也會抑制P-醣蛋白，使得藥物能夠突破腸壁，敞開大門地進入體內循環。「分解、排出」這兩道手續同時被抑制，因此和葡萄柚、蔓越莓一起服用的藥物，其濃度有可能會在病人的體內過高，而導致藥物中毒。（如：抗凝血藥物的濃度過高，可能會導致異常的出血）\n柚子和藥物也會有不良的交互作用嗎？\n網路上有張照片，鏡頭裡的婦人上臂瘀青，起因據稱是同時服用抗凝血劑香豆素和中秋節常見的水果－柚子。這是真的嗎？筆者決定查詢是否有臨床案例的報告，結果遍尋不著香豆素和柚子（大白柚，Pomelo）的臨床案例，但仍搜尋到許多藥物和柚子之間，會產生交互作用的臨床案例及研究，顯示柚子和藥物一起食用，「有可能」會對病人服藥結果有不良影響，仍需謹慎視之。內容簡附於下表，詳情請爬文相關文獻\n\n\n\n水果\n藥物\n簡述\n文獻\n\n\n大白柚\n抗排斥藥（cyclosporine）\n健康的人體試驗\nClinical Pharmacology & Therapeutics, 2006, 79, 255\n\n\n大白柚\n抗排斥藥（tacrolimus）\n大鼠實驗\nDrug Metabolism and Pharmacokinetics, 2011, 27, 242\n\n\n蔓越莓\n抗凝血劑（warfarin）\n臨床案例。案例死亡\nThe BMJ, 2003, 327, 1454\n\n\n蔓越莓\n抗凝血劑（warfarin）\n臨床案例\nClinical Therapeutics, 2007, 29, 1730-1735\n\n\n葡萄柚\n心臟用藥（cilostazol）和阿斯匹靈（aspirin）\n臨床案例\nJournal of Clinical Pharmacy and Therapeutics, 2007, 32, 457\n\n\n\n\n寫到最後，筆者有兩點結論\n1.柚子和某些藥物一起食用，「有可能」會對病人有不良的結果。\n2.任何關於健康的網路資訊，都值得進一步查詢。包含本篇文章。如有疑慮，強烈建議連繫醫藥專業人員作進一步的諮詢。\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\n最後附上美國食品藥物管理署（U.S. Food and Drug Administration, FDA）官網所寫的資料，那幾類的藥物跟葡萄柚一起吃，可能會有不良的交互作用：\n\n某些降膽固醇用藥，如：辛伐他汀（Zocor, simvastatin)、立普妥（Lipitor, atorvastatin）和普伐他汀（Pravachol, pravastatin）\n某些降血壓藥用，如：硝苯地平（Nifediac, Afeditab）\n某些抗排斥用藥，如：新體睦軟（Sandimmune, Neoral）\n某些抗焦慮用藥，如：丁螺環酮（BuSpar, buspirone）\n某些治療心律不整用藥，如：臟得樂（Cordarone, Nexterone）\n某些抗過敏、發炎用藥，如：艾來（Allegra, fexofenadine）\n\n寫在文末\n「柚子最好不要跟某些藥一起吃」，這個知識有多少人知道呢？此篇之前，筆者和身為醫檢師的好友都僅知道葡萄柚在國外有數起藥物中毒的案例，但卻不知道在台灣比較常見的柚子也有類似的爭議。（藥害救濟基金會的官方網頁也有提出此訊息，連結請見參考文獻）\n有點無奈，台灣的科學研究是很優秀的，而民眾對於科學的知識接受度也很高，那為什麼這麼貼近日常生活的健康知識，卻不能夠普及到廣大的民眾？中間的知識傳播落差，要交給誰來補足呢？\n但也有可能只有筆者和醫檢師好友不知道這個知識而已，希望是這樣。\n\n本文感謝衛生福利部台東醫院檢驗科張昱維（Yu-Wei Chang）協助。\n\n參考文獻\n\nEgashira K, Sasaki H, Higuchi S, Ieiri I. (2011) Food-drug Interaction of Tacrolimus with Pomelo, Ginger, and Turmeric Juice in Rats, Drug Metabolism and Pharmacokinetics, 27, 242-247\nGrenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. (2006) Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans, Clinical Pharmacology & Therapeutics, 79, 255-262\nKanoko Egashira, Hisakazu Ohtani, Suwako Itoh, Noriko Koyabu, Masayuki Tsujimoto, Hideyasu Murakami, and Yasufumi Sawada (2004) Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein, Drug Metabolism and Disposition, 32, 828-833\nChristine H. Paeng, Michael Sprague and Cynthia A. Jackevicius (2007) Interaction Between Warfarin and Cranberry Juice, Clinical Therapeutics, 29, 1730-1735\nMunir Pirmohamed (2013) Drug-grapefruit juice interactions, The BMJ, 346, DOI: 10.1136/bmj.f1\nRafe Suvarna, Munir Pirmohamed, Leigh Henderson (2003) Possible interaction between warfarin and cranberry juice, The BMJ, 327, 1454\nYing-Ku Lin, Ming-Thau Sheu, Chia-Hui Huang, and Hsiu-O Ho (2009) Development of a Reversed-Phase High-Performance Liquid Chromatographic Method for Analyzing Furanocoumarin Components in Citrus Fruit Juices and Chinese Herbal Medicines, Journal of Chromatographic Science, 47, 211-215\nTaniguchi, H. Ohtani, T. Ikemoto, A. Miki, S. Hori and Y. Sawada (2007) Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice, Journal of Clinical Pharmacy and Therapeutics, 32, 457\n黃宗賢，葡萄柚汁之藥物交互作用，藥學雜誌，第97期\n「柚」到中秋分外甜注意藥食交互作用。財團法人藥害救濟基金會官方網頁。 http://www.tdrf.org.tw/ch/05knows/kno_02_main.asp?bull_id=5275\nGrapefruit Juice and Medicine May Not Mix. 美國FDA官方網頁。 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm292276.htm\n\n\n\n您最近是不是也有以下的感受？\n1.各類議題中的科學及專業知識日益複雜，想懂實在太難。\n2.資訊爆炸、真假難辨、覺得無所適從，甚至想不聽不看。\n3.擔心身邊的人受偽科學與謠言所誤，但不知道該怎麼辦。\n這時候你需要「科學思辨力」幫助你，建立自己的邏輯、跨過複雜議題討論的門檻、提升資訊選擇、處理與溝通的能力。\n用 12 堂課讓你成為更能面對未來變化的公民吧！早鳥優惠只到10/2 ，還不快手刀購買！\n課程內容詳見：《科學思辨力》"],["topImageUrl","https://pansci.asia/wp-content/uploads/2015/09/6f1da0734b7efade0844dea672023201.jpg"],["error",null]]},{"__iterable":"Map","data":[["title","柚子＋藥等於服毒-？吃柚禁忌還有這款喔？是真的嗎?"],["url","http://www.rumtoast.com/5853/柚子＋藥等於服毒-？吃柚禁忌還有這款喔？"],["summary","謠言這樣說：最近正式文旦產季，柚子類的謠言也是很不少呢！最知名的就是這則「柚子＋藥等於服毒？」的謠言，謠言是這樣說的，「原來柚子含有一種特殊的酶，這種酶能與很多藥物結合，使藥物迅速進入血液，加強藥物的作用。把柚子汁和一些降膽固醇藥一起服用，既能增強藥物降膽固醇的作用，又能導致肌肉萎縮。與降血壓藥物同用，則會導致低血壓和肌肉萎縮…。」謠言其實還沒結束，後面還很長，不過今天要破解的重點已經講到了，究竟吃柚禁忌是什麼呢？破解關鍵點：吃柚禁忌之柚子＋藥等於服毒？\n根據調查，食藥署的確是有提醒民眾，包括柚子、葡萄柚跟某些藥物合併使用，會增加藥物不良反應的機率，像是某些降血壓藥、statin類降血脂藥、抗心律不整藥、免疫抑制劑，所以如果有在服用以上藥物的民眾，食藥署建議最好別吃太多柚子，淺嚐就好。\n柚子跟某些藥物不合～連食藥署都已經提醒了！\n咱們不廢話～直接看食藥署的原文。「衛生福利部食品藥物管理署(簡稱:食藥署)提醒民眾，柚子跟葡萄柚與某些藥物併用，可能增加藥物不良反應(風險)發生之機率，例如某些降血壓藥、statin類降血脂藥、抗心律不整藥、免疫抑制劑等(常見成分如附件)，故建議正在服藥之民眾，可應景淺嚐幾瓣無妨，但切勿大量食用，如有交互作用之疑問，可諮詢藥師，以避免不良反應之發生。\n柚子和葡萄柚一樣都富含「呋喃香豆素(furanocoumarin)」成分，該成分會不可逆地抑制小腸及肝臟中的代謝酵素CYP450 3A4，由於許多藥物皆由該酵素代謝，所以可能導致藥物血中濃度升高之情形，而增加發生不良反應(毒性)之機率，且特別注意的是，其抑制藥物代謝的作用可長達數小時甚至兩三天，即使間隔服藥也無法完全避免。\n食藥署建議正在服藥之民眾，應儘量避免食用該類水果，如欲食用，淺嚐幾瓣即可，切勿大量食用，或是於食用前，詳閱藥品仿單(說明書)或諮詢藥師，確認是否有藥物交互作用之風險，服藥期間若有不尋常的症狀亦應立即就醫。」\n所以看起來有在服用上述提到藥物的民眾們，真的要十分注意啊。不過呢，在調查的過程中，約翰走鹿另外發現「財團法人藥害救濟基金會」也有相關的報導，但內容卻有些出入。\n財團法人藥害救濟基金會與食藥署的說法大部分都相同，但藥害救濟基金會卻也提到，目前是以葡萄柚與藥物的交互作用作為主要研究，柚子的研究文獻並不多，但因為柚子與葡萄柚的成分雷同，且有部分研究也顯示柚子有提高藥物血中濃度的現象出現，美國家庭醫學也還是建議，服藥期間最好避免吃柚子或葡萄柚。\n可能與柚子、葡萄柚會產生交互影響的藥物。（圖翻攝財團法人藥害救濟基金會）\n柚子導致藥物過量？醫學教授持不同觀點\n但約翰走鹿另外也發現，在擔任過多所醫學院教授的林慶順教授所架設的「科學的養生保健」網站中有著不同觀點，林教授提到新聞報導說，有婦人因為吃柚子又服藥導致中風癱瘓，所以林教授決定深入調查。\n林慶順教授發現，曾經有團隊在1991年時研究過柚子是否會造成藥物過量的現象，但20多年來卻只有8個嚴重不良的案例發生，但都不是中風或死亡，而且並沒有辦法直接證實柚子跟西藥過量有直接關係。林教授也發現2016年時有篇醫學研究報告得出了一個結論，「葡萄柚汁並不應該是服用他汀類藥物的禁忌。」這只是許多認為柚子不會導致藥物過量報告中的其中一篇。\n所以～寫了那麼落落長，還是沒得出一個結論嗎？約翰走鹿認為，以目前的情況來說，柚子導致藥物過量的結論可能無法完全肯定，不過不吃柚子、葡萄柚其實對各位的人生也不會有什麼影響，但藥物過量卻可能讓各位GG，就連持不同觀點的林慶順教授也說，不吃柚子不是什麼難事，建議還是遵照藥品的指示，避免吃柚子或喝柚子汁囉。\n文旦、柚子的報告也是有一些的～\n【柚子跟文旦哪裡不一樣？麻豆、鶴岡文旦哪個強？】\n\n【文旦等級怎麼分？越小顆真的越好嗎？來聽柚農怎麼說！】\n\n\n\n\n假好心or真有其事的社會吐司(2016年4月18日)"],["topImageUrl","http://www.rumtoast.com/wp-content/uploads/2016/08/18762085684_dc7892efaa_z169.jpg"],["error",null]]}]}],["createdAt","2019-09-30T14:23:12.900Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",4],["user",{"__iterable":"Map","data":[["id","j4S8C_gooTjXnlbjEIA9pYAgP4mA6F_DyPCORZZx6i8FbBUeQ"],["name","細節的苓雅李維"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎Hi-Life VIP"],["url","https://appsto.re/tw/sNfmhb.i"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n\n \n \n \n \n Hi-Life\n \n \n \n \n \n #25 in Lifestyle\n \n \n \n \n \n \n \n \n\n 2.1, 107 Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n Hi-Life Enjoy Your Life!Hi-Life VIP 為會員提供Hi點優惠兌換、店到店寄件、優惠訊息、超值購等多元服務，處處給您驚喜與便利，立即下載加入會員就有好康註冊禮喔！萊爾富總有新鮮事！快載Hi-Life VIP，消費輕鬆累點，優惠、便利一把罩！【會員中心】快速設定會員卡資訊、會員資料及查看優惠票券夾；消費時出示會員條碼即可進行累點！我們還增加了財政部發票載具設定，減少紙本電子發票，讓生活更便利！【我的點數】一目了然的點數資料及兌換記錄，輕鬆兌換優惠商品，還能贈送點數給親朋好友！【我的票券】會員於門市消費購買超值購可存入票券匣，便利管理超值購票券與點數兌換的票券以及會員專屬的免費兌換票券。【店到店寄貨服務】可於Hi-Life VIP上填寫寄貨單資料，至萊爾富門市Life-ET印出後於櫃台完成店到店寄貨服務；只要輸入寄件代碼即可快速查詢貨件狀況，讓您隨時隨地掌握配送進度！【最新消息】提供萊爾富最新促銷活動及優惠訊息，給您最優惠的商品及最便利的服務！【更多服務】萊爾富官方網站、Facebook、Instagram以Line等社群網站，歡迎一同成為萊爾富的粉絲！我們會不定期舉辦各種活動～快來追蹤我們吧！\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 2.10.0\n 11 Sep 2018\n \n\n 萊爾富自家Hi Pay上線啦！1.首次綁台新卡，送大杯熱美式乙杯!2.首次消費滿100元，再送大杯熱美式乙杯!!3. 9/14前，首次消費滿100元，再送10,000Hi點!!!4.持Hi Pay消費Hi點2倍送!!!!詳細活動方式，請見APP最新消息:)\n \n \n \n 2.9.1\n 15 Aug 2018\n \n\n 1. 首次註冊，贈送好禮2. 首次消費滿100元，再加送1,000Hi點3. 提高Hi點贈送上限，點數交流更方便4. 17咖啡日，每月17~19日，會員專屬買一送一\n\n\n \n \n \n 2.9.0\n 15 May 2018\n \n\n 1. 107/4/1起到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App3. 雲端超商超好買，優惠商品好划算！跨店領取還能贈送好朋友唷\n \n \n \n 2.8.0\n 20 Apr 2018\n \n\n 1. 107/4/1起到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App3. 雲端超商超好買，優惠商品好划算！跨店領取還能贈送好朋友唷\n \n \n \n 2.7.0\n 13 Apr 2018\n \n\n 1. 到萊爾富消費1元=1點，每1元都享有點數回饋～2. 會員繳代收，每筆還能加贈50Hi點！更多活動請見Hi-Life VIP App\n \n \n \n 2.5.7\n 15 Jan 2018\n \n\n 按鈕視覺優化：新按鈕優化，新年新氣象～新增「萊儲值」功能：Life-ET上的E購卡與遊戲點數，現在也能在APP上挑選囉！挑選商品更方便～\n \n \n \n 2.5.6\n 20 Dec 2017\n \n\n 新增「消費金額查詢」功能：會員現在就能在App上查詢消費金額囉！(不含菸品、代收、代售、手續費)新增「代收記錄查詢」功能：繳交代收、停車費、信用卡費的記錄，都能在App上查詢囉！記錄查詢好方便～\n\n\n \n \n \n 2.5.5\n 18 Dec 2017\n \n\n 新增「消費金額查詢」功能：會員現在就能在App上查詢消費金額囉！(不含菸品、代收、代售、手續費)新增「代收記錄查詢」功能：繳交代收、停車費、信用卡費的記錄，都能在App上查詢囉！記錄查詢好方便～\n\n\n \n \n \n 2.5.4\n 15 Nov 2017\n \n\n 手機條碼申請介面優化：改善無法輸入載具條碼的狀況。綁定載具後，消費累點同時也能將發票存入載具唷！\n\n\n \n \n \n 2.5.3\n 19 Oct 2017\n \n\n 手機條碼申請，連結優化：發票載具設定，新增手機條碼申請功能！透過APP就可以申請手機條碼，發票存入載具，更佳方便啦～\n\n\n \n \n \n 2.5.2\n 18 Sep 2017\n \n\n (1) 超值購票券匣，贈送功能優化：到門市櫃台前，看超值購DM，購買現場超值購，存入APP，贈送親友更方便<3(2) Widget小工具優化：快使用Widget小工具，直接在手機桌面就可以進行累點啦！(3) 推播功能優化：每次都錯過小萊的超值優惠嗎？打開推播通知功能！讓您第一手掌握，成為VIP~\n\n\n \n \n \n 2.5.1\n 15 Aug 2017\n \n\n (1) Widgets小工具新上線：到小萊消費，集點更輕鬆！不用開啟APP，也能直接顯示會員條碼，超開心～(2) 雲端冰箱按鈕開通：豐富商品任你選！優惠價格、分次享用、跨店領取～還能分享給親朋好友一起同樂！\n\n\n \n \n \n 2.5.0\n 17 Jul 2017\n \n\n (1) 點數兌換篩選功能：豐富的小萊商品，讓你快速尋找！再也不用在茫茫大海中尋覓所愛～(2) 點數兌換瀏覽優化：商品不用一支一支看，多品項瀏覽，讓你不會再錯過任何一支！(3) 廣告頁面縮放功能：廣告看不清怎麼辦？就把它放大吧！\n\n\n \n \n \n 2.4.0\n 26 Jun 2017\n \n\n (1) 超值購兌換流程優化(2) 廣告頁面視覺優化(3) 點數兌換頁面視覺優化\n\n\n \n \n \n 2.3.0\n 20 Jun 2017\n \n\n (1) 超值購兌換流程優化(2) 廣告頁面視覺優化(3) 點數兌換頁面視覺優化\n\n\n \n \n \n 2.2.4\n 14 May 2017\n \n\n (1)按鈕介面優化(2)推播功能優化(3)遊戲功能擴充\n\n\n \n \n \n 2.2.1\n 17 Apr 2017\n \n\n 1. 最愛門市新增2. 累點按鈕優化3. 寄件服務優化\n\n\n \n \n \n 2.1.3\n 15 Mar 2017\n \n\n 1. 財政部發票載具功能優化2. 使用介面優化\n\n\n \n \n \n 2.1.1\n 10 Feb 2017\n \n \n \n\n \n\n \n\n \n \n \n \n \n 11 Sep 2018Version 2.10.0\n \n \n \n \n\n 萊爾富自家Hi Pay上線啦！1.首次綁台新卡，送大杯熱美式乙杯!2.首次消費滿100元，再送大杯熱美式乙杯!!3. 9/14前，首次消費滿100元，再送10,000Hi點!!!4.持Hi Pay消費Hi點2倍送!!!!詳細活動方式，請見APP最新消息:)\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n \n \n \n \n 滿滿更新加油吧\n\n\n \n 28 Feb 2018\n \n\n\n\n 可能才出不久很多東西不是很完整可以學一下別的超商一些東西\n\n\n\n\n \n\n \n\n \n \n 滿滿更新加油吧\n\n\n \n 28 Feb 2018\n \n\n\n\n \n\n 可能才出不久很多東西不是很完整可以學一下別的超商一些東西\n\n\n \n\n\n\n\n \n \n \n \n 無言到爆\n\n\n \n 12 Jul 2018\n \n\n\n\n 註冊後一直等不到驗證碼，一直按從新發送，結果一天後才收到，收到後又沒辦法使用，原因超過三次了！結果剛才看到有人四月多就有這種狀況，現在七月了還存在，這真的很有效率！董事長不管事了嗎？養了一推IT在睡覺！\n\n\n\n\n \n\n \n\n \n \n 無言到爆\n\n\n \n 12 Jul 2018\n \n\n\n\n \n\n 註冊後一直等不到驗證碼，一直按從新發送，結果一天後才收到，收到後又沒辦法使用，原因超過三次了！結果剛才看到有人四月多就有這種狀況，現在七月了還存在，這真的很有效率！董事長不管事了嗎？養了一推IT在睡覺！\n\n\n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Hi-Life INTERNATIONAL CO.,LTD\n \n \n \n Size\n 32.2 MB\n \n \n \n Compatibility\n \n\n Requires iOS 8.0 or later. Compatible with iPhone, iPad and iPod touch.\n\n\n \n\n \n \n Languages\n \n\n Traditional Chinese\n\n\n \n\n \n \n Age Rating\n You must be at least 17 years old to download this application.\n \n \n \n Infrequent/Mild Simulated Gambling\n \n \n \n Gambling and Contests\n \n \n Copyright\n © Hi-Life International Co., Ltd.\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is1-ssl.mzstatic.com/image/thumb/Purple118/v4/80/6b/3e/806b3e69-6cbe-135e-c0a9-4d259bc907b4/AppIcon-1x_U007emarketing-85-220-4.png/1200x630wa.png"],["error",null]]},{"__iterable":"Map","data":[["title","Hi-Life VIP - Apps on Google Play"],["url","https://play.google.com/store/apps/details?id=com.hilife.vipapp"],["summary","Hi-Life Enjoy Your Life!Hi-Life VIP 為會員提供Hi點優惠兌換、店到店寄件、優惠訊息、超值購等多元服務，處處給您驚喜與便利，立即下載加入會員就有好康註冊禮喔！萊爾富總有新鮮事！快載Hi-Life VIP，消費輕鬆累點，優惠、便利一把罩！【會員中心】快速設定會員卡資訊、會員資料及查看優惠票券夾；消費時出示會員條碼即可進行累點！我們還增加了財政部發票載具設定，減少紙本電子發票，讓生活更便利！【我的點數】一目了然的點數資料及兌換記錄，輕鬆兌換優惠商品，還能贈送點數給親朋好友！【我的票券】會員於門市消費購買超值購可存入票券匣，便利管理超值購票券與點數兌換的票券以及會員專屬的免費兌換票券。【店到店寄貨服務】可於Hi-Life VIP上填寫寄貨單資料，至萊爾富門市Life-ET印出後於櫃台完成店到店寄貨服務；只要輸入寄件代碼即可快速查詢貨件狀況，讓您隨時隨地掌握配送進度！【最新消息】提供萊爾富最新促銷活動及優惠訊息，給您最優惠的商品及最便利的服務！【更多服務】萊爾富官方網站、Facebook、Instagram以Line等社群網站，歡迎一同成為萊爾富的粉絲！我們會不定期舉辦各種活動～快來追蹤我們吧！"],["topImageUrl","https://lh3.googleusercontent.com/2j5rnoMzBb0hnQinVUWDR3u90gA6wKow958tNyHSZD-1MaZZqAR5vd5iHTiATUtcfw"],["error",null]]}]}],["text","萊爾富最近推出的APP，只要花三分鐘依照下面的步驟完成任務，照片裡面包含兩杯咖啡，一瓶養樂多，一條77乳加巧克力跟茶葉蛋全都免費....\n\n步驟一:\n手機下載Hi-Life Vip APP\n【iPhone App Store 下載】\nhttps://appsto.re/tw/sNfmhb.i\n\n【安卓Play Store下載】\nhttps://play.google.com/store/apps/details?id=com.hilife.vipapp\n\n* 下載完後用電話號碼註冊會員\n* 並在【推薦門市】一欄填寫【】<==可不填\n\n 註冊完後會送你一杯大杯咖啡跟100點！！！\n\n這時候就完成任務一了！\n\n步驟二:\n到【我的點數】選取【點數兌換】\n換一個100點內的東西，預設兌換養樂多70點 \n（這裡請不要把點數都換完，請留一些進行步驟三)\n\n步驟三:\n* 到【我的點數】選取【點數贈送】\n* 輸入贈送的號碼(必須要是會員)，\n可兩人申請互相贈送\n( 如果步驟二點數不小心換完，這邊就沒辦法贈送了)\n\n步驟三這邊做完，在【我的票卷】裡面就會有一杯咖啡、一條77乳加、紅利點數兌換內會有一個養樂多，這時候只要去萊爾富兌換養樂多後，又會贈送一顆茶葉蛋跟一杯咖啡。"],["id","AVqaMM-kyrDaTqlmmqBl"],["createdAt","2017-03-04T16:39:34.562Z"]]}],["reply",{"__iterable":"Map","data":[["id","AV0bcScbyCdS-nWhubvI"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","NOT_RUMOR"],["text","萊爾富行銷活動。活動期間至106/05/09兌換期限至106/05/23\n都已經過期囉\n"],["reference","https://www.facebook.com/hihilife/posts/10155076696901474:0\n萊爾富超商Hi-Life"],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","萊爾富超商Hi-Life"],["url","https://www.facebook.com/hihilife/posts/10155076696901474:0"],["summary","萊爾富超商Hi-Life贊贊贊助贊 · 2017年2月14日 · 【Hi-Life VIP│小萊會員專屬APP全新上線📲】各位粉絲快快揪團闖關拿好禮，小萊會員專屬APP全新上線，只要至App Store/Google Play下載「Hi-Life VIP」，並完成以下任務即可獲得優惠好康，每月15日再加碼！iPhone 7 Plus等著你萊拿！ 🎁 任務1：完成「會員註冊」，立即獲得「大杯熱美式咖啡乙杯 + Hi點：100點」。 🎁 任務2：首次使用Hi點進行「點數兌換」，立即獲得「茶葉蛋乙顆」。 🎁 任務3：首次使用Hi點進行「點數贈送」，立即獲得「七七乳加巧克力乙條」。 🎁 任務4：完成任務1至3，再獲得「大杯熱美式咖啡乙杯」。活動期間：即日起至106/05/09 兌換期限：即日起至106/05/23 完成上述所有任務者，即可獲得iPhone 7 Plus抽獎機會~ 106/03/15、04/15、05/15，分別抽出3支i Phone 7 Plus。總共送出📱 📱 📱 📱 📱 📱 📱 📱 📱 i Phone 7 Plus喔！【按讚分享+留言】：「_____(tag朋友)，小萊會員專屬APP全新上線，完成任務就抽i Phone 7 Plus唷！」 #萊爾富 #HiLife #HiCafé #HiLifeVIP #App #上線 #會員 #任務 #優惠 #好康 #抽獎 #iPhone7Plus #美式咖啡 #Hi點"],["topImageUrl","https://scontent.ftpe7-1.fna.fbcdn.net/v/t1.0-9/16684196_10155076696901474_653876264179105621_n.png?_nc_cat=109&oh=a49b94d1ffa004842e401133fc32f25e&oe=5C565857"],["error",null]]}]}],["createdAt","2017-07-07T05:06:26.718Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",null],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","NOWnews 今日新聞"],["url","https://www.facebook.com/nownews"],["summary","社群查看全部444,825 人說這讚423,626 個人正在追蹤關於查看全部NOWnews.com 今日新聞http://www.nownews.com www.nownews.comsocialservice@nownews.com用戶444,825 個讚1,043 個打卡次此專頁按讚的粉絲專頁IFUN NOW保庇 NOW今日觀點相關的粉絲專頁聯合報媒體／新聞公司壹週刊雜誌東森新聞廣播與媒體製作公司蘋果日報台灣媒體／新聞公司udn.com 聯合新聞網媒體／新聞公司TVBS 新聞媒體／新聞公司ETtoday新聞雲媒體／新聞公司Yahoo!奇摩新聞新聞媒體網站中時電子報新聞媒體網站國家地理雜誌雜誌中央社新聞粉絲團新聞媒體網站自由時報媒體／新聞公司快點TV媒體／新聞公司蘋果日報即時新聞媒體／新聞公司三立新聞媒體／新聞公司愛奇藝台灣站媒體／新聞公司遠見雜誌出版商商業周刊（商周.com）雜誌大家來說鬼媒體／新聞公司民視新聞媒體／新聞公司查看更多triangle-down地標台北市NOWnews 今日新聞中文(台灣) · English (US) · Español · Português (Brasil) · Français (France)隱私政策 · 使用條款 · 廣告 · Ad Choices · Cookie · 更多 Facebook © 2018貼文NOWnews 今日新聞贊贊贊助贊 · 5 分鐘 · 拉拉太美了❤️(#瞎到天編：已被閃瞎)nownews.com緊牽老公比爾賈　徐佳瑩曬婚紗照甜喊：家宴達成！ | 娛樂 | NOWnews 今日新聞金曲歌后徐佳瑩（LaLa） 8 月在臉書宣布和交往 3 年的導演男友比爾賈登記結婚的喜訊，今（22）日更在社群網站上 po 出婚紗照，開心報喜「家宴達成！」徐佳瑩和比爾賈交往 3 年，兩人雖相差 11 歲，但感情相當穩定，今（2018.....NOWnews 今日新聞贊贊贊助贊 · 32 分鐘 · 演員轉導演的潤東讓人深深著迷呢😍(#瞎到天編)nownews.com金鐘專訪／何潤東全心投入導演職：沒入圍演員奬是對的 | 娛樂 | NOWnews 今日新聞何潤東出道20年首度執導《翻牆的記憶》入圍第53屆金鐘獎8項大獎，當時何潤東發表感言時曾說：「彌補了收視的遺憾。」確實，《翻牆》探討的多為社會黑暗面、校園霸凌，並不屬於大眾喜愛的口味，加上沒有配合與無線台做....顯示全部影片欲改善老屋問題　義消分隊長參選新北市議員拚監督51國瑜不要跟紫棋搶唱Hook啊 XDDD (#助海編)\n \n韓國瑜 #高雄市長候選人 #政見Rap1547為什麼他們可以那麼狠心！！ (#助海編)4027查看全部相片顯示全部查看更多"],["topImageUrl","https://scontent.ftpe7-1.fna.fbcdn.net/v/t1.0-1/p200x200/22050172_10155343315677663_8574432092587348135_n.jpg?_nc_cat=1&oh=8ea12ccee835e00231f2222d39a22877&oe=5C5CBA38"],["error",null]]},{"__iterable":"Map","data":[["title","‎今日新聞"],["url","https://goo.gl/HWEXx"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n 《NOWnews今日新聞》APP提供每日600則以上最新、最快即時新聞，還有多元化深度報導及多樣化影音節目，提供最完整的新聞資訊；它是新聞APP程式，更是一個無時無刻不貼近你視聽需求的全方位工具。NOW News跟你想的不一樣！就從NOWnews開始！-- -- -- -- -- 你一定要下載NOWnews App的四大理由-- -- -- -- --1. 每日最即時的新聞推播，從出門天氣到周遭大小事，掌握重要資訊不漏接。2. 政治、財經、生活、運動、娛樂、國際、社會、旅遊、美食、3C、消費、地方等軟硬性內容，多元化主題深入新聞核心，每日幫你專題解析新聞重點。3. 重量級人物面對面訪談Live直播，針對時下熱門議題與網友即時互動。4. 多元化主題標籤，多元化主題深入新聞核心，帶領讀者解析新聞重點，並深度探討熱門專題。-- -- -- -- -- -四大NOWnews APP功能及特色-- -- -- -- -- -◆即時新聞：24小時即時更新國內外最新資訊，重要新聞推播，不錯過重大頭條新聞。◆多元影音：利用影音方式呈現熱門新聞、議題，直擊新聞現場。◆精選圖輯：提供新聞現場高畫質優質圖片，第一手現場幕後花絮。◆嚴選特輯：因應時下熱門話題提供特輯專區，完整新聞內容整理，全方位了解趨勢。《NOWnews今日新聞》於2008年4月正式上線，是臺灣第一個，同時也是臺灣最大、最即時的網路原生新聞網站，它還是臺灣前10大網站之一。《NOWnews今日新聞》以多元資訊內容為主，每日產製逾600則新聞，類別包括：政經、生活、運動、娛樂、國際、社會、地方等軟硬性新聞。《NOWnews今日新聞》官網： http://www.nownews.com/手機版官網： https://m.nownews.comFacebook 粉絲團： https://www.facebook.com/nownews/LINE官方帳號：NOWnews\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 4.2.3\n 6 Feb 2018\n \n\n 更新10週年logo修正圖片顯示異常其他bugfix\n\n\n \n \n \n 4.2.2\n 19 Dec 2017\n \n\n 新增支援iOS 11圖片資料更新\n\n\n \n \n \n 4.2.1\n 11 Oct 2017\n \n\n 新增介面更新暫時下架直播暫時下架我的最愛圖輯其他錯誤修正\n\n\n \n \n \n 4.2.0\n 16 Aug 2017\n \n\n 新增左側漢堡選單顯示版本資訊新增內頁置頂按鈕修正圖片模糊問題修復內頁崩潰問題修復推播格式判斷錯誤修復內頁載圖尺寸錯誤\n \n \n \n 4.1.9\n 15 Jul 2017\n \n\n 修復推播格式判斷錯誤修復內頁載圖尺寸錯誤調整影音新聞配置影音廣告音量問題\n\n\n \n \n \n 4.1.8\n 3 Jul 2017\n \n\n 版面調整並做資料更新\n\n\n \n \n \n 4.1.7\n 23 Jun 2017\n \n\n 緊急修復推播異常\n\n\n \n \n \n 4.1.6\n 19 Jun 2017\n \n\n 修復黑屏無法使用修復推播無法關閉其他問題修復\n\n\n \n \n \n 4.1.5\n 14 Jun 2017\n \n\n 直播功能調整其他問題修正\n\n\n \n \n \n 4.1.4\n 28 Apr 2017\n \n\n 修正直播bar版面顯不完整修正直播bar在某些系統版本無法使用其他bug fix\n\n\n \n \n \n 4.1.3\n 24 Apr 2017\n \n\n 1.新增直播BAR功能當我們有最新的直播實況會透過ＡＰＰ來提醒您唷2.其他bugfix\n\n\n \n \n \n 4.1.2\n 19 Apr 2017\n \n\n 修復推播數字顯示異常修正直播部分功能其他錯誤修正\n\n\n \n \n \n 4.1.1\n 10 Mar 2017\n \n\n 1. UI大改版 2. 新增推播功能 3. 新增直播收看\n\n\n \n \n \n 4.1.0\n 12 Jan 2017\n \n\n 修正第三方套件Key值錯誤\n\n\n \n \n \n 4.0.9\n 7 Jan 2017\n \n\n 緊急修復異常套件\n\n\n \n \n \n 4.0.8\n 30 May 2016\n \n\n 修正網路異常錯誤修正其他錯誤\n\n\n \n \n \n 4.0.7\n 14 Apr 2016\n \n\n 修正 weChat 分享無法支援 iOS 9.3修正新聞加載異常修正其他錯誤\n\n\n \n \n \n 4.0.6\n 2 Dec 2015\n \n\n 1.新增微博新聞分享2.新增WeChat新聞分享\n\n\n \n \n \n 4.0.5\n 29 Oct 2015\n \n\n 本次修正項目：1.上拉新聞加載2.內頁新聞分享3.N瞎拼加入HappyGo4.網路狀態判斷5.修正支援iOS 96.圖集列表圖尺寸修正7.網路斷線狀態判斷\n\n\n \n \n \n 4.0.4\n 19 Sep 2015\n \n\n 本次修正項目：1.修正內頁新聞圖片尺寸不正常顯示2.修正圖集與顯示內容不符合問題3.下拉更新即時取得分類最熱新聞4.新增首頁蓋版廣告5.其他程式優化\n\n\n \n \n \n 4.0.3\n 25 Aug 2015\n \n\n 全新介面更新1.選單改採左上方隱藏試選單2.內頁介面更新3.新聞瀏覽更快速4.圖集瀏覽更加便利5.新增內頁可直接選取字體大小\n \n \n \n 4.0.2\n 5 Jul 2013\n \n\n 效能優化、修復錯誤(新版支援iOS 5.0以上, 舊iOS版本還請更新)\n\n\n \n \n \n 4.0.0\n 1 Apr 2013\n \n\n - 界面更新 * 美化界面 * 新增圖集功能, 包含影劇 / 正妹 / 要聞 / 新奇 / 寵物等數十萬張圖庫 * 透過 \"往下拉\", 可以自動更新 * 透過 \"往上滑\", 可一直讀取更舊的新聞 * 透過 \"左右滑動\", 可以切換分類 / 內文 * 新增白天黑夜主題切換模式, 顯示不同的顏色與背景 * 用戶可調整新聞內容的字體大小以符合需求- 自訂分類 * 可以選擇, 訂閱/取消訂閱分類- 即時通知 * 如遇重大訊息公佈, 可以即時提醒您\n \n \n \n 2.2.3\n 9 Dec 2012\n \n\n NOW購了沒手機購物網站上線囉！！提供優質商品，安全的交易平台。好康驚喜天天有！你今天NOW購了沒！\n\n\n \n \n \n 2.0\n 17 Nov 2010\n \n\n update iPhone and iPod touch Screenshots.\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n\n 更新10週年logo修正圖片顯示異常其他bugfix\n\n\n \n\n \n \n\n \n \n Ratings and Reviews\n \n \n \n \n \n \n \n 新版好用\n\n\n \n 2 Jul 2018\n \n\n\n\n 很乾淨的介面新聞分類清楚\n\n\n\n\n \n\n \n\n \n \n 新版好用\n\n\n \n 2 Jul 2018\n \n\n\n\n \n\n 很乾淨的介面新聞分類清楚\n\n\n \n\n\n\n\n \n \n \n \n 我會分享成功。\n\n\n \n 16 Jul 2016\n \n\n\n\n 我是台灣人，我是黃獨立，我主張台灣人都愛有台灣獨立建國成功活命贏得勝利，所有的台灣人都愛有活命，所有的台灣人都愛有在，愛有梨的台灣人。\n\n\n\n\n \n\n \n\n \n \n 我會分享成功。\n\n\n \n 16 Jul 2016\n \n\n\n\n \n\n 我是台灣人，我是黃獨立，我主張台灣人都愛有台灣獨立建國成功活命贏得勝利，所有的台灣人都愛有活命，所有的台灣人都愛有在，愛有梨的台灣人。\n\n\n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n NOWnews Network Co.,Ltd\n \n \n \n Size\n 56 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.3 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 頻繁/強烈的粗話或低俗幽默\n \n \n \n 頻繁/強烈的卡通或幻想暴力\n \n \n \n 頻繁/強烈的色情內容與裸露\n \n \n \n 頻繁/強烈的驚悚/恐怖題材\n \n \n \n 頻繁/強烈的成人/性暗示題材\n \n \n \n 頻繁/強烈的模擬賭博\n \n \n \n 頻繁/強度醫藥/醫療資訊\n \n \n \n 頻繁/強烈的現實暴力\n \n \n \n 頻繁/強烈的酒精、菸草或藥物使用或相關內容\n \n \n Copyright\n © NOWnews.com\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is5-ssl.mzstatic.com/image/thumb/Purple128/v4/7d/f5/02/7df502c6-adc6-68f4-624c-3845c8238a8e/AppIcon-1x_U007emarketing-0-0-GLES2_U002c0-512MB-sRGB-0-0-0-85-220-0-0-0-4.png/1200x630wa.png"],["error",null]]},{"__iterable":"Map","data":[["title","NOWnews今日新聞 - Google Play 應用程式"],["url","https://goo.gl/oPBNJ"],["summary","《NOWnews今日新聞》APP提供每日600則以上最新、最快即時新聞，還有多元化深度報導及多樣化影音節目，提供最完整的新聞資訊；它是新聞APP程式，更是一個無時無刻不貼近你視聽需求的全方位工具。NOW News跟你想的不一樣！就從NOWnews開始！----------你一定要下載NOWnews App的四大理由----------1. 每日最即時的新聞推播，從出門天氣到周遭大小事，掌握重要資訊不漏接。2. 政治、財經、生活、運動、娛樂、國際、社會、旅遊、美食、3C、消費、地方等軟硬性內容，多元化主題深入新聞核心，每日幫你專題解析新聞重點。3. 重量級人物面對面訪談Live直播，針對時下熱門議題與網友即時互動。4. 多元化主題標籤，多元化主題深入新聞核心，帶領讀者解析新聞重點，並深度探討熱門專題。-----------四大NOWnews APP功能及特色-----------◆即時新聞：24小時即時更新國內外最新資訊，重要新聞推播，不錯過重大頭條新聞。◆多元影音：利用影音方式呈現熱門新聞、議題，直擊新聞現場。◆精選圖輯：提供新聞現場高畫質優質圖片，第一手現場幕後花絮。◆嚴選特輯：因應時下熱門話題提供特輯專區，完整新聞內容整理，全方位了解趨勢。《NOWnews今日新聞》於2008年4月正式上線，是臺灣第一個，同時也是臺灣最大、最即時的網路原生新聞網站，它還是臺灣前10大網站之一。《NOWnews今日新聞》以多元資訊內容為主，每日產製逾600則新聞，類別包括：政經、生活、運動、娛樂、國際、社會、地方等軟硬性新聞。《NOWnews今日新聞》官網： http://www.nownews.com/手機版官網： https://m.nownews.comFacebook 粉絲團： https://www.facebook.com/nownews/LINE官方帳號：NOWnews"],["topImageUrl","https://lh3.googleusercontent.com/VOq0mkKn52NOPZDUiTA8H2irRQT52FBiOetnT-bWDEeXOiFtGU6Lnyu4ziTP1mhatsuD"],["error",null]]}]}],["text","親愛的朋友您好！(haha)\n歡迎加入NOWnews成為您的好友\n我們將一天發送2次重點新聞及精彩圖片\n提供最即時的新聞情報(clap)\n讓您一手掌握不錯過！(ok)(ok)\n\n想隨時了解更多天下事，快按讚加入NOWnews粉絲團：\nhttps://www.facebook.com/nownews\n\n(chick)NOW新聞都在行動APP上\n》》iOS APP請點這裡\nhttps://goo.gl/HWEXx\n》》Android APP請點這裡\nhttps://goo.gl/oPBNJ"],["id","5487035768113-rumor"],["createdAt","2017-01-11T12:30:00.000Z"]]}],["reply",{"__iterable":"Map","data":[["id","AV0oJH0HyCdS-nWhub56"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","NOT_ARTICLE"],["text"," 測試用之無意義訊息。"],["reference",""],["hyperlinks",{"__iterable":"List","data":[]}],["createdAt","2017-07-09T16:17:46.251Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_8SU6w_lKU8142Pd-hyVJRULJNF7mjehuE3om7Vc6i8c"],["name","滿足的✖東勢✖艾薇拉"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","Diabetes drug is promising Alzheimer's treatment after 'significantly reversing' memory loss"],["url","http://www.independent.co.uk/news/health/alzheimers-diabetes-drug-memory-loss-reverse-disease-treatment-degenerative-a8133681.html"],["summary","A drug developed for type 2 diabetes significantly reverses memory loss and could have potential as a new treatment for Alzheimer’s disease and other neurodegenerative diseases, scientists say.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The study, by UK and Chinese universities, is the first to look at a new combined diabetes drug and found improvements in several characteristic symptoms of Alzheimer’s.\n \n\n \n \n \n \n \n\n\n\n \n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Lead researcher Professor Christian Holscher, from Lancaster University, said these “very promising outcomes” show multi-action drugs developed for type 2 diabetes “consistently show neurological protective effects”.\n \n\n \n \n \n \n \n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Independent academics said a reduction in nerve-cell-killing protein molecules was particularly interesting and this was likely to be another avenue in the search for an elusive drug to combat dementia.\n \n\n \n \n \n \n \n\n\n\n\n\n \n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n He has previously reported optimistic findings from an older diabetes drug, liraglutide, and clinical trials in humans are currently under way.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n This latest study, published in the journal Brain Research, looked at a “triple action” treatment that combine three different drugs for type 2 diabetes, acting on biological pathways that could also have an impact on dementia.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n \n\n \n \n \n Type 2 diabetes is a known risk factor for Alzhemier’s disease and impaired production of insulin – the hormone that people with diabetes don’t produce sufficiently to control their blood sugar – is linked to brain degeneration.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The identification of this link had a twofold benefit, according to charities.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n It opened up new research and drug development opportunities, such as this study.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n But it also means that by making lifestyle changes, like eating healthily and exercising, patients can avoid developing type-2 diabetes and lower their risk of Alzheimer’s disease as well.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n There are currently half a million people living with Alzheimer’s disease in the UK and more than five million people with diabetes, both conditions pose a major cost to the NHS, and health systems worldwide.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n \n\n \n \n \n The treatment in this study combined; GLP-1, GIP and glucagon, which, like insulin protect against neurological deterioration, and tested them in mice with genetic mutations that cause Alzheimer’s disease.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n After two months of daily injections the mice were shown to significantly improve their performance in a maze designed to test memory.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n Treated mice also had lower levels of proteins which clump together and form plaques in the brains of people with Alzheimer’s disease, inhibiting nerve cells’ ability to communicate and causing them to die.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n The study also found these mice lost nerve cells to the disease at a slower rate and had lower levels of nerve inflammation.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n It concludes that the triple treatment “holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease”.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n \n \nThe seven Alzheimer's risk factors\n\n\n\n\n \n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n \n\n \n \n \n The Alzheimer’s Society, a charity which part-funded the latest study research, said that after 15 years without a new drug for Alzheimer’s disease the promising results from these crossover treatments, which are already known to be safe for humans, are likely to bring earliest benefits.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n Professor Holscher added that further tests to compare its benefits against other potential treatments, and its effects in humans were needed.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n\n\n\n\n\n \n \n \n \n \n But Professor John Hardy, a professor of neuroscience, at University College London who was not involved in the trial, said the study was “a first step, at best” towards a Alzheimer’s drug for humans.\n \n\n \n \n \n \n \n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n\n\n\n\n\n \n \n \n \n \n “The results showing less amyloid deposition of amyloid in mice treated with glucagon receptor stimulating drugs is interesting,” he said.\n \n\n \n \n \n \n \n \n “However, it should be noted that several other drugs have shown positive results in mice models of Alzheimer’s disease and then failed in human trials.”\n \n\n \n \n \n \n \n \n Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK, echoed this, but added: “There is a long road between studies that show an effect in animals and treatments in the hands of patients, and scientists will only be able to realise the potential of promising findings like these if we continue to invest in research.”"],["topImageUrl","https://static.independent.co.uk/s3fs-public/thumbnails/image/2015/04/14/21/web-alzheimers-2-alamy.jpg"],["error",null]]},{"__iterable":"Map","data":[["title","Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease"],["url","https://www.sciencedirect.com/science/article/pii/S0006899317304596"],["summary","AbstractType 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD). Previous studies have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that have anti-diabetic properties show very promising effects in animal models of AD. Glucagon (Gcg) is a hormone and growth-factor, and the Gcg receptor is expressed in the brain. Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. In the present study, the effects of the TA were evaluated in the APP/PS1 transgenic mouse model of AD. The TA was injected once-daily (10 nmol/kg i.p.) for two months. The results showed that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a spatial water maze test. Moreover, the drug reduced levels of the mitochondrial pro-apoptotic signaling molecule BAX, increased the anti-apoptotic signaling molecule Bcl-2 and enhanced the levels of BDNF, a key growth factor that protects synaptic function. Levels of synaptophysin were enhanced, demonstrating protection from synaptic loss that is observed in AD. Neurogenesis in the dentate gyrus was furthermore enhanced as shown in the increase of doublecortin positive cells. Furthermore, TA treatment reduced the total amount of β-amyloid, reduced neuroinflammation (activated microglia and astrocytes), and oxidative stress in the cortex and hippocampus. Thus, these findings show that novel TAs are a promising lead for the design of future treatment strategies in AD.Previous Next KeywordsInflammationGrowth factorBDNFBrainInsulinNeurodegeneration1. IntroductionAlzheimer’s disease (AD), is a progressive neurodegenerative disease, characterized clinically by progressive memory loss, cognitive decline, and aberrant behavior [1]. Currently, there is no treatment can improve this condition. Epidemiological studies have shown that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD) (Luchsinger et al., 2004, Ohara et al., 2011). The underlying mechanism is most likely that insulin signaling is impaired in the brains of AD patients (Moloney et al., 2010, Talbot et al., 2012). This motivated research in drugs that have shown good effects in treating diabetes to investigate if they could be helpful in treating AD as well. Previous studies have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can play a neuroprotective role in the brain and show very promising effects in animal models of AD (Duffy and Holscher, 2013, Faivre and Holscher, 2013b, Li et al., 2010, McClean et al., 2011, McClean and Holscher, 2014). Glucagon (Gcg) is a hormone and growth-factor, and the Gcg receptor is expressed in the brain (Hoosein and Gurd, 1984, Mayo et al., 2003). Activation of the receptor can activate neuronal activity and cellular Ca2+ signaling and may have neuroprotective properties (Ayush et al., 2015). Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. This novel drug has been developed as a potential treatment for diabetes (Finan et al., 2015). No studies have been published that test the neuroprotective effects of this novel drug. We therefore tested this promising TA in the APPSWE/PS1dE9 mouse model of AD. This mouse model recapitulates some of the hallmarks of AD, such as memory loss, synaptic loss, reduction of synaptic plasticity, reduction of neurogenesis in the dentate gyrus, chronic inflammation in the brain, and formation of amyloid plaques in the brain (Duffy and Holscher, 2013, Goto et al., 2008, Hamilton et al., 2011, Hamilton and Holscher, 2012, McClean et al., 2011). We tested the effects of TA in this transgenic mouse model and evaluated the neuroprotective effects. We analyzed memory formation, hippocampal neurogenesis, the expression levels of Brain Derived Neurotrophic Factor (BDNF) (Blurton-Jones et al., 2009), mitochondrial apoptosis signaling proteins, neuroinflammation and oxidative stress levels.2. Results2.1. TA-treatment improved the learning and memory impairment of APP/PS1 mice in the water mazeA two-way ANOVA found a significant difference between groups (p < 0.0001) and over time (p < 0.001). In the Morris water test, it was observed that the control mice, APP/PS1 mice and TA-treated APP/PS1 mice had a similar escape latency (P > 0.05). On day 5, the average escape distance in searching for the hidden platform in the APP/PS1 mice was significantly longer than that in the control mice (P < 0.05). Compared to the APP/PS1 group, the TA-treated APP/PS1 group’s average escape distance was decreased (P < 0.01). There was no difference in swimming speed among these three groups in training days (P > 0.05).Then on day 6, the platform was removed and the probe trail test was conducted. A one way ANOVA analysis showed an overall difference between groups. The APP/PS1 mice spent less time in the target quadrant (P < 0.01) and had fewer times passing through the original position of the hidden platform (P < 0.01), compared with control mice. In the TA-treated APP/PS1 group, the time spent in target quadrant (P < 0.05) and the frequencies to cross the platform significantly increased (P < 0.05), compared to the APP/PS1 group Fig. 1.Download high-res image (302KB)Download full-size imageFig. 1. The novel TA improved the learning ability of APP/PS1 mice in the spatial water maze task. (A) The escape latency and swimming speed in the training trails. (B) The percentage of time in target quadrant and crossing platform times in the probe trials. The circle indicates the position of the platform during acquisition (C) Representative swimming tracks of the probe trial. * = P < .05, ** = P < .01 compared to the control group, ## = P < .01, # = P < .05 compared to the APP/PS1 group; Two-way ANOVA with Bonferroni repeated measures post hoc tests.2.2. TA-treatment ameliorated amyloid plaques in the brains of APP/PS1 miceIn the immunohistochemical analysis, we analyzed the amount of amyloid plaques present in the brains of APP-PS1 mice. A one-way ANOVA found an overall difference on the amyloid deposits in the cortex (F = 31.10, P < 0.0001) and the hippocampus (F = 30.38, P < 0.0001) of mice between groups. The Aβ1-42 depositions in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased the deposition (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 2.Download high-res image (211KB)Download full-size imageFig. 2. TA treatment reduced amyloid deposits in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared to the control group; ### = P < .001 compared to the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.3. TA-treatment reduced the chronic inflammation response in the cortex and hippocampus of the APP/PS1 miceIn the immunohistochemical analysis, an anti-GFAP antibody was used as an indication of activated astrocytes. A one-way ANOVA found an overall difference on the GFAP expression in the cortex (F = 77.03, P < 0.0001) and the hippocampus (F = 86.51, P < 0.0001) of mice between groups. The levels of GFAP in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 3.Download high-res image (362KB)Download full-size imageFig. 3. TA-treatment reduced the number of GFAP positive cells in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA. Scale bar in image D: 50μm. A higher magnification image has been added to show stained astroglia. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.In the immunohistochemical analysis, an anti-IBA1 antibody was used as an indication of microglia activation. A one-way ANOVA found an overall difference on the IBA-1 expression in the cortex (F = 28.71, P < 0.0001) and the hippocampus (F = 66.42, P < 0.0001) of mice between groups. The levels of IBA-1 in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001, P < 0.01) compared to the APP/PS1 group. N = 6 per group. See Fig. 4.Download high-res image (347KB)Download full-size imageFig. 4. TA treatment reversed the increase of IBA-1 positive cells in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. A higher magnification image has been added to show stained microglia. *** = P < .001 compared to the control group; ## = P < .01, ### = P < .001 compared to the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.4. TA-treatment suppressed oxidative stress in the cortex and hippocampus of APP /PS1 miceIn the immunohistochemical analysis, 4-HNE was measured as an indicator of lipid peroxidation. A one-way ANOVA found an overall difference on the 4-HNE expression in the cortex (F = 60.60, P < 0.0001) and the hippocampus (F = 35.22, P < 0.0001) of mice between groups. The expressions of 4-HNE in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.001) compared to the APP/PS1 group. N = 6 per group, see Fig. 5a.Download high-res image (397KB)Download full-size imageFig. 5. Oxidative stress was reduced by the TA. 5A. TA-treatment reduced the increase of 4-HNE levels in the cortex and hippocampus in APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared with controls; ###=P < .001 compared to the APP/PS1 group. 5B. TA treatment reduced the increase of 8-OHdG levels in the cortex and hippocampus of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100 μm. *** = P < .001 compared to the control group; ## = P < .01, ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures ***post hoc tests. N = 6 per group.In the immunohistochemical analysis, 8-OHdG was measured as an indicator of DNA oxidation. A one-way ANOVN found an overall difference on the 8-OHdG expression in the cortex (F = 38.72, P < 0.0001) and the hippocampus (F = 56.60, P < 0.0001) of mice between groups. The expressions of 8-OHdG in the cortex and hippocampus of the APP/PS1 mice were significantly higher than that in the control mice (P < 0.001), while TA-treatment group significantly decreased (P < 0.01, P < 0.001) compared to the APP/PS1 group. N = 6 per group, see Fig. 5b.2.5. TA-treatment increased immature neurons in the dentate gyrus of APP/PS1 miceIn the immunohistochemical analysis, numbers of neurogenesis, assessed by doublecortin (DCX). A one-way ANOVN found an overall difference on the DCX positive cell in the dentate gyrus (F = 43.61, P < 0.0001) of mice between groups. The numbers of DCX were much reduced in the APP/PS1 mice (P < 0.001) compared to the control mice. While TA-treatment partially prevented the reduction (P < 0.001) compared to the APP/PS1 mice. N = 6 per group. See Fig. 6.Download high-res image (169KB)Download full-size imageFig. 6. TA-treatment enhanced neurogenesis and increased numbers of DCX positive cell numbers in the dentate gyrus of APP/PS1 mice. A: control group; B: APP/PS1 group; C: APP/PS1+TA group. Scale bar in image A: 100 μm. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.6. TA-treatment reversed the decrease of BDNF levels in the hippocampus of APP/PS1 miceBDNF, a key neurotrophic factor in the brain, was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 20.01, P < 0.001). The expression of BDNF in hippocampus was reduced in APP/PS1 group (P < 0.001) compared to the control group. TA-treatment reversed the decreased (P < 0.05) compared to the APP/PS1 group. N = 6 per group. See Fig. 7a.Download high-res image (304KB)Download full-size imageFig. 7. A) TA-treatment increased levels of BDNF in the hippocampus of APP/PS1 mice. *** = P < .001compared with the control group; # = P < .05 compared with the APP/PS1 group. N = 6 per group. B) TA-treatment increased levels of synaptophysin in the hippocampus of APP/PS1 mice. *** = P < .001 compared with the control group; ## = P < .01 compared with the APP/PS1 group. N = 6 per group. C) TA-treatment increased the ratio of BAX/Bcl-2 in the hippocampus of APP/PS1 mice. *** = P < .001 compared with the control group; ### = P < .001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post hoc tests. N = 6 per group.2.7. TA-treatment reversed the reduction of synaptophysin levelsSynaptophysin (SYN), a synaptic markers, was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 20.46, P < 0.001). The level of SYN in hippocampus was decreased in the APP/PS1 group (P < 0.001) compared to the control group. While TA-treatment prevent the reduction (P < 0.01) compared to the APP/PS1 group. N = 6 per group. See Fig. 7b.2.8. TA-treatment showed potential anti-apoptotic effects by decreasing the BAX/Bcl-2 ratio in APP/PS1 miceThe expression of apoptotic proteins, including Bcl-2 (that suppress apoptosis) and BAX (that promotes apoptosis), was detected by Western blot analysis. A one-way ANOVA found an overall difference between groups (F = 77.64, P < 0.001). The ratio of BAX/Bcl-2 in hippocampus was increased (P < 0.001) compared to the control group. While TA-treatment partly decreased the ratio of BAX/Bcl-2 (P < 0.001) compared to the APP/PS1 group. N = 6 per group. See Fig. 7c.3. DiscussionThe results demonstrate for the first time that the novel GLP-1/GIP/Gcg receptor agonist has clear neuroprotective effects in the APP/PS1 mouse model of AD. Memory formation in the spatial water maze task was improved by the drug, and the amyloid plaque load in the cortex and hippocampus was reduced. This result confirms our previous findings that single GLP-1 or GIP analogues can protect from memory loss in this mouse model of AD (Faivre and Holscher, 2013a, Faivre and Holscher, 2013b, McClean et al., 2011, McClean and Holscher, 2014). The chronic inflammation response as seen in the activation of microglia and astrocytes is much reduced by the novel TA, similar to single GLP-1 or GIP receptor agonists (Duffy and Holscher, 2013, Ji et al., 2016a, McClean et al., 2011). Levels of the peroxidized lipid 4-HNE that also acts as a pro-apoptotic signal in mitochondria have been reduced by the TA. 4-HNE is one of the markers of membrane lipid peroxidation induced by cytotoxic radicals such as OH. 4-HNE has cytotoxic, mutagenic and genotoxic properties and 4-HNE is reported to stimulate apoptosis via caspase 3 activation and by inducing mitochondrial damage as shown in cytochrome c release (Ji et al., 2001). The levels of the mitochondrial apoptosis signal BAX (Kim et al., 2005) were also reduced. Importantly, the anti-apoptotic signaling molecule B-cell lymphoma 2 (Bcl-2) which is active in functioning mitochondria that have normal inner membrane voltage potentials (Kavitha et al., 2013) is upregulated by the TA, adding to the neuroprotective effect. The level of chronic oxidative stress as measure by the levels of the oxidized nucleotide 8-Hydroxiguanosine (8-OHdG) was also reduced by the drug. Neurogenesis in the dentate gyrus was normalized. Importantly, the levels of the key growth factor BDNF were normalized in the brain. BDNF has shown clear neuroprotective effects in a range of animal models of disease (Allen et al., 2013, Benedetti et al., 2014, Blurton-Jones et al., 2009, Nagahara et al., 2013). An important factor of BNDF activity is that it maintains synaptic activity and protects synapses from stressors (Kuipers and Bramham, 2006). The observation that the synaptic marker synaptophysin was expressed at normal levels after TA treatment also indicates that synaptic numbers and function was improved in the AD mouse. We have shown previously that GLP-1 and GIP analogues protect synapses from amyloid induced stress and keeps them functional (Faivre and Holscher, 2013b, Gault and Holscher, 2008a, Gault and Holscher, 2008b, McClean and Holscher, 2014).Recently, multiple receptor agonists have been developed to treat type II diabetes (Finan et al., 2013, Finan et al., 2015). We have tested novel dual GLP-1/GIP receptor agonists that showed good neuroprotective effects that are superior to single GLP-1 analogues (Cao et al., 2016, Jalewa et al., 2017, Ji et al., 2016b, Yuan et al., 2017). The novel dual agonist DA3-CH was found to be superior to liraglutide in a mouse model of Parkinson’s disease (Yuan et al., 2017), demonstrating that the strategy of activating more than one incretin receptor type offers an advantage over single receptor agonists. Here, we show that a novel triple receptor agonist also shows promise as a potential treatment for AD, but further dose–response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drug is superior to previous ones.GLP-1, GIP and glucagon are members of the growth factor family (Hölscher, 2016). Their respective receptors are classic 7-membrane spanning domain, G-protein coupled receptors that activate cAMP synthesis (Campbell and Drucker, 2013, Doyle and Egan, 2007, Holst et al., 2011). The activation of the second messenger cascade cAMP-PKA-CREB induces a number of cytoprotective processes, including the normalization of energy utilization, cell repair and growth-factor related gene expression (Holscher, 2014, Jalewa et al., 2016, Perry and Greig, 2004, Sharma et al., 2013). Importantly, GLP-1 and GIP also have anti-inflammatory properties. Astroglia and microglia express the receptors, and activating these reduce the inflammation response (Duffy and Holscher, 2013, Jalewa et al., 2017, Parthsarathy and Holscher, 2013, Spielman et al., 2017). Chronic inflammation is a main driver of neurodegenerative disorders, and a reduction of the inflammation in the brain shows protective effects (Akiyama et al., 2000, Clark et al., 2012, Lee et al., 2010).Based on the impressive preclinical data that demonstrate neuroprotection of such drugs, clinical trials have started that investigate the neuroprotective effects of the GLP-1 receptor agonists exendin-4 (Byetta, Bydureon®) and liraglutide (Victoza®) in patients with AD or with Parkinson disease (PD). A pilot study testing the GLP-1 analogue liraglutide in AD patients showed promising results. In a double blind, placebo controlled trial, AD patients showed no deterioration in brain activity as measured in the 18FDG-PET scan after 12 months of drug treatment. In contrast, the placebo group showed clear reductions in cortical activity as expected for this progressive neurodegenerative disease (Gejl et al., 2016). A phase II clinical trial is currently ongoing (Hölscher, 2016). A pilot trial testing exendin-4 in PD patients has shown good effects (NCT01174810). This open-label study tested the effects of exendin-4 in 45 patients. There were clear improvements in the motor coordination as shown in the MDS-UPDRS part 3 assessment, and cognition was improved as measured by the Mattis DRS-2 test battery that had been designed to evaluate cognitive impairments in PD patients (Aviles-Olmos et al., 2013). Patients were re-tested 12 months later, and the differences in motor performance and cognitive scores were still visible (Aviles-Olmos et al., 2014). A phase II double-blind, placebo controlled clinical trial that tested the once-weekly formulation of exendin-4, Bydureon®, confirmed the results of the pilot study. The drug group did not deteriorate in the MDS-UPDRS part 3 assessment after 48 weeks of treatment, and after 12 weeks of a wash-out period, the disease-modifying effect was still visible. In contrast, the placebo group deteriorated over time as would be expected in this disease (Athauda et al., 2017). In addition, a phase II trial testing liraglutide in PD patients has started, testing patients in a double blind, placebo controlled trial for one year (NCT02953665). A further clinical trial testing the GLP-1 receptor agonist Lixisenatide in PD patients is in planning.These very promising preclinical and the first clinical outcomes demonstrate the efficacy of these novel multiple receptor agonists that originally were developed to treat type II diabetes, but have shown consistent neuroprotective effects in several studies. In the present study, the novel TA improved learning and memory, reduce amyloid plaque load, chronic inflammation and oxidative stress, as well as mitochondrial stress signaling, and improved BDNF release and synaptic markers while normalising neurogenesis in the dentate gyrus. The novel triple GLP-1/GIP/Gcg receptor agonist holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease.4. Materials and methods4.1. Peptide and chemicalsThe triple GLP-1/GIP/Gcg used in this study was synthesized by China Peptides Co, Ltd. (Shanghai, China) to 95% purity. The identity and purity of the peptide was confirmed by reversed-phase HPLC and characterized using matrix assisted laser resorption/ionization time of flight (MALDI–TOF) mass spectrometry. The peptide was stored in dry form and dissolved in double-distilled water containing 0.9% NaCl2 before experiments. A Bi-cinchoninicacid (BCA) protein assay kit was purchased from Apply gen Technologies Inc. (Beijing, China). 3, 3-diaminobenzidine (DAB) was purchased from ZSGB-BIO Co. (Beijing, China). The primary antibodies recognizing Aβ1-42, IBA-1, BDNF, 4-Hydroxynonenal (4-HNE), 8-Hydroxyguanosine (8-OHdG), synaptophysin (SYN) and β-actin were obtained from Abcam (Cambridge, UK). The primary antibody GFAP, Bcl-2, and BAX were obtained from Boster Biotechnology (Wuhan, China). The primary antibody doublecortin (DCX) buy from Santa Cruz Biotechnology. HRP-labeled goat anti-rabbit immunoglobulin was obtained from Abcam (Cambridge, UK). The biotinylated goat anti-rabbit IgG, biotinylated rabbit anti-goat IgG, avidinbiotin peroxidase complex reagent was purchased from Boster Biotechnology (Wuhan, China). All other reagents used in the research were of analytical grade and of the highest quality commercially available. The peptide sequence was as follows (Finan et al., 2015):HXQGTFTSDKSKYLDERAAQDFVQWLLDGGPSSGAPPPSX = aminoisobutyric acid, K = γE-C16 acylation (with a C16 fatty acid).4.2. Animals and treatmentsAPP/PS1 transgenic mice were purchased from the Academy of Military Medical Sciences (AMMS, China), were maintained in a constant temperature (22 ± 1 °C) and humidity (relative 30%) under a 12 h light/dark cycle in animal house. As well as age-matched non-AD mice, which are wild-type animals as control. When animals were 6 months of age, TA was dissolved in saline. The dose was a once-daily injection of 10 nmol/kg body weight ip. for two months. Injections were given in the morning (8:00 am). Control mice received equal volumes of saline solution. All experimental procedures involving animals were approved by the Institutional Animal Care Committee of Shanxi Medical University and conform to the guidelines of National Institute of Health (NIH) guideline (NIH publication No. 85-23. Revised 1985). They were divided into three different groups (n = 12). (i): control group treated with saline only; (ii): APP/PS1 group treated with saline only; (iii): APP/PS1 group treated with TA. At the end of drug treatments, measurements of behavioral change, neuronal damage, oxidative stress and inflammatory markers were conducted.4.3. Morris water maze testThe water maze test is a standard method for assessing learning and memory in animals. The water maze (WM) task was performed 5 days after two months intraperitoneal injection. The apparatus was a circular, white painted pool (150 cm in diameter and 60 cm in height) which was filled to a depth of 40 cm with warm water at a temperature 23 ± 2 °C to avoid hypothermia, and was surrounded by a white curtain around the pool. The pool was divided into four quadrants with four starting locations, north (N), east (E), south (S) and west (W), the starting quadrant was randomly chosen. A perspex platform (diameter, 10 cm) was located in a specific location during the acquisition trials and submerged approximately 1.0 cm below the surface of the water. A video camera was mounted directly above the pool to record the movement and the trail of the mice. During the acquisition phase, each mouse was subjected to four consecutive training trials on each day. The mouse was gently placed in the water between the quadrants, and allowed 60 s to search the hidden platform. If it failed to find the platform within 60 s, it was guided to the platform and allowed to remain there for 10 s. Training continued for 5 days. On the sixth day, the hidden platform was removed and each mouse was allowed to swim in the pool for 60 s. The mean time spent in all four quadrants and the target area for searching the hidden platform was recorded.4.4. Brain tissue preparationHalf of the animals were decapitated after anesthetization with ethyl carbamate, hippocampus tissues were immediately isolated and stored at −80 °C for further investigations. The second half of each group was used for immunohistochemistry analysis. Animals were perfused intracardially with saline and cold 4% paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde for 24 h.4.5. ImmunohistochemistryFor DAB staining, fixed tissues were embedded in paraffin. Coronal sections (5 μm thick) of the brains were cut on a Leica microtome for immunohistochemistry. Paraffin was removed from the tissue sections with xylene, and the sections were rehydrated in graded ethanol solutions. Endogenous peroxidase activity was blocked with 3% H2O2 for 10 min at room temperature. Antigen retrieval was performed by heating in 10 mmol/L citrate buffer (pH 6.0) for 10 min. After blocked with 5% BSA, sections were incubated with the primary antibody for doublecortin (goat anti-DCX; 1:50), GFAP (rabbit anti-GFAP; 1:100), IBA-1 (goat anti-IBA1; 1:200), 4-Hydroxynonenal antibody (goat anti-4 HNE; 1:200) and anti-8 Hydroxyguanosine antibody (goat anti-8 OHdG; 1:200) at 37 °C for 2 h. For the Anti-8 OHdG histology, enzymatic antigen retrieval with 10 μm/ml proteinase K for 40 min at 37 °C was performed. To detect amyloid deposits, the primary antibody was Aβ1-42 (rabbit anti-Aβ1-42; 1:100), brain sections were pre-incubated with 70% formic acid and incubated at 4 °C for 24 h. They were rinsed in PBS and incubated with biotinylated goat anti-rabbit IgG or biotinylated rabbit anti-goat IgG at 37 °C for 0.5 h and incubated with the avidin-biotin peroxidase complex reagent at 37 °C for 0.5 h. Samples were stained in DAB solution in the presence of H2O2. All stained sections were viewed and photographed under a Zeiss light microscope, and images were captured by Motic Images Plus2.0ML software. The numbers of DCX positive neurons, the areas of Aβ1-42, GFAP, IBA-1, 4-HNE and 8-OHdG positive cells were determined using Image-pro plus6.0 software. The software counts objects that are defined in size and staining threshold by the user. This automated process avoided user bias.4.6. Western blotThe hippocampal tissues from mice was homogenized in ice cold RIPA buffer (containing 1% Triton X-100, 0.1% SDS, 1% deoxycholate) and PMSF (phenyl-methylsulfonyl fluoride). The homogenate was centrifuged 12,000 rpm/min for 5 min at 4 °C before taking the supernatant. Tissue containing 60 μg of protein was separated on 10–12% gradient Bis–Tris gel with molecular marker and electrophoresed in running buffer at 120 mV for 90 min followed by transfer to the PVDF membrane. Following protein transfer, the membrane was washed in TBST (tris buffered saline with 0.05% Tween-20, pH 8) and blocked in 5% skim milk for 1 h. Then incubated overnight at 4 °C with rabbit anti-synaptophysin (SYN) (1:10,000), rabbit anti-Bcl-2 (1:400), rabbit anti-BAX (1:400), rabbit anti-BDNF (1:5000), after three washes in TBS further incubation for 2 h at room temperature with the HRP-labeled goat anti-rabbit immunoglobulin (1:5000). In some cases, the blots were stripped and reprobed with a rabbit anti-β-actin (1:5000) to ensure equal sample loading. The bound antibodies were then visualized by ECL-enhanced chemiluminescence (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. Western blot images were captured with a chemiluminescent imaging system (Sage Creation, Beijing, China). All bands were quantified using the image system of Alpha View SA.4.7. Statistical analysisThe data were presented as the mean ± standard error of mean (S.E.M.) and analyzed by one-way or two way ANOVA followed by Bonferroni’s multiple comparison test using the software Prism 5 (Graph Pad Software Inc, La Jolla, CA, USA). Statistical significance is defined as P < 0.05.ContributorsJT, WL and YL conducted the experiments, LL and CH conceived the experiment and wrote the manuscript.AcknowledgementsThis work was funded by the Ministry of Human Resources and Social Security, Shanxi Province [(2010)255], by a Shanxi Scholarship Council of China, and supported by a grant from the Alzheimer Society UK. The authors declare no conflict of interestAppendix A. Supplementary dataReferencesAkiyama et al., 2000H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, T. Wyss-CorayInflammation and Alzheimer’s diseaseNeurobiol. Aging, 21 (2000), pp. 383-421Allen et al., 2013S.J. Allen, J.J. Watson, D.K. Shoemark, N.U. Barua, N.K. PatelGDNF, NGF and BDNF as therapeutic options for neurodegenerationPharmacol. Ther., 138 (2013), pp. 155-175Athauda et al., 2017D. Athauda, K. Maclagan, S.S. Skene, M. Bajwa-Joseph, D. Letchford, K. Chowdhury, S. Hibbert, N. Budnik, L. Zampedri, J. Dickson, Y. Li, I. Aviles-Olmos, T.T. Warner, P. Limousin, A.J. Lees, N.H. Greig, S. Tebbs, T. FoltynieExenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trialAviles-Olmos et al., 2013I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, T. Soderlund, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. FoltynieExenatide and the treatment of patients with Parkinson’s diseaseJ. Clin. Invest., 123 (2013), pp. 2730-2736Aviles-Olmos et al., 2014I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P.E. Fmedsci, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, T. FoltynieMotor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s diseaseJ. Parkinson’s Dis., 4 (2014), pp. 337-344Ayush et al., 2015E.A. Ayush, Y. Iwasaki, S. Iwamoto, H. Nakabayashi, M. Kakei, T. YadaGlucagon directly interacts with vagal afferent nodose ganglion neurons to induce Ca(2+) signaling via glucagon receptorsBiochem. Biophys. Res. Commun., 456 (2015), pp. 727-732Benedetti et al., 2014E. Benedetti, B. D'Angelo, L. Cristiano, E. Di Giacomo, F. Fanelli, S. Moreno, F. Cecconi, A. Fidoamore, A. Antonosante, R. Falcone, R. Ippoliti, A. Giordano, A. CiminiInvolvement of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE)Cell Cycle, 13 (2014), pp. 1335-1344Blurton-Jones et al., 2009M. Blurton-Jones, M. Kitazawa, H. Martinez-Coria, N.A. Castello, F.J. Muller, J.F. Loring, T.R. Yamasaki, W.W. Poon, K.N. Green, F.M. LaferlaNeural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProc. Natl. Acad. Sci. U.S.A., 106 (2009), pp. 13594-13599Campbell and Drucker, 2013J.E. Campbell, D.J. DruckerPharmacology, physiology, and mechanisms of incretin hormone actionCell Metab., 17 (2013), pp. 819-837Cao et al., 2016L. Cao, D. Li, P. Feng, L. Li, G. Xue, G. Li, C. HölscherA novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brainNeuroreport, 37 (2016), pp. 384-391Clark et al., 2012I. Clark, C. Atwood, R. Bowen, G. Paz-Filho, B. VisselTumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationalesPharmacol. Rev., 64 (2012), pp. 1004-1026Doyle and Egan, 2007M.E. Doyle, J.M. EganMechanisms of action of glucagon-like peptide 1 in the pancreasPharmacol. Ther., 113 (2007), pp. 546-593Duffy and Holscher, 2013A.M. Duffy, C. HolscherThe incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s diseaseNeuroscience, 228 (2013), pp. 294-300Faivre and Holscher, 2013aE. Faivre, C. HolscherD-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse modelJ. Alzheimers Dis., 35 (2013), pp. 267-283Faivre and Holscher, 2013bE. Faivre, C. HolscherNeuroprotective effects of D-Ala2GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse modelAlzheimers Res. Ther., 5 (2013), pp. 20-28Finan et al., 2013B. Finan, T. Ma, N. Ottaway, T.D. Muller, K.M. Habegger, K.M. Heppner, H. Kirchner, J. Holland, J. Hembree, C. Raver, S.H. Lockie, D.L. Smiley, V. Gelfanov, B. Yang, S. Hofmann, D. Bruemmer, D.J. Drucker, P.T. Pfluger, D. Perez-Tilve, J. Gidda, L. Vignati, L. Zhang, J.B. Hauptman, M. Lau, M. Brecheisen, S. Uhles, W. Riboulet, E. Hainaut, E. Sebokova, K. Conde-Knape, A. Konkar, R.D. DiMarchi, M.H. TschopUnimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humansSci. Transl. Med., 5 (2013), p. 209ra151Finan et al., 2015B. Finan, B. Yang, N. Ottaway, D.L. Smiley, T. Ma, C. Clemmensen, J. Chabenne, L. Zhang, K.M. Habegger, K. Fischer, J.E. Campbell, D. Sandoval, R.J. Seeley, K. Bleicher, S. Uhles, W. Riboulet, J. Funk, C. Hertel, S. Belli, E. Sebokova, K. Conde-Knape, A. Konkar, D.J. Drucker, V. Gelfanov, P.T. Pfluger, T.D. Muller, D. Perez-Tilve, R.D. DiMarchi, M.H. TschopA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodentsNat. Med., 21 (2015), pp. 27-36Gault and Holscher, 2008aV.A. Gault, C. HolscherGLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloidEur. J. Pharmacol., 587 (2008), pp. 112-117Gault and Holscher, 2008bV.A. Gault, C. HolscherProtease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloidJ. Neurophysiol., 99 (2008), pp. 1590-1595Gejl et al., 2016M. Gejl, A. Gjedde, L. Egefjord, A. Møller, S.B. Hansen, K. Vang, A.B. Rodell, H. Braendgaard, H. Gottrup, A. Schacht, N. Møller, B. Brock, J. RungbyIn Alzheimer’s disease, six-month treatment with glp-1 analogue prevents decline of brain glucose metabolism: randomized, placebo-controlled double-blind clinical trialFront. Aging Neurosci., 8 (2016), pp. 1-10Goto et al., 2008Y. Goto, T. Niidome, H. Hongo, A. Akaike, T. Kihara, H. SugimotoImpaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's diseaseEur. J. Pharmacol., 583 (2008), pp. 84-91Hamilton et al., 2011A. Hamilton, S. Patterson, D. Porter, V.A. Gault, C. HolscherNovel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJ. Neurosci. Res., 89 (2011), pp. 481-489Hamilton and Holscher, 2012A. Hamilton, C. HolscherThe effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's diseaseBrain Res., 1449 (2012), pp. 83-93Holscher, 2014C. HolscherInsulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseasesBiochem. Soc. Trans., 42 (2014), pp. 593-599Hölscher, 2016C. HölscherGLP-1 and GIP analogues as novel treatments for Alzheimer’s and Parkinson’s diseaseCardiovasc. Endocrinol., 5 (2016), pp. 93-98Holst et al., 2011J.J. Holst, R. Burcelin, E. NathansonNeuroprotective properties of GLP-1: theoretical and practical applicationsCurr. Med. Res. Opin., 27 (2011), pp. 547-558Hoosein and Gurd, 1984N.M. Hoosein, R.S. GurdIdentification of glucagon receptors in rat brainProc. Natl. Acad. Sci. U.S.A., 81 (1984), pp. 4368-4372Jalewa et al., 2016J. Jalewa, M.K. Sharma, C. HolscherNovel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cellsJ. Neurochem., 139 (2016), pp. 55-67Jalewa et al., 2017J. Jalewa, M. Sharma, S. Gengler, C. HölscherA novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson’s diseaseNeuropharmacology, 117 (2017), pp. 238-248Ji et al., 2001C. Ji, V. Amarnath, J.A. Pietenpol, L.J. Marnett4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c releaseChem. Res. Toxicol., 14 (2001), pp. 1090-1096Ji et al., 2016aC. Ji, G.F. Xue, G. Li, D. Li, C. HolscherNeuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's diseaseRev. Neurosci., 27 (2016), pp. 61-70Ji et al., 2016bC. Ji, G.F. Xue, C. Lijun, P. Feng, D. Li, L. Li, G. Li, C. HolscherA novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDFBrain Res., 1634 (2016), pp. 1-11Kavitha et al., 2013M. Kavitha, J. Nataraj, M.M. Essa, M.A. Memon, T. ManivasagamMangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease miceChem. Biol. Interact., 206 (2013), pp. 239-247Kim et al., 2005S.J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, C.H. McIntoshGlucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expressionJ. Biol. Chem., 280 (2005), pp. 22297-22307Kuipers and Bramham, 2006S.D. Kuipers, C.R. BramhamBrain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapyCurr. Opin. Drug Discov. Dev., 9 (2006), pp. 580-586Lee et al., 2010Y.J. Lee, S.B. Han, S.Y. Nam, K.W. Oh, J.T. HongInflammation and Alzheimer's diseaseArch. Pharm. Res., 33 (2010), pp. 1539-1556Li et al., 2010Y. Li, K. Duffy, M. Ottinger, B. Ray, J. Bailey, H. Holloway, D. Tweedie, T. Perry, M. Mattson, D. Kapogiannis, K. Sambamurti, D. Lahiri, N. GreigGLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's diseaseJ. Alzheimers Dis., 19 (2010), pp. 1205-1219Luchsinger et al., 2004J.A. Luchsinger, M.X. Tang, S. Shea, R. MayeuxHyperinsulinemia and risk of Alzheimer diseaseNeurology, 63 (2004), pp. 1187-1192Mayo et al., 2003K.E. Mayo, L.J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, D.J. DruckerInternational Union of Pharmacology. XXXV. The glucagon receptor familyPharmacol. Rev., 55 (2003), pp. 167-194McClean et al., 2011P. McClean, V. Parthsarathy, E. Faivre, C. HölscherThe diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's diseaseJ. Neurosci., 31 (2011), pp. 6587-6594McClean and Holscher, 2014P.L. McClean, C. HolscherLixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseaseNeuropharmacology, 86C (2014), pp. 241-258Moloney et al., 2010A.M. Moloney, R.J. Griffin, S. Timmons, R. O'Connor, R. Ravid, C. O'NeillDefects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signallingNeurobiol. Aging, 31 (2010), pp. 224-243Nagahara et al., 2013A.H. Nagahara, M. Mateling, I. Kovacs, L. Wang, S. Eggert, E. Rockenstein, E.H. Koo, E. Masliah, M.H. TuszynskiEarly BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic miceJ. Neurosci., 33 (2013), pp. 15596-15602Ohara et al., 2011T. Ohara, Y. Doi, T. Ninomiya, Y. Hirakawa, J. Hata, T. Iwaki, S. Kanba, Y. KiyoharaGlucose tolerance status and risk of dementia in the community: the Hisayama studyNeurology, 77 (2011), pp. 1126-1134Parthsarathy and Holscher, 2013V. Parthsarathy, C. HolscherThe type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brainEur. J. Pharmacol., 700 (2013), pp. 42-50Perry and Greig, 2004T.A. Perry, N.H. GreigA new Alzheimer's disease interventive strategy: GLP-1Curr. Drug Targets, 5 (2004), pp. 565-571Sharma et al., 2013M. Sharma, J. Jalewa, C. HolscherNeuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to Methylglyoxal stressJ. Neurochem., 128 (2013), pp. 459-471Spielman et al., 2017L.J. Spielman, D.L. Gibson, A. KlegerisIncretin hormones regulate microglia oxidative stress, survival and expression of trophic factorsEur. J. Cell Biol., 96 (2017), pp. 240-253Talbot et al., 2012K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, A. Stucky, R.L. Fuino, K.R. Kawaguchi, A.J. Samoyedny, R.S. Wilson, Z. Arvanitakis, J.A. Schneider, B.A. Wolf, D.A. Bennett, J.Q. Trojanowski, S.E. ArnoldDemonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive declineJ. Clin. Invest., 122 (2012), pp. 1316-1338Yuan et al., 2017Z. Yuan, L. Li, P. Feng, G. Xue, C. Ji, G. Li, C. HölscherA novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson’s disease© 2017 Elsevier B.V. All rights reserved."],["topImageUrl","https://ars.els-cdn.com/content/image/1-s2.0-S0006899317X0022X-cov150h.gif"],["error",null]]}]}],["text","阿茲海默症(Alzheimer’s disease)疾病對於病人及家屬皆會帶來很大的影響，然而至目前為止，疾病的發生機轉及可能的治療方式卻仍在研究階段。《Cell Reports》日前刊登中國山西醫科大學(Shanxi Medical University)的最新發表，研究團隊表示，原先發展用來治療糖尿病的特定藥物，有機會反轉阿茲海默症的記憶喪失症狀。第二型糖尿病已知為阿茲海默症的風險因子之一，其病程會影響到胰島素的分泌，而在過去的研究中亦曾發現，這個影響人體血糖調節的荷爾蒙，其分泌不足可能與大腦的退化情形有關。本篇研究中，作者發現結合第二型糖尿病的特定藥物，可能改善數項阿茲海默症的獨特病徵。作者表示，這項研究發現，有助於未來發展阿茲海默症及其它神經退化疾病的新治療方法。\n \n新聞出處：Alzheimer's treatment: Diabetes drug holds promise for fighting disease after 'significantly reversing' memory loss《Independent》\nhttp://www.independent.co.uk/news/health/alzheimers-diabetes-drug-memory-loss-reverse-disease-treatment-degenerative-a8133681.html\n研究刊登在《Cell Reports》第1678卷第64-74頁\nhttps://www.sciencedirect.com/science/article/pii/S0006899317304596\n "],["id","AWEET-BFyCdS-nWhunGr"],["createdAt","2018-01-17T13:29:59.107Z"]]}],["reply",{"__iterable":"Map","data":[["id","AWEElGNbyCdS-nWhunHT"],["user",{"__iterable":"Map","data":[["id","AVriAlOoyrDaTqlmmqhC"],["name","Lin"],["avatarUrl",null],["level",22]]}],["type","RUMOR"],["text","美國布朗大學沃倫阿爾伯特醫學院（The Warren Alpert Medical School of Brown University）的蘇珊教授（Suzanne de la Monte），後續發現阿茲海默症患者不一定有第一型或第二型糖尿病，但腦部也會出現血糖代謝異常的狀況，因此認為阿茲海默症和糖尿病有高度相似性，因此學者提出阿茲海默症為第三型糖尿病的說法。"],["reference","http://www.cofit.me/229093913535506/4688052\n飲食與生活習慣的改善，才是預防阿茲海默症的根本"],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","This area is password protected [401]"],["url","http://www.cofit.me/229093913535506/4688052"],["summary","This area is password protected"],["topImageUrl",""],["error",null]]}]}],["createdAt","2018-01-17T14:44:49.119Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_Pj0EHwRC4AHx_jeeEKxoaelKUOy7S7mNL8H7IVrRARM"],["name","溫和的南澳莉斯"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎發票集點王-唯一能中獎兩次的對獎機"],["url","http://cmy.tw/006RpJ"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n 歡慶年度改版狂抽免費好禮\n \n CWMoney.NET\n \n \n \n \n \n #1 in 財經\n \n \n \n \n \n \n \n \n\n 4.7, 6.4K Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n ｜雙平台全榜冠軍，用戶認證、擊敗抖音｜財務榜與熱門榜前十名常客｜Dcard、Ptt、多個社群網友熱情推薦｜用發票自動記帳集點，消費無所遁形｜超多好禮獎不完，點數加倍獎品爽拿！▼　發票集點王功能特色【快掃快對 + 自動對獎】- 掃描發票左方 QR Code， 0.5 秒迅速記帳- 開獎日自動對獎通知，絕不錯過中獎發票【雲端發票 + 愛心條碼 + 載具管理】- 支援手機條碼綁定與桌面 Widget 功能- 方便管理所有載具歸戶- 選擇想幫助的公益團體，還能捐贈發票、用愛關懷弱勢。【點數回饋 + 刮刮樂拉霸獎不完】- 每張發票都給予點數回饋- 天天掃天天送，集點還能免費抽獎- 周末限時加倍送、節慶大放送- 拉霸機、當日發票刮刮樂小遊戲【消費分析】- 能依時間地點分析常用店家、最愛品牌、消費時段與每月支出變化，掌握開支去向。- 小資、豪門都需要的究級理財術【豐盛好禮 + 點數狂飆】- 小米、Sony、7-11、名牌好禮等不定時上架- 每天都可換各式商城好禮- 也很歡迎廠商聯名，一起照顧用戶【傳統發票也不落掉 + 精準記帳】- 末3碼自助輸入快速對獎（不列入計點）- 記錄金額與備註，讓每筆消費都清清楚楚！【系統設定】- 內建不打擾用戶設定！- 可選擇開啟或關閉聲音與震動功能　　　　　　　　　　　　　　　　　　　　　　　　　　　　小資族最愛理財神器！最棒的雲端發票對獎機就在這裡。　　　　　　　如發現 APP 可改善或有更好的功能建議，請聯繫我們～若覺得 APP很棒，歡迎分享給好友，讓更多人知道唷▼ 隨時追蹤最新消息粉絲專頁：http://cmy.tw/006Q5Y LINE@：http://cmy.tw/0069o0發票集點王，給您高效率高回饋的美好生活。\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 3.00\n 20 Sep 2018\n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n 2.63\n 25 Aug 2018\n \n\n 1.修正已知問題\n\n\n \n \n \n 2.62\n 17 Aug 2018\n \n\n 1.新增主題色 2.修復已知問題\n\n\n \n \n \n 2.61\n 8 Aug 2018\n \n\n 1.修正掃描功能\n\n\n \n \n \n 2.60\n 4 Aug 2018\n \n\n 1.新增消費時間、地點、金額分析圖表功能2.新增中獎率分析3.修復已知問題\n\n\n \n \n \n 2.54\n 28 Jul 2018\n \n\n 1.修正發票數量顯示錯誤問題\n\n\n \n \n \n 2.53\n 6 Jul 2018\n \n\n 1. 優化手機條碼同步功能2. 修正發票重複出現的問題3. 感謝這段時間使用者的意見與支持，我們會努力持續優化！\n\n\n \n \n \n 2.52\n 28 Jun 2018\n \n\n 1. 修正 iPhone 5 與 5C 閃退現象2. 優化相關體驗！\n\n\n \n \n \n 2.51\n 25 Jun 2018\n \n\n - 對 iOS 新舊版本的支援更完美了！- 解決同步發票重覆顯示、部分手機閃退的問題- 優化拉霸機與大家最愛的當日發票刮刮樂- 修正用戶提出的重大問題，感謝大家長期的回饋與支持！\n\n\n \n \n \n 2.5\n 19 Jun 2018\n \n\n - 全新功能！可愛喵喵拉霸機來囉！- 全新粉紅色甜美介面登場- 掃描引擎大升級、商城顯示優化- 刮刮樂顯示速度調整，稍稍提速！- 可同時在線人數大幅提升，降低當機率- 增加頁面下拉更新資訊功能- 加大觸控範圍，按鈕更好點囉！- iOS 11 SDK 正式更新- 修正更多使用者提交的bug與建議，感謝大家讓發票集點王變得更好！\n\n\n \n \n \n 2.43\n 22 May 2018\n \n\n 1.新增馬上對獎按鈕2.修復已知問題\n\n\n \n \n \n 2.41\n 3 May 2018\n \n\n 1.手機條碼Widget小工具功能修復2.掃描中自動切換掃描引擎，增加辨識率3.修復已知臭蟲\n\n\n \n \n \n 2.40\n 20 Apr 2018\n \n\n 1.新增掃描當日發票獎勵-刮刮樂功能2.新增分享活動-分享到Line賺點數3.修復已知問題\n\n\n \n \n \n 2.32\n 12 Apr 2018\n \n\n 1.修復馬上對獎按鈕失效的問題\n\n\n \n \n \n 2.31\n 3 Apr 2018\n \n\n 1.發票掃描功能優化，提升掃瞄速度50%!!! (建議立即更新)2.改善「燒機」模式3.修正部份小臭蟲\n\n\n \n \n \n 2.30\n 31 Mar 2018\n \n\n 1.新增手動對獎功能2.新增打卡分享贈點活動3.手動收回成就訊息\n\n\n \n \n \n 2.21\n 28 Mar 2018\n \n\n 1.修正手機條碼無法綁定的問題\n\n\n \n \n \n 2.20\n 24 Mar 2018\n \n\n 1.新增開獎通知2.修正已知問題\n\n\n \n \n \n 2.10\n 17 Mar 2018\n \n\n 1.優化使用者體驗2.修正已知問題\n\n\n \n \n \n 2.01\n 10 Mar 2018\n \n\n 1.修正閃退問題\n\n\n \n \n \n 2.00\n 6 Mar 2018\n \n\n 1.新增成就功能，達成任務累積點數2.新增發票同步功能3.修正已知問題\n\n\n \n \n \n 1.91\n 14 Feb 2018\n \n\n 1.修復手動輸入發票閃退問題2.修正ios11以下版本，活動頁面跑版問題\n\n\n \n \n \n 1.90\n 11 Feb 2018\n \n\n 1.新增年節特別活動2.新增手機條碼使用說明3.新增手機條碼自動同步功能4.修正已知問題\n\n\n \n \n \n 1.81\n 27 Jan 2018\n \n\n 1.Fix Bug\n\n\n \n \n \n 1.80\n 23 Jan 2018\n \n\n 1.新增碎碎念語音功能2.優化使用者體驗3.修正已知問題\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.7 out of 5\n 6.4K Ratings\n \n \n\n \n \n \n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n\n \n\n \n\n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n \n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n\n \n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n \n\n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n \n \n\n\n\n\n \n \n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n\n \n\n \n\n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n \n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n\n \n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n \n\n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n \n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Chips Century Co., Ltd\n \n \n \n Size\n 76.3 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.0 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 偶而/輕微的模擬賭博\n \n \n \n 賭博與競賽\n \n \n Copyright\n © 2017 Money Inc\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is4-ssl.mzstatic.com/image/thumb/Purple118/v4/ac/c8/32/acc8326a-7cd4-bce8-c562-10f95b1d8cbd/AppIcon-1x_U007emarketing-85-220-0-5.png/1200x630wa.png"],["error",null]]}]}],["text","诶　你聽說了嗎? (surprise)\n免費霜淇淋+冰拿鐵...\n下載發票集點王APP\n立馬掃發票兌換！(beer)\n👉http://cmy.tw/006RpJ\n\n方法：\n1. 掃發票集點\n2. 兌換免費下午茶\n3. 每月還自動幫你對發票"],["id","1g3rnkfqsnr7k"],["createdAt","2018-05-17T05:44:41.778Z"]]}],["reply",{"__iterable":"Map","data":[["id","vx7UbGMBSH_MLFhIQ2Is"],["user",{"__iterable":"Map","data":[["id","AWF-ZCWLhutQxxU6trl0"],["name","重新來升等"],["avatarUrl","https://www.gravatar.com/avatar/?s=100&d=mp"],["level",14]]}],["type","NOT_ARTICLE"],["text","這是商業活動廣告"],["reference",""],["hyperlinks",null],["createdAt","2018-05-17T06:40:40.240Z"]]}]]},{"__iterable":"Map","data":[["article",{"__iterable":"Map","data":[["replyCount",1],["references",{"__iterable":"List","data":[{"__iterable":"Map","data":[["type","LINE"]]}]}],["replyRequestCount",1],["user",{"__iterable":"Map","data":[["id","j4S8C_raOUFJvrXmf2AaDgJBFY_mxk6goIley02YaMVYWCoe8"],["name","嚴以律已的褒忠艾倫"],["avatarUrl",null],["level",0]]}],["hyperlinks",{"__iterable":"List","data":[{"__iterable":"Map","data":[["title","‎發票集點王-唯一能中獎兩次的對獎機"],["url","https://www.money.com.tw/go/invoice?referrer=ios_share"],["summary","This app is only available on the App Store for iOS devices.\n\n\n \n \n \n \n \n\n\n \n\n\n \n \n\n \n\n \n\n \n \n \n 歡慶年度改版狂抽免費好禮\n \n CWMoney.NET\n \n \n \n \n \n #1 in 財經\n \n \n \n \n \n \n \n \n\n 4.7, 6.4K Ratings\n\n \n \n \n \n \n \n \n Free\n \n \n \n \n \n \n \n\n\n \n iPhone Screenshots\n \n \n\n\n \n \n Description\n \n\n ｜雙平台全榜冠軍，用戶認證、擊敗抖音｜財務榜與熱門榜前十名常客｜Dcard、Ptt、多個社群網友熱情推薦｜用發票自動記帳集點，消費無所遁形｜超多好禮獎不完，點數加倍獎品爽拿！▼　發票集點王功能特色【快掃快對 + 自動對獎】- 掃描發票左方 QR Code， 0.5 秒迅速記帳- 開獎日自動對獎通知，絕不錯過中獎發票【雲端發票 + 愛心條碼 + 載具管理】- 支援手機條碼綁定與桌面 Widget 功能- 方便管理所有載具歸戶- 選擇想幫助的公益團體，還能捐贈發票、用愛關懷弱勢。【點數回饋 + 刮刮樂拉霸獎不完】- 每張發票都給予點數回饋- 天天掃天天送，集點還能免費抽獎- 周末限時加倍送、節慶大放送- 拉霸機、當日發票刮刮樂小遊戲【消費分析】- 能依時間地點分析常用店家、最愛品牌、消費時段與每月支出變化，掌握開支去向。- 小資、豪門都需要的究級理財術【豐盛好禮 + 點數狂飆】- 小米、Sony、7-11、名牌好禮等不定時上架- 每天都可換各式商城好禮- 也很歡迎廠商聯名，一起照顧用戶【傳統發票也不落掉 + 精準記帳】- 末3碼自助輸入快速對獎（不列入計點）- 記錄金額與備註，讓每筆消費都清清楚楚！【系統設定】- 內建不打擾用戶設定！- 可選擇開啟或關閉聲音與震動功能　　　　　　　　　　　　　　　　　　　　　　　　　　　　小資族最愛理財神器！最棒的雲端發票對獎機就在這裡。　　　　　　　如發現 APP 可改善或有更好的功能建議，請聯繫我們～若覺得 APP很棒，歡迎分享給好友，讓更多人知道唷▼ 隨時追蹤最新消息粉絲專頁：http://cmy.tw/006Q5Y LINE@：http://cmy.tw/0069o0發票集點王，給您高效率高回饋的美好生活。\n \n \n \n \n\n \n \n What's New\n \n \n \n Version History\n \n \n 3.00\n 20 Sep 2018\n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n 2.63\n 25 Aug 2018\n \n\n 1.修正已知問題\n\n\n \n \n \n 2.62\n 17 Aug 2018\n \n\n 1.新增主題色 2.修復已知問題\n\n\n \n \n \n 2.61\n 8 Aug 2018\n \n\n 1.修正掃描功能\n\n\n \n \n \n 2.60\n 4 Aug 2018\n \n\n 1.新增消費時間、地點、金額分析圖表功能2.新增中獎率分析3.修復已知問題\n\n\n \n \n \n 2.54\n 28 Jul 2018\n \n\n 1.修正發票數量顯示錯誤問題\n\n\n \n \n \n 2.53\n 6 Jul 2018\n \n\n 1. 優化手機條碼同步功能2. 修正發票重複出現的問題3. 感謝這段時間使用者的意見與支持，我們會努力持續優化！\n\n\n \n \n \n 2.52\n 28 Jun 2018\n \n\n 1. 修正 iPhone 5 與 5C 閃退現象2. 優化相關體驗！\n\n\n \n \n \n 2.51\n 25 Jun 2018\n \n\n - 對 iOS 新舊版本的支援更完美了！- 解決同步發票重覆顯示、部分手機閃退的問題- 優化拉霸機與大家最愛的當日發票刮刮樂- 修正用戶提出的重大問題，感謝大家長期的回饋與支持！\n\n\n \n \n \n 2.5\n 19 Jun 2018\n \n\n - 全新功能！可愛喵喵拉霸機來囉！- 全新粉紅色甜美介面登場- 掃描引擎大升級、商城顯示優化- 刮刮樂顯示速度調整，稍稍提速！- 可同時在線人數大幅提升，降低當機率- 增加頁面下拉更新資訊功能- 加大觸控範圍，按鈕更好點囉！- iOS 11 SDK 正式更新- 修正更多使用者提交的bug與建議，感謝大家讓發票集點王變得更好！\n\n\n \n \n \n 2.43\n 22 May 2018\n \n\n 1.新增馬上對獎按鈕2.修復已知問題\n\n\n \n \n \n 2.41\n 3 May 2018\n \n\n 1.手機條碼Widget小工具功能修復2.掃描中自動切換掃描引擎，增加辨識率3.修復已知臭蟲\n\n\n \n \n \n 2.40\n 20 Apr 2018\n \n\n 1.新增掃描當日發票獎勵-刮刮樂功能2.新增分享活動-分享到Line賺點數3.修復已知問題\n\n\n \n \n \n 2.32\n 12 Apr 2018\n \n\n 1.修復馬上對獎按鈕失效的問題\n\n\n \n \n \n 2.31\n 3 Apr 2018\n \n\n 1.發票掃描功能優化，提升掃瞄速度50%!!! (建議立即更新)2.改善「燒機」模式3.修正部份小臭蟲\n\n\n \n \n \n 2.30\n 31 Mar 2018\n \n\n 1.新增手動對獎功能2.新增打卡分享贈點活動3.手動收回成就訊息\n\n\n \n \n \n 2.21\n 28 Mar 2018\n \n\n 1.修正手機條碼無法綁定的問題\n\n\n \n \n \n 2.20\n 24 Mar 2018\n \n\n 1.新增開獎通知2.修正已知問題\n\n\n \n \n \n 2.10\n 17 Mar 2018\n \n\n 1.優化使用者體驗2.修正已知問題\n\n\n \n \n \n 2.01\n 10 Mar 2018\n \n\n 1.修正閃退問題\n\n\n \n \n \n 2.00\n 6 Mar 2018\n \n\n 1.新增成就功能，達成任務累積點數2.新增發票同步功能3.修正已知問題\n\n\n \n \n \n 1.91\n 14 Feb 2018\n \n\n 1.修復手動輸入發票閃退問題2.修正ios11以下版本，活動頁面跑版問題\n\n\n \n \n \n 1.90\n 11 Feb 2018\n \n\n 1.新增年節特別活動2.新增手機條碼使用說明3.新增手機條碼自動同步功能4.修正已知問題\n\n\n \n \n \n 1.81\n 27 Jan 2018\n \n\n 1.Fix Bug\n\n\n \n \n \n 1.80\n 23 Jan 2018\n \n\n 1.新增碎碎念語音功能2.優化使用者體驗3.修正已知問題\n\n\n \n \n \n\n \n\n \n\n \n \n \n \n \n \n\n 歡慶一週年！超skr的新功能與獎品都來了發票集點王祝大家都能對中這期發票！1. 全版掃描畫面來了！再也不怕對不到發票2. 點數明細全新上線！每筆回饋都清清楚楚3. 載具管理登場，會員卡管理加速開發中4. 愛心碼功能實裝！全家一起做公益5. 排行榜機制變更，淚水與怨恨通通退散！5. 全新刮刮樂亮相！點數加倍送等你來拿～6. 系統設定大變身，快換上喜歡的主題色！7. 商城歷史紀錄改版，另同步優化載入速度\n \n \n \n \n \n\n \n \n Ratings and Reviews\n \n \n \n 4.7 out of 5\n 6.4K Ratings\n \n \n\n \n \n \n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n\n \n\n \n\n \n \n 還蠻方便的，但還是有些小缺失喲。\n\n\n \n 27 Jul 2018\n \n\n\n\n \n\n 希望獎品的項目能再開放多一些，不然感覺僧多粥少好辛苦呀！還有，同步化之後，掃描出來的購物明細資料全部都顯示「查詢不到資料」是否是系統發生故障或問題了，再麻煩工程人員們修正一下囉！辛苦你們了⋯⋯ 謝謝，感恩大家 ^ _ ^\n\n\n \n\n \n Developer Response\n\n\n \n 30 Jul 2018\n \n \n \n\n 您好，謝謝您對發票集點王的肯定，小編會努力幫忙爭取更多獎項唷。最近吃喝玩樂週週抽有新增很多獎項，本週獎品是Samsung J7 Prime和7-11電子禮券喔，請您趕緊把握機會喔！另外，7/19-8/9間，每週四提供限量兌換全家商品，中午12點準時開搶，也請您多多支持喔！即時補貨通知，請關注我們的 LINE@ 。關於「查詢不到資料」的部分，可能商家尚未上傳發票資料、或網路延遲，資料尚未匯入，還請您多多包含喔。\n\n\n \n \n\n\n\n\n \n \n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n\n \n\n \n\n \n \n 如何兌換抽中的獎品？\n\n\n \n 2 Aug 2018\n \n\n\n\n \n\n 沒有說明如何兌奬在系統通知中奬後不知要如何去兌換奬品\n\n\n \n\n \n Developer Response\n\n\n \n 6 Aug 2018\n \n \n \n\n mario panama您好，請問您是抽中哪個產品呢？如果是禮券或全家小額商品，我們會提供給您禮券序號或商品的兌換序號；如果是健康營養品類的商品，我們會直接寄送給您。若您兌換或抽中後沒有收到商品，請您來信客服信箱並提供帳號跟兌換截圖，我們查驗後會迅速補寄給您喔！👉客服信箱 iking@berich.net.tw👉 FB：https://goo.gl/rZ827n 👉Line@ID：@iking\n\n\n \n \n\n\n\n\n \n \n\n\n\n \n \n \n Information\n \n \n Seller\n \n Chips Century Co., Ltd\n \n \n \n Size\n 76.3 MB\n \n \n \n Compatibility\n \n\n 需要 iOS 9.0 或以上版本。與 iPhone、iPad 及 iPod touch 相容。\n\n\n \n\n \n \n Languages\n \n\n 英語\n\n\n \n\n \n \n Age Rating\n 您必須年滿 17 歲才能下載此 App。\n \n \n \n 偶而/輕微的模擬賭博\n \n \n \n 賭博與競賽\n \n \n Copyright\n © 2017 Money Inc\n \n \n Price\n Free\n \n\n \n \n \n \n \n\n \n \n \n App Support\n \n \n Privacy Policy\n \n \n \n\n \n \n Supports\n \n \n \n \n \n Family Sharing\n\n \n\n Up to six family members will be able to use this app with Family Sharing enabled."],["topImageUrl","https://is4-ssl.mzstatic.com/image/thumb/Purple118/v4/ac/c8/32/acc8326a-7cd4-bce8-c562-10f95b1d8cbd/AppIcon-1x_U007emarketing-85-220-0-5.png/1200x630wa.png"],["error",null]]}]}],["text","【發票集點王】\n獨樂樂不如眾樂樂, 邀請好友賺點數! 安裝最快速最好用的發票對獎App!\n到設定中\"分享賺點數\"輸入分享碼\"3VAG\", 馬上現拿500點分享紅利!\n https://www.money.com.tw/go/invoice?referrer=ios_share"],["id","3bm4a7vo4vsge"],["createdAt","2018-07-05T12:54:35.858Z"]]}],["reply",{"__iterable":"Map","data":[["id","mjqvamQBbZnN2I-EYJc6"],["user",{"__iterable":"Map","data":[["id","AVqVwjqQyrDaTqlmmp_a"],["name","MrOrz"],["avatarUrl","https://avatars2.githubusercontent.com/u/108608?s=100"],["level",18]]}],["type","NOT_ARTICLE"],["text","這是 android app 促進下載量的促銷廣告。"],["reference",""],["hyperlinks",null],["createdAt","2018-07-05T13:43:55.710Z"]]}]]}]}],["searchArticles",{"__iterable":"List","data":[]}],["searchReplies",{"__iterable":"List","data":[]}]]}]]},"replyDetail":{"__iterable":"Map","data":[["state",{"__iterable":"Map","data":[["isLoading",false],["isAuthLoading",false],["isReplyLoading",false]]}],["data",{"__iterable":"Map","data":[["reply",null],["originalReplyConnection",null]]}]]},"auth":{"__iterable":"Map","data":[["state",{"__iterable":"Map","data":[["isLoading",false],["isDialogShown",false]]}],["user",null]]}}

Sizzly Jam: Roast Game App - App Store

現有回應

增加新回應

你可能也會對這些類似文章有興趣